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Upon this gifted age, in its dark hour,
Rains from the sky a meteoric shower
Of facts . . . they lie unquestioned, uncombined.
Wisdom enough to leech us of our ill
Is daily spun; but there exists no loom
To weave it into fabric. 
Edna St. Vincent Millay,
excerpt from “Upon this age, that never speaks its mind,”
 from Collected Poems, 1939. 
Reprinted with permission from The Edna St. Vincent Millay Society.
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Introduction
Invasive fungal disease
Invasive fungal disease (IFD) can be life-threatening. In the past two decades, the incidence of 
these infections increased significantly, largely because of the increasing size of the populations 
at risk [1]. Although IFDs can affect people with intact immune systems as well, the vast majority 
of these infections occur as opportunistic infection in the immunocompromised host. IFDs can 
be caused by both yeast and filamentous molds. Yeasts are a type of fungi that consist of solitary 
cells that reproduce by budding, whereas molds occur in the form of hyphae: long, tubular 
branches with multiple, genetically identical nuclei which grow by apical extension [2]. The most 
common forms of IFD in the immunocompromised host include invasive candidiasis (yeast) and 
invasive aspergillosis (mold).
Invasive candidiasis
Yeasts such as Candida spp. are part of our normal microbial flora on mucosal surfaces (primarily 
the gut and oral cavity, though the skin may also provide a habitat), from where they may 
migrate into the blood in patients with varying underlying diseases or host factors, causing 
invasive disease (invasive candidiasis), most often presented as candidemia [3]. At a later stage, 
candidemia can undergo secondary dissemination to organs (e.g. eyes, liver, spleen, bones, heart 
valves, central nervous system) or present as deep-seated candidiasis [3, 4]. 
The pathogenesis of invasive candidiasis constitutes three major components: (1) increased 
fungal burden or colonisation, mostly resulting from the use of broad-spectrum antibiotics; (2) 
disruption of normal mucosal skin barriers induced by disease, drugs or trauma; and (3) immune 
impairment (e.g. neutropenia) [5, 6]. Not suprisingly, invasive candidiasis occurs most frequently in 
immunocompromised hosts and critically ill patients [6], with mortality rates reported to be as 
high as 40%, despite the use of antifungal therapy [3]. 
Invasive aspergillosis
Molds such as Aspergillus spp. are saprophytic filamentous fungi and found widely in the 
environment. They are commonly found in both the outdoor environment and the indoor 
environment, including hospitals [7]. Invasive aspergillosis, i.e. Aspergillus hyphae penetrating the 
lung tissue and entering the bloodstream via the distal airways and alveolar spaces of the lung [8], is 
a serious opportunistic infection that mainly affects immunocompromised patients, particularly 
patients with hematologic malignancies (e.g. leukemia), solid-organ and hematopoietic stem 
cell transplant patients; patients on prolonged corticosteroid therapy, patients suffering from 
genetic immunodeficiencies (e.g. chronic granulomatous disease); and HIV-positive individuals [9]. 
In these high-risk populations, mortality rates for invasive aspergillosis range from 40 to 90% [10, 11]. 
Other pathogens besides Candida spp. and Aspergillus spp. that cause IFD in the immunocom-
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promised host are Mucorales spp. (zygomycosis), Fusarium and Scedosporium spp. (hyalohypho-
mycosis). Although these infections are less common, they are associated with a high mortality 
rate (66% for zygomycosis in patients with malignancies, 50-70% for Fusarium infections and up 
to 95% for S.prolificans in immunocompromised patients) [12, 13].
Antifungal drugs in clinical use
Based on their mode of action (Figure 1), antifungal drugs frequently administered for systemic use 
have been grouped into four classes, namely, triazoles (fluconazole, itraconazole, posaconazole, 
voriconazole, isavuconazole), echinocandins (anidulafungin, caspofungin, micafungin), polyenes 
([lipid complexes of] amphotericin B) and fluoro-pyrimidines (flucytosine [5-FC]).
Triazoles act by targeted inhibition of the cytochrome (CYP) P450 dependent enzyme lanosterol 
demethylase, thereby interrupting the synthesis of ergosterol. This inhibition leads to depletion 
of ergosterol and the accumulation of sterol precursors in the fungal cell membrane, causing 
increased membrane permeability and inhibition of fungal growth [14].
Echinocandins act by non-competitive inhibition of β-(1,3)-glucan synthase, thereby blocking 
the synthesis of this major component of the fungal cell wall. This compromises cellular structural 
integrity and morphology, ultimately resulting in osmotic lysis of the fungal cell [15].
Figure 1. Schematic overview of current antifungal agents and their mechanism of action. 
Adapted with permission from [18].
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ß - (1,3)  - glucan
Phospholipid bilayer:
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CHAPTER 1
Amphotericin B acts by binding directly to membrane sterols (especially ergosterol) in the fungal 
cell membrane. Through self-assembly of amphotericin B molecules, ionic transmembrane 
channels are formed that cause the fungal cell to leak intracellular contents (e.g. potassium), 
subsequently leading to cell death [16]. 
The pyrimidine analog 5-FC itself has no intrinsic antifungal activity, but once it has been taken 
up by fungal cells, it is converted to 5-fluorouracil (5-FU). Metabolites of 5-FU act by inhibiting the 
DNA and RNA synthesis in the nucleus of the fungal cell [17].
Clinical pharmacology of antifungal drugs
Clinical pharmacology is the scientific discipline that studies the effect of drugs in humans, 
focussing on the application and translation of basic pharmacological principles into clinical 
practice [19]. Clinical pharmacology is traditionally subdivided into two subdisciplines that involve 
the relationships between dose, drug exposure, and response in patients: the pharmacoki-
netics and pharmacodynamics of a drug. Pharmacokinetics refers to the study of absorption, 
distribution, metabolism and excretion over time, and is often referred to as “what the body 
does to the drug”. Pharmacodynamics on the other hand studies the relationship between 
drug concentration and the resulting effect, including the efficacy or therapeutic response, and 
toxicity. In general, this is defined as “what the drug does to the body”, but for antifungal drugs 
this is rather referred to as “what the drug does to the (fungal) target” [19, 20].
The relationship between the drug plasma concentrations and efficacy can be established in 
a pharmacokinetic/pharmacodynamic (PK/PD) index, which can be predictive of therapeutic 
outcomes in humans [21]. The antifungal effect is described by the shape of the concentra-
tion-time profile, which can be summarised by three parameters: the area under the plasma 
concentration-time curve (AUC), the peak plasma concentration (C
max
) and the time (T) of plasma 
antifungal drug concentrations above a certain threshold. These measures are then related to the 
minimum inhibitory concentration (MIC), which represents a standardised measure of antifungal 
potency, resulting in the PK/PD indices AUC/MIC, C
max
/MIC and T>MIC [20, 22]. 
Knowledge on the pharmacokinetics, pharmacodynamics and PK/PD indices of antifungal 
drugs are critically important in the treatment of IFDs. More specifically, appropriate selection 
of the systemic antifungal drug and subsequent dosing should be based on criteria 
such as (1) the antifungal strategy i.e. prophylaxis, diagnostic driven, empirical, or targeted 
therapy [2, 23, 24], (2) fungal species including their susceptibility to the drug, (3) focus of the 
infection, and (4) considerations relating to the pharmacokinetics and pharmacodynamics of 
these drugs [25]. In this context, the primary goal of clinical pharmacology is to focus on the fourth 
criterion and apply pharmacokinetic and pharmacodynamic principles to the safe and effective 
therapeutic management of drugs in an individual patient (and eventually patient populations) 
by increasing the efficacy and decreasing toxicity of a patient’s drug therapy [19]. 
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The clinical pharmacology of antifungal drugs may be different in special patient populations 
compared with healthy volunteers, for instance due to pathophysiologic factors or the use of 
concomitant medication increasing the risk of drug-drug interactions. Measurement of plasma 
or serum concentrations may then guide therapy with antifungal drugs. Ideally, to gain a 
better insight into the clinical pharmacology of antifungal drugs, a conceptual structure which 
serves to support further research is essential. In this thesis, we focussed on building a clinical 
pharmacology framework for the safe and effective use of triazoles and echinocandins in 
particular, as these drugs represent two important classes for the treatment of IFD (key pharma-
cokinetic parameters of both these antifungal drug classes in healthy volunteers are summarized 
in Table 1). Three aspects are addressed in this thesis: (1) antifungal pharmacokinetics in special 
patient populations, (2) antifungal drug-drug interactions, and (3) interlaboratory quality control 
and therapeutic drug monitoring.
Current challenges in the clinical pharmacology of antifungal drugs 
Antifungal pharmacokinetics in special patient populations
Traditionally, studies for registration of a drug conducted by the manufacturer (pre-approval 
studies) include healthy volunteers or highly selected patients with the focus on a single variable 
(e.g. liver -or renal function) [31]. Because the pharmacokinetics of antifungal drugs in the target 
population are likely to be influenced by numerous factors, including age (children vs. adults), 
body surface area and body composition (normal weight vs. obesity), disease status (e.g. critically 
ill and burn patients), organ dysfunction (renal and hepatic impairment) and administration 
of concomitant medications, it is often unknown if these factors alter the pharmacokinetic 
parameters (i.e. volume of distribution, clearance) of antifungal drugs and if the recommended 
dose is suitable for the target population. By performing clinical studies after regulatory 
approval of the drug (post-marketing), one can find out whether or not the concentration/effect 
relationship, and thus efficacy of the drug, is affected. For this last step, the MIC of the offending 
pathogen should also be incorporated to determine if the PK/PD target is met.
Antifungal drug-drug interactions
Among the factors known to influence the pharmacokinetics of antifungal agents, drug-drug 
interactions most probably play the most significant role. 
Drug interactions can be categorized as either pharmacokinetic or pharmacodynamic. 
Pharmacokinetic interactions are most frequent and commonly involve drug-metabolising 
enzymes or transporters. The metabolic enzymes, mainly found in the liver and intestine, are 
involved in two types of reactions. During phase I reactions, mainly catalysed by cytochrome 
P450 (CYP) enzymes, the water solubility of the parent compound is increased (mainly by 
20
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oxidation, reduction and/or hydrolysis). Phase II reactions involve conjugation of a more polar 
molecule to the parent drug or metabolised drug to further increase water solubility and 
facilitate more rapid excretion [32]. In addition, another potential mechanism for drug interactions 
is at the site of drug-transporters (e.g. P-glycoprotein (P-gp) and Breast Cancer Resistance Protein 
(BCRP]), as they mediate access of drugs to drug-metabolising enzymes and regulate drug 
concentrations in different tissues [33]. 
In general, drugs can be substrates, inhibitors and/or inducers of drug-metabolising enzymes 
and drug-transporters. Therefore, it is important to keep in mind that drug interactions between 
antifungal drugs and concomitant medications can influence the pharmacokinetics of both 
drugs (‘two-way interactions’), causing devastating effects for the patient. Because antifungal 
agents differ markedly in their affinity for metabolising enzymes and transporters, the clinical 
relevance of antifungal drug interactions varies substantially [34, 35].
Managing potential drug interactions may be challenging for clinicians and pharmacists, 
especially when multiple interacting agents are used. Adding to this complexity, theoretical 
data are not always sufficient to predict pharmacokinetic interactions, as unexpected drug 
interactions with antifungal drugs may occur. The absence of data to support an interaction does 
not mean absence of the interaction, for instance with drugs that recently received regulatory 
approval such as isavuconazole. Ideally, the healthcare professional should have access to a 
comprehensive, up-to-date overview of drug interactions with antifungal agents. This overview 
should describe the underlying mechanism and scientific evidence as well as offer tailor-made 
clinical advice on how to manage these interactions.
Interlaboratory quality control
To evaluate the pharmacokinetics of antifungal drugs in special patient populations, to assess the 
effect of drug interactions, and to be able to individualize drug dosing by means of therapeutic 
drug monitoring (TDM), an analytical assay to measure plasma or serum concentrations has to 
be available. Intralaboratory (internal) method validation and intralaboratory quality control 
procedures, such as validation of equipment and qualification of technicians, should ensure that 
bio-analytical methods have sufficient accuracy, precision and specificity. In addition, interlabo-
ratory (external) quality control or proficiency testing is essential to verify whether the methods 
of analysis and subsequent TDM results conform to expectations of the quality required for 
patient care and research [36]. For this reason, participation in proficiency testing programs should 
be mandatory for laboratories analysing antifungal drugs.
Therapeutic drug monitoring
In general, drugs used for life-threatening diseases with a proven PK/PD relationship, small 
therapeutic range, large interindividual variation in pharmacokinetics and pharmacodynamics, 
and severe adverse effects are particular good candidates for TDM [37]. By performing TDM, 
21
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one can individualise the drug dosing based on the measurement and interpretation of drug 
concentrations, usually in plasma or serum [38]. In the clinical setting, there is evidence to support 
the contention that plasma concentrations above a certain concentration may be predictive of 
efficacy for the antifungal drugs voriconazole, posaconazole, itraconazole, and flucytosine [39-42], 
though this has yet to be shown in prospective trials. The importance of TDM of these antifungals 
is acknowledged and therefore recommended in several guidelines for the treatment of 
IFDs [23, 24, 43-45]. On the other hand, trials to evaluate this practice are often not performed or data 
is not conclusive enough to support the use of routine TDM [46]. Therefore, the added value of 
TDM in clinical practice should be evaluated and demonstrated where possible. For fluconazole, 
echinocandins and polyenes, it remains to be investigated whether or not TDM can be used to 
optimize the treatment of IFDs.
Building a clinical pharmacology framework for the safe and effective use of antifungal 
agents
Despite research that has been conducted in the field of clinical pharmacology of antifungal 
drugs, several aspects remain untouched or unknown, as described in Box 1.
The overarching aim of this thesis was to improve the understanding of the clinical 
pharmacology of antifungal drugs in order to optimize their safe and effective use in patients 
at risk or suffering from IFD. In pursuit of this aim, we build a framework to prevent that the very 
same questions in future research do not have to be re-answered.
Box 1. Current challenges in the clinical pharmacology of antifungal drugs.
• The pharmacokinetics of antifungal drugs in special patient populations need to be 
elucidated
• Knowledge on the influence of concomitant drugs on the pharmacokinetics of 
antifungal drugs and vice versa remains incomplete
• For the healthcare professional, it seems impossible to be conversant with all possible 
drug interactions. Sources must be made available to facilitate rapid, bedside drug 
interaction checks
• To improve the quality of the analysis of antifungal drugs, participation of laboratories in 
proficiency testing programs should be standard practice and results of such programs 
need to be evaluated 
• The added value or impact of TDM in clinical practice should be evaluated and 
demonstrated where possible, e.g. by conducting a large, prospective trial.
22
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In this, we addressed three major topics or sections, as outlined below: Section I is devoted 
to the evaluation of the pharmacokinetics of antifungal drugs in special patient populations. 
Section II of this thesis focuses on the management of pharmacokinetic drug interactions 
between antifungal drugs and other frequently used concomitant medications in clinical 
practice. Section III of this thesis focuses on interlaboratory quality control and TDM.
Scope of this thesis
Section I. Antifungal pharmacokinetics in special patient populations
Special patient populations are subject to severely altered pharmacokinetic characteristics 
(due to e.g. physiological changes and interacting concomitant medications), which may 
compromise the safe and efficacious use of antifungal agents. In chapter 2 we reviewed the 
pharmacokinetic behaviour of echinocandins in special patient populations. In chapter 3, we 
investigated micafungin pharmacokinetics in intensive care unit patients and set out to explore 
the parameters that influence micafungin plasma concentrations in this population. In chapter 4, 
we describe the pharmacokinetics of anidulafungin in morbidly obese subjects (BMI >40kg/m2). 
Section II. Antifungal drug-drug interactions
Although prophylactic or therapeutic use of antifungal drugs has substantially improved 
treatment outcome of IFD, effective treatment is complicated by the high potential for drug 
interactions. 
In particular, the antifungal class of triazoles may interfere with the metabolism of many drugs 
causing clinically significant drug interactions [34]. In chapter 5, we provide guidance for adequate 
management of drug interactions between azoles and immunosuppressants. 
The myriad of potential drug interactions between antifungal drugs and concomitant medications 
make it almost impossible for the clinician to be conversant with these possible drug interactions. 
Their potential consequences should be assessed in the light of the individual patient, and failure to 
recognise a drug interaction may produce deleterious consequences to the patient. We describe 
the development of a real-time knowledgebase of drug interactions with antifungal agents and 
concomitant medications (available at http://www.fungalpharmacology.com), providing expert 
recommendations to clinicians on how to handle interactions with these drugs (chapter 6).
Although many drug interactions involving antifungal drugs are caused by inhibition of 
CYP-enzymes, inhibition of ABC-transporters is also a common mechanism underlying drug-drug 
interactions (see Antifungal drug-drug interactions). These efflux pumps are also thought to play 
a crucial role in the inexplicable (non-CYP mediated) drug interactions with antifungal agents. In 
chapter 7, we investigated the inhibitory potential of antifungal drugs on ABC transporters P-gp, 
MRP1–5, BCRP and BSEP in vitro.
23
Introduction
Section III. Interlaboratory quality control and therapeutic drug monitoring
In 2007, Radboud university medical center initiated an international proficiency testing (PT) 
program for the measurement of azole antifungal drugs [47]. We evaluated the 5 year data of 
the PT program (2008–2012), aiming to assess the overall performance of laboratories as well as 
possible explanations for inaccuracies (chapter 8). 
In clinical practice, TDM can be of great benefit in patients receiving voriconazole. In pediatric 
patients, it has been demonstrated that interpatient variability in voriconazole exposure is large 
[48, 49]. Dose targeting based on TDM may therefore help to individualize the voriconazole doses 
and optimize treatment. In chapter 9, we assessed the impact of TDM-based dose adaptations 
on voriconazole target attainment in pediatric patients. 
Finally, we complete this thesis with a general discussion (chapter 10) that addresses the clinical 
impact of our research. The main findings in this thesis will be reviewed and placed in perspective 
of future research on antifungal agents. 
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Abstract 
Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs 
are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin 
and micafungin. While their antifungal activity overlaps, there are substantial differences in 
pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins 
including age (pediatrics vs adults), body surface area and body composition (normal weight 
vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney 
and liver impairment). Subsequent effects of altered exposure might impact efficacy and 
safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a 
specific patient or patient population. This review provides up-to-date information on PK data of 
anidulafungin, caspofungin and micafungin in special patient populations. Patient populations 
addressed are neonates, children and adolescents, obese patients, patients with hepatic or 
renal impairment, critically ill patients (including burn patients) and patients with hematologic 
diseases
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Introduction
Patient populations at risk of developing invasive candidiasis or candidemia are the lowbirth 
weight premature neonates, patients admitted to intensive care units (ICU) and patients 
with underlying immunodeficiencies (e.g. HIV, leukemia). In addition, advanced age, renal- or 
hepatic impairment, neutropenia, immune suppression, catheter use, total parenteral nutrition, 
abdominal surgery, the use of broad-spectrum antibiotics and mechanical ventilation are 
associated risk factors [1, 2]. Invasive candidiasis contributes highly to morbidity and mortality in 
these patient populations [3, 4].
Echinocandins are first line treatment for non-neutropenic and neutropenic adult and pediatric 
patients with candidemia or a suspected invasive candidiasis with distinguished differences in label 
indications between the echinocandins [5-13]. An overview of the labeled indications is provided 
in Table 1. The group of echinocandins consists of three drugs: anidulafungin, caspofungin 
and micafungin. Echinocandins are selective inhibitors of the synthesis of β-(1,3)-D-glucan, an 
integral component of the fungal cell wall which is absent in human cells [11-13]. This results in 
osmotic fragile cell walls and ultimately lysis of fungal cells [14].
For treatment of Candida infections in adults, all available guidelines have given comparable 
recommendations for the echinocandins; for pediatric patients the recommendations differ per 
drug, as shown in Table 2 [5-10]. 
Importantly, typical patient categories in whom Candida infections occur suffer from underlying 
predisposing diseases characterized by highly variable physiology that may cause changes 
in volume of distribution, protein binding, and metabolism or clearance [15-18]. As exposure to 
echinocandins is thought to be the intermediary link between the doses administered and 
responses achieved, these differences in exposures are likely clinically relevant. Indeed, evolving 
in vitro data, results from experiments in animal models, and a clinical study, suggest that systemic 
plasma concentrations of echinocandins relate to the clinical response [19-21].
Table 1. Label indications.
Anidulafungin [13] Caspofungin [11] Micafungin [12]
Treatment of invasive candidiasis in adult or pediatric patients + +
Treatment of invasive candidiasis in adult (non-)neutropenic patients +
Treatment of invasive aspergillosis in adult or pediatric patients who 
are refractory to or intolerant of amphotericin B, lipid formulations of 
amphotericin B and/or itraconazole
+
Empirical therapy for presumed fungal infections (such as Candida or 
Aspergillus in febrile, neutropenic adult or pediatric patients
+
Treatment of esophageal candidiasis in patients for whom intrave-
nous therapy is appropriate
+
Prophylaxis of Candida infection in patients undergoing allogeneic 
hematopoietic stem cell transplantation or patients who are expected 
to have neutropenia (absolute neutrophil count <500 cells/μl) for 10 
or more days
+
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Clearly, there is an urgent need for a comprehensive and up-to-date overview on the effect of 
patient characteristics and disease states on the pharmacokinetics (PK) of the echinocandins. 
Knowledge on the population PK of echinocandins in specific conditions could be translated 
into individual patients in an attempt to optimize echinocandin drug exposure and the outcome 
of Candida infections and to use or not to use these drugs in their best way possible.
Therefore, in this review an overview of the PK of the three licensed echinocandins, anidulafungin, 
caspofungin and micafungin, is provided. After a general introduction of PK mainly based on 
data in healthy volunteers, we selected the following special patient populations for in-depth 
review – neonates, children and adolescents, obese patients, patients with hepatic impairment, 
patients with renal impairment, critically ill patients (including burn patients) and patients with 
hematologic diseases. Next we put these PK data into perspective and consider priorities for 
future research.
Methodology
A literature search was conducted in August 2014 using search engines PubMed and Embase. 
Search terms included ‘echinocandin’, ‘anidulafungin’, ‘caspofungin’, ‘micafungin’, ‘pharmacoki-
netics’ and ‘pharmacodynamics’ and the search was restricted to human data. A total of 110 
articles were selected by the authors based on the abstracts, of which 72 were included for 
this review. Snowballing from reference lists of identified articles was used to obtain additional 
articles.
Table 2. European Society of Clinical Microbiology and Infectious Diseases recommendations for use of echinocandins in neonates and 
children [7].
Explanation of strength of ESCMID recommendation and quality of evidence: A: strong support for recommendation for use; B: moderate support 
of recommendation for use; C: marginal support for recommendation of use; D: recommendation against use. Level I: evidence from at least on 
properly designed randomized controlled trial; Level II: evidence from at least on well-designed clinical trial, without randomization; from cohort 
of case-controlled analytic studies (preferably from more than one centre); from multiple time series; or from dramatic results of uncontrolled 
experiments; Level III: evidence from opinions of respected authorities, based on clinical experience, descriptive case studies[123].
Anidulafungin Caspofungin Micafungin
Invasive candidiasis in neonates BII
Invasive candidiasis in pediatric hematological stem cell transplant patients AI
Invasive candidiasis treatment in children BII AI AI
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General PK of echinocandins
Anidulafungin
Anidulafungin is a semi-synthetic lipopeptide which is synthesized from a fermentation product 
of Aspergillus nidulans [22]. It is administered by intravenous infusion (200 mg loading dose on 
the first day of treatment, followed by 100 mg once daily [q.d.]). To prevent infusion-associated 
reactions (such as dyspnea, angioedema, hypotension and bronchospams caused by histamine 
release), the maximum rate of infusion is 1.1 mg/min. PK parameters in healthy volunteers of 
anidulafungin are described in detail in Table 3.
Absorption, distribution, metabolism, elimination 
Bioavailability after oral administration is very limited (2–7%) with a high variability in PK 
parameters [22]. Therefore, all clinical studies have been performed with intravenous adminis-
tration of anidulafungin. Anidulafungin shows linear PK after doses of 15–300 mg [22-24]. Plasma 
concentrations comparable with steady-state conditions are reached at the second dose after a 
loading dose of 200 mg on day 1 of treatment, followed by 100 mg q.d. thereafter [22, 25]. 
Protein binding is approximately 99% [22]. The volume of distribution is approximately 0.6 l/kg [22]. 
Anidulafungin undergoes non-enzymatic metabolism to a ring-opened, linear peptide that 
lacks antifungal activity [26]. This degradation product is further degraded to tertiary products via 
an enzymatic pathway [26]. Anidulafungin intact drug (<10%) and tertiary degradation products 
are eliminated via the bile in feces; almost no intact drug or degradation products are found in 
urine (<1%), indicating negligible renal clearance [22, 26]. The elimination half-life is approximately 
24 h. Total body clearance (1 l/h) is independent of dose or repeated administration [22].
Table 3. Steady-state pharmacokinetic parameters of anidulafungin, caspofungin and micafungin in healthy volunteers.
CL: Clearance; N/A: Not available T1/2: Half-life time; Vd: Volume of distribution.
Anidulafungin Caspofungin Micafungin (100mg)
Loading dose 200 mg 70 mg No loading dose
Daily dose 100 mg 50 mg 50-150 mg
AUC0-24 (mg∙h/l) 110 97.6 132.6
Cmin (mg/l) 3.3 1.4 N/A
Cmax (mg/l) 7.2 12.1 8.8
Vd (l/kg) 0.6 N/A 0.25-0.27
CL (l/h) 0.96 0.63 0.63
T1/2 (h) 40-50 10.6 (β-phase) 14.7
Protein binding 99% 97% >99%
Ref. [22] [32, 35, 104] [12, 42, 45, 84]
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Drug-drug interactions
As anidulafungin does not have any cytochrome P450 (CYP450) involvement, few clinically 
relevant metabolic drug interactions can be expected [13]. No clinically relevant changes occurred 
in PK of anidulafungin when co-administered with cyclosporine A, voriconazole, tacrolimus, 
amphotericin B and rifampin [13, 27-31]. 
Safety
Anidulafungin is considered relatively safe. Very common adverse effects (≥1:10) include 
hypokalemia, diarrhea, and nausea; common adverse effects (≥1/100 to <1/10) are hyperglycemia, 
convulsions, headache, hypo- and hypertension, bronchospasms, dyspnea, vomiting, increases 
in alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin, cholestasis, rash, 
pruritus and increases in serum creatinine [13]. 
Caspofungin
Caspofungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Glarea 
lozoyensis [11]. It is administered by intravenous infusion in a recommended dose of a single 
70 mg loading dose on the first day of treatment, followed by 50 mg q.d. Dose adjustments 
are advised in patients >80 kg (regular loading dose followed by an augmented maintenance 
dose of 70 mg q.d.) and patients with moderate or severe hepatic impairment classified by the 
Child-Pugh scoring system (regular loading dose on day 1 followed by a reduced maintenance 
dose of 35 mg q.d.). PK parameters of caspofungin are described in detail in Table 3.
Absorption, distribution, metabolism, elimination 
Caspofungin shows linear PK after single doses of 15–210 mg, but modest nonlinear PK was 
observed after multiple dosing [32, 33]. Caspofungin exposure (AUC0-24) and trough concentrations 
(Cmin) increase after multiple dosing; the amount of accumulation is dose-dependent [32]. After 
a loading 70 mg loading dose on day 1 followed by 50 mg q.d., steady state is reached around 
day 6 [32]. 
Protein binding of caspofungin, mostly to albumin, is population-dependent ranging from 
approximately 92% in patients with invasive candidiasis to approximately 97% in healthy 
volunteers [11]. Immediately after infusion of single and multiple doses, a short distribution phase 
(α-phase) is followed by a dominant β-phase of 11 h post-dosing, which is followed by a γ-phase 
of 2–3 days at low doses, and even longer at higher doses [32].
Caspofungin degrades spontaneously to a ring-opened intermediate compound (M0). Further 
metabolism occurs through peptide hydrolysis and subsequent N-acetylation to more polar 
metabolites (M1 and M2) [11].
Elimination of caspofungin is very slow (~0.6–0.7 l/h) [34]. About 24–30 h post dose, the major 
component in plasma and urine is unchanged caspofungin, with the M0-metabolite being a 
minor component [35]. Five days post-dose, the major component in plasma is the M0-metabolite, 
while the major components in urine were the M1- and M2-metabolites [35]. Over 27 days 75% of 
37
Antifungal pharmacokinetics in special patient populations 
the administered dose is excreted via urine and feces (40% and 34% respectively) [34, 35].
Drug-drug interactions
Caspofungin does not interact with CYP450 isoenzymes. Moreover, it is not a substrate for 
P-glycoprotein. Caspofungin is transported into hepatocytes by the hepatic transport protein 
OATP1B1 [36]. Interactions between caspofungin and other drugs have been established: 
cyclosporine A increases caspofungin exposure (AUC) by approximately 35% with unaltered 
cyclosporine A exposure [37]. Caspofungin reduces tacrolimus exposure, maximal plasma 
concentration (Cmax) and Cmin by 20, 16 and 26%, respectively [38]. Rifampin causes an increase in 
caspofungin exposure of 60% on day 1 of and a decrease of 30% on day 14, possibly caused by 
initial inhibition and subsequent induction of transporter proteins [39]. When co-administered 
with CYP450 enzyme-inducers (e.g. rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, 
carbamazepine and etravirine), a dose increase of caspofungin is advised [11]. Co-administration of 
caspofungin with itraconazole, amphotericin B, nelfinavir and posaconazole does not influence 
PK of either drug [11, 38-40]. 
Safety
Adverse events of caspofungin up to 150 mg q.d. are mild and rarely lead to treatment 
discontinuation and appear not to be dose-dependent [11, 41]. No very common adverse reactions 
(>1/10) were observed [11]. Common adverse events (≥1/100 to <1/10) are decreased hematocrit 
levels, decreased white blood cell count, hypokalemia, headache, phlebitis, dyspnea, nausea, 
diarrhea, vomiting, increase in liver enzymes (ALT, AST, alkaline phosphatase and bilirubin), 
rash, pruritus, erythema, hyperhidrosis, arthralgia, pyrexia, chills, infusion site pruritus and 
hypoalbuminemia [11].
Micafungin
Micafungin is a water-soluble cyclic semi-synthetic hexapeptide synthesized from a fermentation 
product of Coleophoma empetri F-11899 [42]. It is administered by intravenous infusion; the 
recommended dose depends on the indication but ranges from 50 to 150 mg q.d. in patients 
>40 kg and from 1 to 3 mg/kg q.d. in patients ≤40kg [12]. If the patient’s response is inadequate, 
the daily dose can be increased to 200 mg/day in patients >40 kg or to 4 mg/kg in patients 
<40 kg [12]. In contrast to anidulafungin and caspofungin, micafungin does not require a loading 
dose. PK parameters of micafungin are described in detail in Table 3.
Absorption, distribution, metabolism, elimination 
Micafungin shows linear PK over a dose range of 12.5–200 mg q.d. and 3–8 mg/kg q.d. [12]. Steady 
state is usually reached within 4–5 days [12].
Plasma protein binding of micafungin is >99%, primarily to albumin, and independent of 
micafungin plasma concentration [42]. It is rapidly distributed into tissues and fluids, with a 
bi-exponential decline in plasma concentration [12]. Volume of distribution at steady state is 
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approximately 18–19 l [12].
Micafungin is the principal circulating form in the systemic circulation [12]. Several CYP isoenzymes 
and both hepatic enzymes arylsulphatase and catechol-O-methyltransferase are involved in the 
biotransformation of micafungin, which partly undergoes oxidative metabolism to M1 (catechol 
form), M2 (methoxy form) and M5 (after hydroxylation of the side chain). Exposure to metabolites 
is low, with approximately 6.5% of the amount of circulating micafungin parent compound 
metabolized to these compounds [12]. In vitro, M2 has similar potency and spectrum of activity as 
the parent compound [12]. 
Total clearance of micafungin is approximately 0.63–1.26 l/h and does not depend on dose [12]. 
The terminal half-life is 14–15 h [42]. Over 28 days, 83% of the administered dose is excreted, of 
which 12% in urine and 71% in feces, all of which are metabolites. [12]. 
Drug-drug interactions
Even though micafungin is a substrate for CYP3A in vitro, hydroxylation by CYP3A is not a major 
pathway for micafungin metabolism in vivo. Moreover, micafungin does not inhibit P-glycoprotein 
[12, 43]. No dose adjustments are needed when micafungin is co-administered with mycophenolate 
mofetil, cyclosporine A, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, 
rifampicin, itraconazole, posaconazole, voriconazole and amphotericin B [12, 40, 44-48]. Micafungin 
increases exposure to itraconazole (22%), sirolimus (21%) and nifedipine (18%) with no further 
clinical significance [12]. Caution should be exercised upon co-administration of micafungin and 
amphotericin B, as micafungin increases exposure to amphotericin B by 30% [49].
Safety
The European Medicine Agency, but not the US FDA, has issued a black box warning for the 
development of foci of altered hepatocytes and hepatocellular tumors, which has been observed 
in rats treated with micafungin for a period of 3 months or longer [12]. The clinical consequence 
of this warning remains subject to debate as up until today no solid evidence has emerged on 
the existence of hepatocellular tumors in humans despite the fact that micafungin is one of the 
most commonly used echinocandins. Common adverse effects (≥1/100 to <1/10) of micafungin 
are leukopenia, neutropenia and anemia, hypokalemia, hypomagnesemia, hypocalcemia, 
headache, phlebitis, nausea, vomiting, diarrhoea, abdominal pain, increases in liver enzymes (AP, 
ALT, AST, bilirubin), rash, pyrexia and rigors [12].
PK in neonates, infants, children & adolescents
Developmental changes in neonates (<1 month), infants (1 month–2 years), children (2–12 
years) and adolescents (>12 years) influence the PK behavior of many different types of drugs. 
Several developmental changes are possibly of influence on echinocandin PK. Altered body 
composition (increased total body water and extracellular water in infants), reduced plasma 
protein binding and higher permeability of the blood-brain barrier could possibly influence the 
volume of distribution of drugs [15, 50, 51]. Hepatic metabolism might be immature at birth and the 
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development of metabolic enzymes (both Phase I and Phase II enzymes) differs for each enzyme 
and for each individual [15, 50, 52]. Due to reduced glomerular filtration rate, renal blood flow, plasma 
protein binding, renal excretion and tubular secretion are reduced in newborns compared with 
adults and differ highly between preterm and term infants [15, 50].
Invasive Candida infections in premature neonates are often complicated by the occurrence of 
meningoencephalitis (prevalence 15–20%) [4, 53]; therefore adequate exposure in CSF has to be 
achieved and blood-brain barrier passage of echinocandins is of particular interest in neonates 
with invasive candidiasis.
Recently, two reviews have been published focussing on the PK and pharmacodynamics of 
antifungals in pediatrics [54, 55]; a more detailed overview on PK of echinocandins in the pediatric 
subpopulations will be given in the next paragraphs and are summarized in Table 4.
Table 4. Pharmacokinetic parameters in (premature) neonates, infants, children and adolescents (plus range for anidulafungin and 
micafungin and 95% CI for caspofungin).
CL: Clearance; D: day; m: Month; Vd: Volume of distribution; y: Year.
Drug and daily 
dose Age
Patients 
(n) AUC0-24 (mg∙h/l) Cmax (mg/l) Vd (l/kg) CL (l/kg/h) Ref.
Anidulafungin
1.5 mg/kg <30 d 8 74.9 (30.4-108.9) 3.9 (2.2-6.7) 1.7 (0.5-4.4) 0.020 (0.013-0.049) [56]
1.5 mg/kg ≥30d-1.5 y 6 97.7 (54.8-278.0) 5.2 (3.6-14.9) 0.9 (0.2-2.8) 0.015 (0.005-0.027) [56]
0.75 mg/kg 2-17 y 12 48.6 (16.5-79.8) 3.83 (0.91-5.98) 0.54 (0.16-0.96) 0.018 (0.010-0.045) [57]
1.5 mg/kg 2-17 y 13 99.5 (43.2-155.7) 7.23 (3.71-12.3) 0.43 (0.31-0.73) 0.016 (0.009-0.031) [57]
Caspofungin
25 mg/m2 neonates 12 N/A 11.1 (8.8-13.9) N/A N/A [58]
50 mg/m2 3 -24 m 9 130.3 (105.3-161.3) 17.2 (13.8-21.5) N/A 0.363 (0.295-0.447) [60]
50 mg/m2 2-11 y 10 115.2 (94.2-140.9) 15.6 (12.6-19.3) N/A 0.467 (0.392-0.556) [60, 61]
70 mg/m2 2-11 y 12 161 20.9 N/A 0.359 [61]
50 mg/m2 12-17 y 8 117.2 (94.7-145.0) 12.9 (10.3-16.1) N/A 0.378 (0.311-0.460) [60, 61]
Micafungin
0.75 mg/kg Prem neon 6 19.0 (10.3-28.3) 2.5 (1.6-3.6) 0.40 (0.28-0.57 0.039 (0.022-0.069) [63]
1 mg/kg Prem neon 6 34.5 (29.7-42.1) 4.2 (2.6-5.6) 0.44 (0.39-0.53) 0.039 (0.028-0.047) [63]
3 mg/kg Prem neon 6 69.0 (48.9-93.1) 9.3 (2.1-15.4) 0.47 (0.29-0.66) 0.039 (0.026-0.052) [63]
7 mg/kg Prem neon 7 258.1 (162.6-643.2) 23.3 (17.4-48.1) 0.34 (0.24-0.59) 0.024 (0.012-0.036) [64]
10 mg/kg Prem neon 6 291.2 (185.3-460.5) 24.9 (19.2-40.0) 0.54 (0.36-0.56) 0.036 (0.024-0.048) [64]
15 mg/kg Prem neon 12 437.5 38.4 1.51 0.035 [66]
4.5 mg/kg 4m-<2 y 9 299.4 (188.0-622.2) 32.8 (18.2-84.8) N/A 0.017 (0.007-0.024) [72]
4.5 mg/kg 2-5 y 31 248.9 (110.0-335.4) 21.1 (8.4-28.7) N/A 0.020 (0.013-0.041) [72]
3 mg/kg 6-11 y 13 247.5 (191.8-300.1) 20.8 (16.8-24.8) N/A 0.012 (0.010-0.015) [72]
4.5 mg/kg 6-11 y 20 278.4 (245.7-325.2) 20.7 (17.9-24.0) N/A 0.016 (0.014-0.018) [72]
3 mg/kg 12-16 y 12 193.3 (158.9-240.1) 20.5 (12.2-44.5) N/A 0.014 (0.010-0.019) [72]
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Anidulafungin
Of the three echinocandins, anidulafungin is the only echinocandin not labeled for use in these 
populations. Experience in controlled trials with anidulafungin in neonates and children has 
been limited due to possible deleterious effects of polysorbate 80 (a surfactant and emulsifier), 
which is an excipient of the anidulafungin formulation. The exact amount of polysorbate 80 in 
these formulations and a threshold for toxicity has not been established.
Neonates & infants
PK parameters were comparable between neonates and infants receiving a 3 mg/kg loading 
dose and 1.5 mg/kg maintenance dose [56]. Using this regimen in neonates and infants similar 
exposure was obtained when compared with children and adolescents (2–17 years) receiving 
the same weight-adjusted dose and compared with adult patients receiving the standard adult 
dose [56].
Children & adolescents
A dose proportional increase in exposure was observed after administration of 0.75 and 
1.5 mg/kg q.d. (both after including loading dose of 1.5 and 3 mg/kg on day 1 respectively) in 
children and adolescents, respectively [57]. Body weight, but not age, influenced inter patient 
variability in clearance and volume of distribution. Exposure found in this patient population 
after administration of weight-based dosages of 0.75 and 1.5 mg/kg q.d. was similar to exposure 
seen in adults treated with 50 and 100 mg q.d., respectively [57].
Caspofungin
Neonates & infants
Limited data suggest that caspofungin at 25 mg/m2 q.d. in neonates and infants <3 months of age 
and 50 mg/m2 q.d. in infants (3 months–2 years) led to similar Cmax compared with adult patients 
receiving 50 mg q.d. [58]. In neonates and infants, Cmin was slightly elevated in comparison with 
older children and adult patients receiving 50 mg/m2 and 50 mg q.d., respectively [58]. Reduced 
hepatic uptake through OATP1B1 in neonates and infants might explain this observation [58].
Limited data on caspofungin concentrations in CSF of neonates showed undetectable to low 
(0–0.16 mg/l) concentrations at a dose of 25 mg/m2 on the first day of therapy [58, 59], but increased 
during treatment resulting in effective CSF concentrations (varying between 0.15 and 0.27 mg/l 
with a CSF/plasma ratio of 6.8%) [59].
Neely et al. showed that children aged 3–24 months receiving 50 mg/m2 q.d. had significant 
higher AUC0-24 and Cmax but similar Cmin on day 1 of therapy compared with adult patients 
receiving 50 mg q.d. [60]. The β-phase half life was shorter in these children compared with adult 
patients (33% decrease) [60]. After multiple doses, Cmax and β-phase half life were still significantly 
different, while AUC0-24 was similar to adult patients [60]. This was also seen when compared with 
PK parameters of adult patients receiving 70 mg q.d. [60].
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Children & adolescents
Walsh et al. described that children aged 2–11 years receiving 1 mg/kg q.d. (max 50 mg) showed 
substantially lower AUC0-24, Cmin and β-phase half life (41% decrease, 67% decrease and 37% 
decrease, respectively) compared with adults receiving 50 mg q.d.; these PK changes were also 
observed in adolescents (12–17 years) receiving 1 mg/kg q.d. [61]. Furthermore, doses of 50 mg/m2 
in children lead to similar or slightly elevated AUC0-24 compared with exposure in adult patients 
receiving dosages of 50 mg q.d. for mucosal candidiasis [61]. Although exposure was identical, 
children’s Cmax was increased with 66–82% while Cmin was decreased by 28% and β-phase half 
life was shorter by 35–37% compared with adults [61].
Adolescents receiving 50 mg/m2 q.d. showed comparable exposure compared with adult 
patients receiving the fixed dose of 50 mg q.d., but the adolescents had an increased Cmax and 
decreased (β-phase) half life [61]. Comparing PK parameters of adolescents with adults receiving 
70 mg q.d., AUC0-24 and Cmin were statistically lower in adolescents (24 and 35%, respectively) [61]. 
Therefore the authors suggested that a somewhat higher absolute dose in adolescents could be 
necessary to achieve similar PK parameters as adult patients receiving 50 mg q.d. [61]. Compared 
with children aged 3–24 months receiving the same dosage per m2, adolescents had a significantly 
lower AUC0-24 and Cmax on day 1, but these differences diminished after multiple dosages [61]. In 
addition, β-phase half life values during the whole treatment period were lower, showing less 
accumulation of caspofungin in children (3–24 months) compared with adolescents (12–17 years) 
and adults [60]. A population based model showed disease state (invasive aspergillosis, invasive 
candidiasis and new onset fever and neutropenia) and weight to be predictive determinants of 
caspofungin PK parameters (AUC0-24 and Cmin for disease state and Cmax for weight, respectively) 
in all children [62].
In summary, in younger children (3–24 months) a higher AUC0-24 and Cmax and a shorter half-life 
time were observed, while in older children (2–17 years) a lower AUC0-24, Cmax and half-life time 
were observed when compared with adult patients.
Micafungin
Neonates and infants
Micafungin has been well studied in neonates and infants compared with the other two 
echinocandins. Premature infants weighing 500–1000 g receiving a single dose of 0.75 mg/kg 
and premature infants weighing >1000 g receiving a single dose of 0.75, 1.5 or 3 mg/kg show 
dose proportionality for AUC0-24 and Cmax and no statistically significant differences in clearance, 
half-life time and volume of distribution [63]. Clearance (per kg bodyweight) of neonates of 
500–1000 g was higher compared with neonates >1000 g [63, 64]. There are conflicting data about 
differences in half-life time and volume of distribution between both groups [63, 64]. The mean 
clearance in neonates >1000 g was approximately 1.7-fold and 2.6-fold greater compared with 
clearance in children from 2 to 8 years and children from 9 to 17 years, respectively [63]. Volume of 
distribution was higher in premature neonates compared to older children as well [63]. A higher 
volume of distribution and clearance were observed as well in very low birth weight infants 
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receiving a prophylactic dose of 1 mg/kg q.d. [65]. 
The higher clearance might be due to alternative metabolic pathways and a higher unbound 
fraction of micafungin [66, 67]. An increase in volume of distribution can be explained by the 
changes in body composition, since the volume of distribution of micafungin is almost 
equal to the extracellular fluid space [12, 15, 63]. Compared with exposure in adult patients with 
invasive candidiasis and esophageal candidiasis, lower exposure was observed in neonates 
receiving a single dose of 0.75–3 mg/kg [63]. Higher dosages might be needed in infants to 
achieve adequate exposure. Increased dosages of 10 mg/kg and 15 mg/kg in neonates have 
resulted in similar exposure as doses of 3–4 mg/kg and 5 mg/kg in adults, respectively [64, 66]. 
Importantly, the increased exposure leads to adequate CSF levels for the treatment of Candida 
meningoencephalitis [64].
Children & adolescents
Of the three echinocandins, micafungin is also the most studied in pediatric patients aged 2–17 
years. Dose ranges of 0.5–3 mg/kg q.d. and 0.5–6.0 mg/kg q.d. have been studied in children 
aged 1–17 and 2–13 years, respectively [64, 68-72]. Observed Cmax and AUC0-24 increased in a dose-pro-
portional manner [68, 69], while clearance and volume of distribution remained constant across 
the mentioned dosage ranges, but clearance and volume of distribution were significantly 
greater (1.3–1.5 times) in children aged 2–8 years compared with children aged 9–17 years [68]. A 
population PK study showed the need for higher (nearly twofold) weight-adjusted dosages in 
children weighing 10–20 kg in comparison with children weighing >20 kg in order to achieve the 
same mean exposure [73]. Most PK studies showed an inverse correlation of weight and/or age 
with clearance for micafungin, except for two studies that did not show statistically significant 
differences in clearance and half-life between younger and older children [69, 71]. 
PK in varying body size composition 
With the increase of bodyweight PK of echinocandins might be altered due to changes in 
volume of distribution and/or clearance. Furthermore, PK in obese patients might be altered 
due to a shift toward more fat tissue in relation to body weight, changes in plasma protein 
constituents, a possible change in hepatic metabolism (e.g. increased glucuronidation) and an 
increase in clearance [17, 74, 75]. PK data of echinocandins in obese patients are scarce.
Anidulafungin
No studies have been published regarding the influence of obesity on the PK of anidulafungin. 
In healthy volunteers, an increase in body weight was shown to increase clearance and volume 
of distribution by <20%, which was not considered to be clinically important [31]. A population 
PK analysis showed body weight to be a significant covariate as AUC decreased with an increase 
in body weight (AUC in a patient weighing 40 kg being 13% higher than in a patient weighing 
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60 kg) [76]. Within a cohort of critically ill patients receiving anidulafungin, a patient of 240 kg 
required 150 mg anidulafungin to achieve similar exposure compared with normal weight 
subjects [77] but it remains unclear if the low exposure was caused by obesity or that it is the 
result of inter patient variability.
Caspofungin
Patients weighing >80 are advised to receive 70 mg q.d. after a regular loading dose on day 1 [11]. 
Lower Cmin concentrations (decreased by 28%) were predicted in surgical ICU patients weighing 
>75 kg [78]. These results were in contrast to a general ICU population and in hematopoietic 
stem cell transplantation recipients where body weight (range 50–99 kg) and BMI were found 
not to influence caspofungin PK [79, 80]. One study formally addressing the effect of obesity on 
caspofungin (weight range 50–150 kg) PK demonstrated no relationship between BMI and 
caspofungin PK; yet an increase in body weight (but not BMI) was found to increase volume of 
distribution and clearance of caspofungin, leading to a decrease in Cmax and AUC (although the 
authors were unable to define a mathematical relationship) [81].
Micafungin
The influence of weight on clearance of micafungin in adult patients was reported in several 
studies, with 66 or 66.3 kg being reported as a breakpoint (in patients weighing ≥66.3 kg, AUC was 
decreased compared with patients weighing <66.3 kg) [82-85]. The relationship between weight and 
clearance in patients ≥66 kg was described by the equation clearance = 1.04 × (weight/66)0.75 [83].
In a critically ill morbidly obese patient weighing 230 kg, the micafungin plasma Cmax was 
significantly lower than in other non-morbidly obese patients (2.93 vs. 5.5 mg/l in hematopoietic 
stem cell transplant recipients), probably caused by enhanced clearance as well [86]. Identical to 
the case of anidulafungin it remains unclear if this is caused by natural variability or attributable 
to changes in PK due to overweight. 
PK in patients with hepatic impairment
Hepatic impairment could influence the PK of many different types of drugs by changes in 
biotransformation of drugs (decreased activity of CYP450 isoenzymes and glucuronidation), 
decreases in biliary excretion and altered plasma protein binding leading to changes in 
distribution and excretion [87]. The Child–Pugh score is a measure of hepatic impairment 
predictive of mortality but is not predictive of the ability of the liver to metabolize drugs [79]. 
Detailed PK parameters are described in Table 5.
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Anidulafungin
No significant changes in PK are observed in patients with mild and moderate hepatic impairment 
when compared to healthy volunteers [88]. However, patients with severe hepatic impairment 
show significant decreased AUC and Cmax values compared with healthy volunteers [88]. AUC 
and Cmax are decreased by 33 and 36% respectively. Clearance and volume of distribution are 
increased by 57 and 78%, respectively [88] but were not considered clinically relevant by the 
authors. However, the most likely explanation for this lower exposure is an increase in volume 
of distribution caused by ascites and edema [88]. In a single severely hepatic impaired patient 
requiring albumin dialysis, anidulafungin PK did not seem to be affected [89]. 
Caspofungin
AUC
0-∞
 was increased by 55 and 76% in patients with mild and moderate hepatic impairment, 
respectively; Cmin and β-phase half life were increased as well in comparison with healthy 
volunteers [90]. After multiple dose administration of caspofungin (70 mg loading dose, followed 
by 35 mg q.d.), moderate PK changes were observed in mild hepatic impairment patients, but 
these changes were not considered clinically relevant [90]. More specifically, on days 1, 7 and 14 
AUC0-24 increased by 17, 26 and 21%, respectively; whereas on days 1, 7 and 14 Cmin increased 
with 50, 70 and 44%, respectively [90]. Multiple dose administration of caspofungin (70 mg 
loading dose followed by 35 mg q.d.) to patients with moderate hepatic impairment showed no 
Table 5. Pharmacokinetic parameters in patients with varying degrees of hepatic impairment by Child-Pugh classification (standard 
deviation for anidulafungin and micafungin).
CL: Clearance; Vd: Volume of distribution.
Drug and (daily) 
dose
Degree of hepatic 
impairment Patients (n) AUC0-24 (mg∙h/l) Cmax (mg/l) Vd (l/kg) CL (l/h) Ref.
Anidulafungin
50 mg Mild 6 56.0  (± 11.7) 2.2 (± 0.3) 0.479 (± 0.115) 0.93 (± 0.22) [88]
50 mg Moderate 6 68.8 (± 14.5) 2.3 (± 0.5) 0.534 (± 0.117) 0.76 (± 0.20) [88]
50 mg Severe 6-7 46.6 (± 14.1) 1.8 (± 0.8) 0.647 (± 0.217) 1.16 (± 0.34) [88]
Caspofungin
70mg loading 
50 mg q.d.
Mild 8 107.59 9.15 N/A N/A [90]
70mg loading 
35 mg q.d.
Moderate 8 116.22 8.82 N/A N/A [90]
Micafungin
100 mg Moderate 8 97.5 (± 19) 7.0 (± 1.9) 0.212 (± 0.037) 1.07 (± 0.17) [84]
100 mg Severe 8 100.1 (± 34.5) 7.3 (± 2.4) 0.272 (± 0.077) 1.10 (± 0.35) [95]
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significant differences in AUC0-24 on days 7 and 14 as compared with healthy volunteers receiving 
the standard dose; Cmax and Cmin were decreased by 20 and 23% and by 71 and 50% on days 7 
and 14, respectively [90]. A maintenance dose reduction to 35 mg q.d. in patients with moderate 
or severe hepatic impairment, as classified by Child-Pugh score, is advised as caspofungin PK is 
affected by the degree of hepatic impairment [11, 90]. Even though the patient populations were 
small (6–8 patients for each degree of hepatic impairment) these results are the rationale for 
dose adjustment in patients with moderate and severe hepatic impairment [90]. The differences 
in caspofungin PK in hepatically impaired patients are possibly due to decreased clearance 
mediated by the uptake transporter OATP1B1 in hepatocytes [90]. In contrast, case reports of 
patients  with mild to moderate hepatic impairment treated with caspofungin 70 or 50 mg q.d. 
showed that dose reductions to 35 mg would possibly have lead to suboptimal exposure of 
caspofungin [91-93]. 
Pediatric patients with hepatic impairment, similar to adult patients, demonstrate high variability 
of caspofungin exposure; PK parameters after a daily dose of 1 mg/kg range from being 
comparable with adult patients to less than half of those seen in adults (AUC0-24, Cmax and Cmin) 
in combination with significant increases in clearance and volume of distribution (155 and 218%, 
respectively) [94]. 
Micafungin
Micafungin exposure in patients with moderate and severe hepatic impairment is decreased in 
comparison with healthy volunteers (98 mg • h/l in patients with moderate hepatic impairment 
vs 126 mg • h/l in healthy volunteers and 100 mg • h/l in patients with severe hepatic impairment 
vs 142mg • h/l in healthy volunteers, respectively) [84, 95]. There is no change in the unbound 
fraction of micafungin in patients with both moderate and severe hepatic impairment compared 
with healthy volunteers [84, 95]. Interestingly, patients with severe hepatic impairment have higher 
plasma concentrations of the M5 metabolite, compared with healthy volunteers [95], possibly due 
to reduced clearance of the M5 metabolite. For patients with both moderate and severe hepatic 
impairment, the differences in exposure was not considered clinically relevant, as a consequence 
no dose adjustments are advised for patients with any grade of hepatic impairment [84, 95]. In 
accordance, in living donor liver transplant recipients, micafungin PK was comparable with 
healthy subjects [96-98]. The latter result was striking as another study demonstrated that higher 
bilirubin levels correlated with higher concentration/dose ratios [97].
PK in patients with renal impairment
Renal impairment and renal replacement therapy influence the excretion of many different 
types of drugs. Renal impairment influences the elimination of drugs and may influence hepatic 
metabolism as well by affecting hepatic blood flow, increasing or decreasing the activity of 
hepatic enzymes and protein binding [99]. 
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Renal replacement therapy could influence PK by increasing volume of distribution, adsorption 
to membranes or changes in excretion. Since renal elimination is only a very minor route of 
elimination for the echinocandins, no large influence of renal impairment is observed. No dose 
adjustments are advised for all three echinocandins in patients with renal impairment or renal 
replacement therapy. Detailed PK parameters are described in Table 6.
Anidulafungin
Patients with varying stages of renal impairment showed no statistical differences in PK 
parameters compared with matched healthy volunteers [88]. PK in patients depending on chronic 
intermittent hemodialysis was comparable with healthy volunteers and was not influenced by the 
time of drug administration in relation to the time of dialysis [88]. Furthermore, no anidulafungin 
concentrations were found in dialysate [88]. Extended daily dialysis (8 h) did not change PK of 
anidulafungin either; nor were measurable anidulafungin concentrations found in dialysate [100]. 
Anidulafungin PK in critically ill patients undergoing continuous venovenous hemofiltration 
(CVVH) or continuous venovenous hemodiafiltration (CVVHDF) were comparable with PK 
in healthy volunteers and patients with a fungal infection and no accumulation was seen 
Table 6. Pharmacokinetic parameters in patients with varying degrees of renal impairment and renal replacement therapy (standard 
deviation for anidulafungin and micafungin).
CL: Clearance; CVVHF: Continuous venovenous hemofiltration; CVVHDF: Continuous venovenous hemodiafiltration; CVVH: Continuous venovenous 
hemodialysis; EDD: Extended daily dialysis; ESRD: End-stage renal disease; Vd: Volume of distribution.
Drug and (daily) dose
Degree of renal 
impairment Patients (n) AUC0-24 (mg∙h/l) Cmax (mg/l) Vd (l/kg) CL (l/h) Ref.
Anidulafungin
50 mg Mild 6 52.5 (± 15.2) 2.2 (± 0.5) 0.440 (± 0.104) 1.01 (± 0.25) [88]
50 mg Moderate 7 58.7 (± 12.3) 2.6 (± 0.8) 0.409 (± 0.108) 0.88 (± 0.19) [88]
50 mg Severe 5 56.5 (± 10.4) 2.4 (± 0.4) 0.514 (± 0.122) 0.91 (± 0.15) [88]
50 mg ESRD,
pre-dialysis
3 48.1 (± 5.0) 1.9 (± 0.2) 0.527 (± 0.053) 1.05 (± 0.10) [88]
50 mg ESRD,
post-dialysis
3 58.0 (± 20.2) 2.6 (± 0.8) 0.510 (± 0.171) 0.94 (± 0.34) [88]
200 mg EDD 1 55.2 5.32 0.842 N/A [100]
200 mg loading 100 mg q.d. CVVHF 10 109.9 (± 49.8) 5.9 (± 2.0) 0.493 (± 0.266) 1.08 (± 0.41) [102]
200 mg loading 100 mg q.d. CVVHDF 12 93.9 (± 19.4) 6.2 (±1.7) N/A N/A [101]
Caspofungin
70 mg loading 50 mg q.d. CVVH 4 107 11.0 0.097 0.456 [105]
70 mg loading 50 mg q.d. CVVHDF 7 141 10.8 0.089 0.357 [105]
Micafungin
100 mg <30ml/min 9 116.2 (± 32.4) 8.7 (± 2.9) 0.215 (± 0.030) 0.93 (± 0.16) [84]
100 mg q.d. CVVHF 10 104.54 (± 22.38) 9.2 (± 2.0) N/A N/A [107]
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within 3 days of treatment [101, 102]. Ultra(dia)filtrate samples did not contain measurable levels of 
anidulafungin [101, 102]. There is discussion on the amount of adsorption to synthetic surfaces and 
saturation of these surfaces, even though the extent of possible adsorption is not considered 
clinically relevant [101, 103].
Caspofungin
In patients with mild renal impairment, no changes in caspofungin PK were observed [104]. 
Increases in exposure to caspofungin were seen in patients with different degrees of renal 
impairment (increases in AUC of 31, 49 and 30% in patients with moderate, severe and end-stage 
renal disease, respectively) [11].
Single-dose and steady-state PK parameters of caspofungin were unchanged during CVVH in 
critically ill patients [105]. Small differences in pre-filter and post-filter concentrations suggest there 
might be some adsorption of caspofungin to the hemofilter membranes, but caspofungin PK 
parameters were not significantly influenced [105].
Micafungin
PK of micafungin was determined after a single dose of 100 mg in patients with a serum 
creatinine clearance <30ml/min [84]. PK of micafungin was unaffected by renal impairment, as 
no significant differences in AUC, Cmax, clearance, volume of distribution or half-life time were 
observed compared with healthy volunteers [84]. Furthermore, micafungin PK was not influenced 
by albumin plasma concentrations [84].
In critically ill patients undergoing CVVH or CVVHDF, micafungin PK was unaffected [106, 107]. During 
CVVHDF plasma samples from the inlet and outlet of the extracorporeal circuit were comparable 
and no micafungin was detected in ultradiafiltrate [106]. No adsorption to or saturation of the 
polysulphone and polyethetersulphone filters was reported [107].
PK in critically ill & burn patients
PK of antimicrobials can be highly variable in critically ill patients compared with healthy 
volunteers, due to several physiological factors such as a hyperdynamic state, third spacing, 
hypoalbuminemia, renal dysfunction, hepatic dysfunction and organ support [16, 108]. Furthermore, 
extracorporeal membrane oxygenation (ECMO) can change PK of drugs due to the addition of 
blood products to the circuit and potential binding of drugs to the surface of the ECMO circuit 
[109]. 
Patients with severe burns have their own specific problems influencing PK of drugs. Volume of 
distribution and clearance can be highly altered due to hypovolemia, hypoalbuminemia, edema 
and low glomerular filtration rate during the first phase of burn injury (<48 h) [110]. During the 
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second phase of burn injury (>48 h after injury) blood flow in kidneys and liver increases and 
exudate leakage occurs [110]. Inter-individual and intraindividual variability in PK of echinocandins 
can therefore be high in these patients. Detailed PK parameters are described in Table 7.
Anidulafungin
Both comparable exposure, as well as reduced exposure (decreases in AUC0-24 of 25% and in Cmin 
of 40%) [77, 111] in critically ill patients compared with healthy volunteers has been reported. Disease 
severity scores and albumin concentrations appear not to influence anidulafungin PK [77, 111]. 
Caspofungin
General critically ill patients
PK data for caspofungin in critically ill patients are also conflicting. In surgical ICU patients 
caspofungin Cmin plasma concentrations were slightly increased compared with healthy 
volunteers (2.16 vs. 1.41 mg/l) and hypoalbuminemia (<23.6 g/l) and higher body weight (>75 
kg) were predictive for lower caspofungin C24-plasma concentrations [78]. Contrary to the surgical 
ICU populations, in a cohort of ICU patients with invasive candidiasis or candidemia receiving 
caspofungin, PK was comparable with those described in literature in healthy volunteers 
and non-critically ill patients are described [79, 105]. No factors that might influence the PK of 
caspofungin were identified [79].
Extracorporeal membrane oxygenation
Data on caspofungin PK in patients on ECMO therapy are limited and with varying results. 
Plasma concentrations of caspofungin varied between undetectable and low compared with 
Table 7. Pharmacokinetic parameters in intensive care unit patients (mean data for anidulafungin, median data for caspofungin and 
micafungin). 
CL: Clearance; Vd: Volume of distribution.
Drug Patients (n) AUC0-24 (mg∙h/l) Cmax (mg/l) Vd (l) CL (l /h) Ref.
Anidulafungin
200/100 q.d. 20 92.7 7.7 38.8 1.3 [77]
200/100 q.d. 20 69.8 4.7 N/A 1.6 [111]
Caspofungin
70/50 or 70/70 mg q.d. 21 107.2 7.51 7.72 0.54 [79]
70/50 or 70/70 mg q.d. 12 100 8.8 7.54 0.36 [105]
Micafungin 
100 mg q.d. 20 78.6 7.22 25.61 1.27 [114]
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adult patients and healthy volunteers and with those in healthy volunteers and surgical ICU 
patients [109, 112]. 
Burn patients
PK of caspofungin of only two patients with burn injuries is reported. One patient demonstrated 
comparable exposure to a reference population whereas the other patient demonstrated a 
decreased exposure [113]. 
Micafungin
General critically ill patients
No data on PK of micafungin in critically ill patients are available apart from one abstract, 
receiving 100 mg q.d., lower total exposure in ICU patients compared to healthy volunteers 
(88 vs 132 mg • h/l) appears to occur, while exposure compared with non-critically ill patients 
was comparable. No relevant covariates that influenced PK of micafungin could be identified in 
this study [114].
Burn patients
Micafungin plasma concentrations after administration of 200–300 mg q.d. in six patients with 
severe burns were found to be comparable with or slightly lower than concentrations found 
in healthy volunteers when normalized for dose and body weight [115]. PK parameters were not 
influenced by hepatic and renal function (including CVVH), albumin concentrations, and surgery 
[115]. Although only investigated in a single subject, micafungin appeared to penetrate into the 
skin tissue [115].
PK in patients with hematologic diseases
Patients with hematologic diseases that undergo intensive treatment with chemotherapy 
might encounter specific organ toxicity as a direct consequence of that treatment or due to 
complications of the treatment at a later stage (e.g. chemotherapy induced hepatotoxicity 
or hepatic impairment due to graft-versus-host-disease). The consequence is that PK of 
echinocandins might be altered in this patient population. PK parameters are described in detail 
in Table 8.
Anidulafungin
Estimated PK parameters in hematopoietic stem cell transplant recipients and patients with 
a hematologic disease receiving labeled dosing of anidulafungin were comparable with 
PK parameters in healthy volunteers [116]. A second study assessed the PK of 200 and 300 mg 
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anidulafungin every 48 h or every 72 h, respectively, in hematopoietic stem cell transplant 
recipients and remission-induction chemotherapy for acute myeloid leukemia patients as 
prophylaxis and found comparable exposure over the days compared with the licensed 
regimen [24]. The latter study demonstrated the dose-linearity of anidulafungin at higher dosages 
up to 300 mg. [24].
Caspofungin
Caspofungin PK in patients with hematologic diseases varies from PK in healthy volunteers: 
plasma clearance is lower, while AUC is higher (increase of 15%) [117, 118]. This might be due to 
interaction between caspofungin and cyclosporine A, or changes in plasma composition 
or saturation of OATP1B1-mediated uptake in liver cells [117, 118]. No covariates (e.g. age, gender, 
creatinine clearance, bilirubin levels) were found to influence the PK of caspofungin in patients 
with hematologic diseases apart from body weight [80, 119]. However, the effect of bodyweight is 
disputable since it is not found in all studies and the effect of body weight on the efficacy of 
caspofungin remains unclear [80, 119].
Table 8. Pharmacokinetic parameters in patients with hematological diseases (standard deviation for caspofungin and micafungin).
a Only 28% of the patients included in this study were patients with a hematological disease. CL: Clearance; Vd: Volume of distribution.
Drug and (daily) dose Patients (n) AUC0-24 (mg∙h/l) Cmax (mg/l) Vd (l/kg) CL (l/h) Ref.
Anidulafungin
200 mg loading, 
100 mg q.d.
140 91.8 N/A 0.50 1.17 [116]
Caspofungin
70 mg loading, 50 mg q.d. 18 117 (28.2) 8.47 (1.95) 0.17 0.45 (0.1) [118]
70 mg loading, 50 mg q.d. 17 110 (26.4) 7.75 (1.86) 0.18 0.48 (0.12) [118]
70 mg q.d. 9 170 13.8 N/A N/A [119]
100 mg q.d. 8 234 19.7 N/A N/A [119]
150 mg q.d. 7 365 29.6 N/A N/A [119]
200 mg q.d. 20 487 39.4 N/A N/A [119]
Micafungin
50 mg q.d. 9 44.3 N/A 0.218 1.06 [47]
100 mg q.d. 8 101.6 N/A 0.209 1.08 [47]
100 mg q.d.a 20 97.11 (29.0) 10.05 (4.37) N/A 1.17 (0.56) [124]
150  mg q.d. 8 166.7 N/A 0.202 0.98 [47]
150 mg q.d. 10 N/A 21.91 (8.49) N/A N/A [120]
150mg q.d. 6 367.2 27.3 0.209 N/A [44]
200 mg q.d. 8 210.6 N/A 0.283 0.96 [47]
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Micafungin
PK of micafungin in patients with hematologic diseases are comparable to those in healthy 
volunteers [44, 47], although acute and chronic graft-versus-host-disease with liver involvement 
and consequent hepatic impairment significantly influenced micafungin Cmax and Cmin (increases 
of 175 and 218%, respectively) [120]. 
Expert commentary & five year view
This review focuses on the PK of echinocandins in different patient populations with a high risk 
for invasive fungal infections. Systemic Candida and Aspergillus infections highly contribute to 
the amount of nosocomial infections in various patient populations and are associated with 
high morbidity and mortality rates [3, 121]. Echinocandins represent a valuable treatment option 
for invasive fungal infections. 
With comparable guideline recommendations, apart from those in children, penetration at the 
site of infection should be taken into account when using echinocandins, thereby noting that 
none of the echinocandins penetrate into CSF, vitreal fluid or urine [122].
There are selected differences in PK between the three echinocandins including the need 
of loading doses for anidulafungin and caspofungin, the metabolic pathways (hepatic vs 
non-hepatic or a combination of both) and the number and extent  of clinical relevant drug-drug 
interactions (see http://www.fungalpharmacology.org for an extensive overview of drug-drug 
interactions with echinocandins). 
However, limited and conflicting data are available concerning the PK behavior of the three 
echinocandins in specific patient populations. Major observations of this review will follow in 
the next paragraph.
In neonates, children and adolescents, anidulafungin is the least studied, because treatment 
with anidulafungin in this group is hampered by the excipient polysorbate. Limited data suggest 
no differences in PK compared with adult patients. PK of caspofungin in neonates and infants 
is somewhat different compared with adult patients due to reduced clearance. For neonates, 
children and adolescents, the richest data are available for micafungin, where PK changes in 
clearance and volume of distribution are age and weight dependent.
Bodyweight appears to influence the PK of all echinocandins alike even though evidence is 
limited: no formal study has been performed for anidulafungin, although bodyweight might 
be of influence on the exposure due to an increase in volume of distribution and clearance, 
as has been reported for caspofungin (a recommended increased daily dose for patients 
>80 kg, however data supporting this have not been published). For micafungin a patients 
weighing >66.3 kg experienced clearance increases and AUC decreases. It is highly likely that 
all echinocandins must be dosed higher in morbidly obese patients. More sophisticated dosing 
algorithms are clearly needed for this population. 
PK changes due to all stages of hepatic impairment are considered not clinically relevant for 
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anidulafungin and micafungin, even though substantial PK changes are observed for both 
drugs. For caspofungin, a dose adjustment is advised for patients with moderate and severe 
hepatic impairment, based on  very limited data.
No dose adjustments are necessary for all three echinocandins in patients with all stages of renal 
impairment or patients undergoing renal replacement therapy, even though PK parameters of 
caspofungin appear to be influenced; furthermore there is debate about possible adsorption of 
anidulafungin and caspofungin to membranes of the renal replacement therapy circuit.
Of note, the maximum tolerable concentration is much higher than achieved under the 
conditions of organ failure (both hepatic and renal impairment). This stresses the possibility of 
safe application of echinocandins under these circumstances without dose modifications.
In critically ill patients, very limited data are available and the data that are available are conflicting. 
For anidulafungin, both similar and lower exposure are observed in ICU patients compared with 
healthy volunteers; for caspofungin higher and similar exposure is observed compared with 
healthy volunteers and other patient populations and for micafungin no formal study has yet 
been published. 
Finally, in hematology patients, PK of all echinocandins is comparable with healthy volunteers, 
despite caspofungin and anidulafungin having a significant interaction with cyclosporine A 
resulting in diminished clearance and  higher exposure of these two echinocandins.
We doubt that the presented differences in PK due to altered metabolism and clearance as well 
as drug-drug interactions between the three echinocandins could be used as a basis for the 
choice of a specific echinocandin but rather for specific groups or categories of patients, the 
echinocandin dose could be adapted to another (fixed) dose, based upon patient characteristics 
or comorbidities. In our opinion, in the setting of clinical failure, therapeutic drug monitoring 
could be of use to identify those patients likely having suboptimal exposure due to  unpredictable 
PK. Specifically pediatric patients with meningoencephalitis, morbidly obese patients and ICU 
patients might benefit from such a tailored approach to warrant optimal exposure. 
Future research should focus on those patient populations in which data are very limited or 
absent, such as pediatric patients, obese patients, critically ill patients (on ECMO or burn patients). 
Second, reduced frequency dosing regimens should be investigated to optimize treatment and 
to increase convenience for patients. Third, an increase in knowledge on PK/PD relations of 
echinocandins and specification of these targets combined with increased knowledge on PK in 
specific patient populations could further optimize echinocandin therapy.
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Abstract 
Micafungin is considered an important agent for the treatment of invasive fungal infections in the 
intensive care unit (ICU). Little is known on the pharmacokinetics of micafungin. We investigated 
micafungin pharmacokinetics (PK) in ICU patients and set out to explore the parameters that 
influence micafungin plasma concentrations. ICU patients receiving 100 mg of intravenous 
micafungin once daily for suspected or proven fungal infection or as prophylaxis were eligible. 
Daily trough concentrations and PK curves (days 3 and 7) were collected. Pharmacokinetic 
analysis was performed using a standard two-stage approach. Twenty patients from the ICUs 
of four hospitals were evaluated. On day 3 (n=20), the median (interquartile range [IQR]) area 
under the concentration-time curve from 0 to 24 h (AUC
0–24
) was 78.6 (65.3 to 94.1) mg•h/liter, the 
maximum concentration of drug in serum (C
max
) was 7.2 (5.4 to 9.2) mg/liter, the concentration 
24 h after dosing (C
24
) was 1.55 (1.4 to 3.1) mg/liter, the volume of distribution (V) was 25.6 (21.3 
to 29.1) liters, the clearance (CL) was 1.3 (1.1 to 1.5) liters/h, and the elimination half-life (t
1/2
) was 
13.7 (12.2 to 15.5) h. The pharmacokinetic parameters on day 7 (n=12) were not significantly 
different from those on day 3. Daily trough concentrations (day 3 to the end of therapy) showed 
moderate interindividual (57.9%) and limited intraindividual variability (12.9%). No covariates of 
the influence on micafungin exposure were identified. Micafungin was considered safe and well 
tolerated. We performed the first PK study with very intensive sampling on multiple occasions 
in ICU patients, which aided in resolving micafungin PK. Strikingly, micafungin exposure in our 
cohort of ICU patients was lower than that in healthy volunteers but not significantly different 
from that of other reference populations. The clinical consequence of these findings must be 
investigated in a pharmacokinetic-pharmacodynamic (PK-PD) study incorporating outcome in 
a larger cohort. (This study is registered at ClinicalTrials.gov under registration no. NCT01783379.)
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Introduction
The incidence of fungal infections continues to pose a serious threat in the intensive care unit 
(ICU) and is associated with a high mortality rate and prolonged duration of ICU and hospital 
stay [1-4]. Almost 20% of all isolated pathogens in ICU patients are determined to be fungi, with 
Candida species accounting for the majority of fungal infections [1]. 
Echinocandins are currently considered the primary treatment for patients with invasive 
candidiasis or candidemia [5, 6]. Micafungin is an intravenous antifungal agent of the echinocandin 
class that exerts potent in vitro and in vivo activity against both Candida and Aspergillus species [7-10]. 
In the clinical setting, micafungin has demonstrated efficacy in treating invasive candidiasis and 
candidemia [11, 12].
ICU patients may be subject to severely altered pharmacokinetic (PK) characteristics compared 
to those of non-critically ill patients. In this population, physiological changes such as organ 
failure (hepatic and/or renal dysfunction) with the consequence of an altered drug volume of 
distribution (V) and/or clearance (CL), the use of organ support (i.e. renal replacement therapy 
and/or extracorporeal membrane oxygenation (ECMO]) and interacting comedications may 
result in highly varied pharmacokinetics of drugs, including antimicrobial agents [13, 14]. In addition, 
V and CL may be subject to increased inter- and intrasubject variability due to altered plasma 
protein binding [15]. Also, it has been hypothesized that disease severity might result in altered 
drug PK behavior [16].
The PK of micafungin is very well defined in non-critically ill patients. Micafungin exhibits linear 
PK over a wide dosage range in adults with steady state being reached by day 4 without the 
need for a loading dose [17]. Specifically, dose adaptations are not required in patients with renal 
or hepatic impairment and renal replacement therapy [18-22]. Nevertheless, there are very limited 
data available on micafungin PK in ICU patients and thus it remains unclear whether the PK is 
altered in this population of critical ill patients due to the above mentioned aspects.
We set up this study to describe the PK of micafungin in ICU patients and explore the parameters 
of influence on interindividual variability in micafungin plasma concentrations. This study aids in 
obtaining more knowledge on drug behavior in a group of highly vulnerable patients.
Materials and Methods
Study design
We performed an open-label, multiple-dose and multi-center observational PK study of 
micafungin in adult ICU patients (registered at ClinicalTrials.gov: under registration no. 
NCT01783379). Our study was conducted in accordance with the Declaration of Helsinki and 
good clinical practice regulations. The study was carried out in The Netherlands in accordance 
with applicable rules concerning the review of research ethics committees and informed 
consent. The study was conducted from January until December 2013 in the ICUs of the Radboud 
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university medical center (Nijmegen), Canisius Wilhelmina Hospital (Nijmegen), Rijnstate Hospital 
(Arnhem), and Erasmus Medical Center (Rotterdam), The Netherlands. 
Study population
Patients admitted to the ICU to receive micafungin for suspected or proven fungal infection 
were eligible if they met the following inclusion criteria: ≥18 years of age on the day of the first 
micafungin dose, not receiving micafungin treatment for >2 days before enrollment, and having 
a central venous or arterial catheter. Patients were excluded who had history of hypersensitivity 
to echinocandins or excipients similar to those found in the micafungin preparation, HIV or 
hepatitis B/C -infection or abuse of alcohol or drugs. An empirical sample size of 20 evaluable 
patients was selected to adequately define micafungin PK [23].
Treatment
All patients received 100 mg of micafungin once daily by intravenous infusion over 1 h [18]. 
Micafungin therapy continued as long as was considered clinically relevant by the treating 
physician. Yet, for the purpose of this study, PK sampling was limited to a maximum of 14 days, 
with an additional 3 days after cessation of therapy.
Baseline parameters
At screening (day 0 of study), the following parameters were registered: age, gender, race, 
weight, height, body mass index (BMI), fat free mass (FFM) (as calculated according to 
Janmahasatian et al. [24]), relevant comedication(s), medical history, indication for admission to the 
ICU, indication for micafungin use, relevant abnormalities (e.g. type of renal replacement therapy, 
mechanical ventilation, excess body fluid), or acute physiology and chronic health evaluation 
II, sequential organ failure assessment (SOFA) and Child-Pugh score. During the study, patient 
comedications, clinical characteristics and relevant abnormalities were recorded on all study 
days. In addition, on days on which PK was measured (i.e., days 3 and 7), weight, BMI, FFM, SOFA 
score, and Child-Pugh score were documented. Microbiological data were obtained throughout 
the study as part of routine patient care. 
Vital signs were monitored immediately before and after micafungin infusion and hourly for the 
first 4 h afterwards on days on which PK was measured.
Laboratory data
Blood was sampled three times a week and on days on which PK was measured for the 
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determination of biochemical and hematologic parameters, including serum electrolytes, 
total protein, albumin, blood urea nitrogen (BUN), aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT), gamma-glutamyl transferase (GGT), alkaline phosphatase (AP), total 
bilirubin, C-reactive protein (CRP), lactate dehydrogenase (LDH), triglycerides, creatinine kinase, 
creatinine, hemoglobin, hematocrit, white blood cell differential, and platelet count.
Pharmacokinetic sampling 
At day 3 (±1 day) of treatment, a PK curve of 10 samples was drawn with sampling times (t) of 
0 (predose), 0.5, 1 (end of infusion), 2, 4, 6, 8, 12, 18, and 24 h postinfusion. A second PK curve of 
six samples was drawn on day 7 with sampling t of 0 (predose), 1, 4, 8, 12, and 24 h postinfusion. 
On all study days up until day 14, trough concentrations 24 h after dosing (C
24
) were drawn 
until 3 days after cessation of therapy. Patients were considered evaluable if at least the first PK 
curve on day 3 was completed. Blood samples (±2 ml) were collected from an indwelling arterial 
catheter in lithium-heparin-containing tubes (nongel) and stored immediately at 4°C. Within 
48 h after collection, samples were centrifuged at 1,900 × g for 5 min. Plasma was aspirated, 
directly transferred to polypropylene tubes, and stored at -80°C.
Safety
In addition to clinical observations, adverse events were reported on all study days. Local 
researchers and physicians determined a potentially causal relationship with micafungin 
administration. 
Analytical assay for micafungin
After pretreatment with a protein precipitation solution (50% acetonitrile, 50% methanol, and 0.1% 
formic acid), analysis was performed with a validated ultraperformance liquid chromatography 
(UPLC) method, using a fluorescence detector (dynamic range for micafungin, 0.01 to 32.40 mg/
liter; concentration-dependent accuracy range [n=15], 97.61% to 101.64%). Intraday precision 
ranged between 1.41% and 5.14% (n=5). In addition, interday precision varied between 0.69% 
and 2.20% (n=15). A stability analysis of micafungin in whole blood confirmed that micafungin 
was stable for a minimum of 7 days at 4°C (mean concentration ± standard deviation [SD], 98.56% 
± 1.91%, n=4).
Micafungin PK data analysis
Pharmacokinetic parameters (area under the concentration-time curve from 0 to 24 h [AUC
0–24
], 
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maximum concentration of drug in serum [C
max
], C
24
, half-life [t
1/2
], volume of distribution [V], 
clearance [CL], and terminal elimination rate constant [k
el
]) were calculated using noncompart-
mental analysis (Phoenix version 6.3). The AUC
0–24
 was calculated using the linear up-log down 
trapezoidal rule. In addition, C
max
 and C
24
 were directly observed from the data. Half-life was 
calculated by ln 2/k
el
, in which k
el
 was determined by linear regression of the terminal points of 
the log-linear plasma concentrationtime curve. V was calculated using the formula dose/AUC • k
el
, 
and CL was calculated as dose/AUC
0–24
. 
A paired t test was performed on the log-transformed pharmacokinetic parameters of days 3 
and 7 in order to detect statistically significant differences over time. Geometric mean ratios 
(GMRs) with a 90% confidence interval (CI) falling entirely within the range of 0.80 to 1.25 were 
considered to indicate no significant differences in pharmacokinetic parameters. Linear regression 
was performed to determine the relationships between the log-transformed pharmacokinetic 
parameters AUC
0–24
, CL, and V and covariates (i.e., gender, age, weight, [plus related parameters 
BMI and FFM]), renal replacement therapy, APACHE II score, SOFA score, Child-Pugh score, 
liver enzyme levels (ALAT, ASAT, AP, bilirubin, GGT, and LDH), and other laboratory parameters 
(albumin, BUN, creatinine, and CRP levels). Statistical analyses were performed using SPSS version 
20.0 (SPSS, Inc., Chicago, IL, USA). A P value of <0.05 was considered statistically significant.
Results
Patients 
Twenty-eight were included from the ICUs of three Dutch hospitals. The fourth hospital did not 
achieve inclusion of evaluable patients. Twenty patients completed the first PK curve on day 3 
and were evaluable for analysis. The remaining 8 patients were withdrawn from the study before 
day 3 due to the removal of a central venous catheter (n=3), switch to fluconazole (n=1), and 
death (n=4). Baseline demographics (n=20) are available in Table 1. Micafungin was administered 
as treatment for suspected or proven fungal infections (n=19) or prophylaxis against fungal 
infections (n=1) caused by Candida spp., Aspergillus spp., or both. Three patients received 
micafungin therapy for longer than the initial study duration of 14 days. In the remaining 17 
patients, study participation was discontinued due to clinical response before day 14 (n=4), 
removal of central venous catheter (n=4), switch to fluconazole (n=2), discharge to another ward 
(n=2), or death (n=5).
Micafungin pharmacokinetics
Subjects received a median of 7 micafungin doses once daily (range, 3 to 14), resulting in a 
total of 20 PK curves on day 3 and 12 PK curves on day 7 (see Table 2). A total of 371 samples 
for PK analysis were drawn. One aberrant concentration was observed in a single patient 
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Demographics
Gender
 Male (n [%]) 8 (40)
 Female (n [%]) 12 (60)
Median age (yr [range]) 68 (20 – 84) 
Race 
Caucasian (n [%]) 20 (100)
Median weight (kg [range]) 76.5 (50 – 134)
Median BMI (kg/m2 [range]) 24.6 (16.3 – 47.5)
Median fat free mass  (% [range]) 48.6 (38.9 – 64.1)
Median dosing administrations (n [range]) 7 (3 – 14)
Total PK curves day 3 (n [%]) 20 (100)
Total PK curves day 7 (n [%]) 12 (60)
Median length of ICU stay (days [range]) 16 (7 – 98)
Clinical characteristics
Elderly (≥ 65 years [%]) 13 (65)
Renal function (n [%])
 MDRD >50 ml/min/1.73m2 11 (55)
 MDRD 31 - 50 ml/min/1.73m2 5 (25)
 MDRD 10 - 30 ml/min/1.73m2 4 (20)
Renal replacement therapy (n [%])
 CVVH 5 (25)
 Intermittent hemodialysis 1 (5)
Intubated (n [%]) 14 (70)
Excess body fluid
 Ascites (n [%]) 1 (5)
 Edema (n [%]) 11 (55)
APACHE II score (n [%])
 ≤20 6 (30)
 >20 14 (70)
 Median (range) 24.5 (5 – 35)
SOFA score (mean [range])
 At screening 9.1 (2 – 19)
 Day 3 8.3 (1 – 18)
 Day 7 7.5 (1 – 12)
Hepatic dysfunction, screening (n [%])
 Child-Pugh class A 3 (15)
 Child-Pugh class B 15 (75)
 Child-Pugh class C 2 (10)
Hepatic dysfunction, day 3 (n [%])
 Child-Pugh class A 1 (5)
 Child-Pugh class B 18 (90)
 Child-Pugh class C 1 (5)
Table 1. Baseline characteristics (n=20).
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*Absolute neutrophil count <0.5*10(9)/L
MDRD: Modification of Diet in Renal Disease formula, CVVH: Continuous Veno-Venous Hemofiltration, APACHE II: Acute Physiology and Chronic 
Health Evaluation II, SOFA: Sequential Organ Failure Assessment. 
Table 1. - Continued  Baseline characteristics (n=20).
Demographics
Hepatic dysfunction, day 7 (n [%])
 Child-Pugh class A 1 (8.3)
 Child-Pugh class B 11 (91.7)
 Child-Pugh class C 0 (0)
Neutropenia * (n [%]) 0 (0)
Hypoalbuminemia (n [%])
 25 – 35 g/L 2 (10)
 15 – 24 g/L 13 (65)
 < 15 g/L 5 (25)
Microbiological characteristics
Infection location (n [%])
 Normally sterile location 20 (100)
 Blood 3 (15)
Species (n [%])
     Candida spp. 20 (100)
 Candida albicans 11 (55)
     non-albicans 12 (60)
 Candida tropicalis 2
 Candida glabrata 2
 Saccharomyces cerevisiae 1
 Candida not speciated 7
     Aspergillus spp. 2 (10)
 Aspergillus fumigatus 1
 Aspergillus niger 1
Candida and Aspergillus spp. 2 (10)
(18.9 mg/liter at t of 19.98 h). Using Grubbs’ test for outliers, this single data point was excluded 
for further analysis (Z, 3.93; critical Z, 2.68; n=19).
The median and interquartile range (IQR) (25 to 75%) AUC
0–24
 on days 3 and 7 were 78.6 
(65.3 to 94.1) mg • h/liter and 65.7 (55.9 to 88.7) mg • h/liter, respectively. The median (IQR) C
max
 
was 7.2 (5.4 to 9.2) mg/liter on day 3 and 6.2 (5.1 to 9.2) mg/liter on day 7. The median (IQR) C
24
 
was 1.6 (1.4 to 3.1) mg/liter on day 3 and 1.6 (1.3 to 2.4) mg/liter on day 7. An overview of all 
pharmacokinetic parameters of micafungin on days 3 and 7 is shown in Table 2 and Fig. 1, 2, and 
3. Daily trough concentrations over time are shown in Fig. 4. At the start of therapy, the median 
C
24
 at t of 24 h differed significantly from that at t of 48 h (P=0.009), whereas the median C
24
 at 
t of 48 h did not differ significantly from that at t of 72 h. No significant difference in C
24
 at later 
time points was seen.
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Table 2. Micafungin pharmacokinetics on day 3 and day 7.
PK curve on day (median [IQR]):
Parameter 3 (n=20) 7 (n=12)
AUC0-24 (mg • h/liter) 78.6 (65.3–94.1) 65.7 (55.9–88.7)
Cmax (mg/liter) 7.2 (5.4–9.2) 6.2 (5.1–9.2)
C24 (mg/liter) 1.6 (1.4–3.1) 1.6 (1.3–2.4)
t1/2 (h) 13.7 (12.2–15.5) 14.4 (12.8–16.3)
V (liter) 25.6 (21.3–29.1) 28.7 (16.8–32.1)
CL (liters/h) 1.3 (1.1–1.5) 1.5 (1.2–1.8)
Kel (1/h) 0.05 (0.04–0.06) 0.05 (0.04–0.05)
Figure 1. Mean plasma concentration (conc.)–time curve of micafungin (100 mg/day) on day 3.
Figure 2. Mean plasma concentration–time curve of micafungin (100 mg/day) on day 7.
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Figure 3. Mean plasma concentration–time curve of micafungin (100 mg/day) on days 3 and 7.
Figure 4. Micafungin (100 mg/day) trough concentrations on days 1 to 13 of therapy. The box plots show the median and IQR (5th to 
95th percentile) values. 
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Figure 5. Correlation of micafungin (100 mg/day) trough concentrations and AUC on days 3 and 7. 
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The GMR for AUC
day7
/AUC
day3
 was 0.97 (90% CI, 0.85 to 1.11). In addition, the GMRs for C
max
 and C
24 
were 0.94 (90% CI, 0.81 to 1.10) and 0.87 (90% CI, 0.59 to 1.28; Table 1), respectively. The median 
interindividual coefficient of variation (CV) of micafungin trough concentrations (day 3 to the end 
of therapy) amounted to 57.9% (95% CI, 57.7 to 58.2; 92 samples) and the median intraindividual 
CV to 12.9% (95% CI, 12.7 to 13.2; n=16) over the same period. The micafungin C
24
 correlated well 
with AUC on day 3 (r
2
=0.919, P<0.01) and day 7 (r
2
=0.983, P<0.01) (see Fig. 5).
Covariates
The micafungin PK parameters AUC
0–24
, CL, and V on days 3 and 7 were not significantly influenced 
by specific covariates (gender, age, weight [including BMI and FFM], renal replacement therapy, 
APACHE II score, SOFA score, Child-Pugh score, liver function enzyme levels [ALAT, ASAT, AP, 
bilirubin, GGT, and LDH]) and other laboratory parameters (albumin, BUN, creatinine, and CRP 
levels). No interacting comedication was identified throughout the course of treatment.
Safety
After the start of micafungin dosing, 18/20 subjects (90%) experienced a total of 65 new or 
aggravated clinical adverse events (AEs) during follow-up. Five serious AEs were reported 
(persistent infections due to anastomotic leak, renal failure, metabolic acidosis, thrombosis, and 
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the need for vasoactive drugs), leading to the death of these five subjects. It was concluded 
that these serious AEs were not related to the administration of micafungin. Of the reported 
65 AEs, four were categorized as possibly related to micafungin therapy (elevated liver function 
enzymes, reported as an increase of >3 times the upper limit of normal). None of these AEs 
resulted in modifications or discontinuation of micafungin therapy.
Discussion
To our knowledge, this cohort of ICU patients is unique in size and sampling intensity with PK 
curves on multiple occasions and daily trough concentrations over the complete course of 
treatment. It reflects a real-life situation with a population being treated for fungal infections. 
This aided us in describing the PK of micafungin in a cohort that is frequently subject to altered 
PK. 
Strikingly, we found much lower exposure in this cohort of ICU patients than the exposure 
described in the literature. Using an unpaired t-test (on mean exposure, standard deviation 
[SD] and number of patients), the exposure in this cohort appeared to be significantly lower 
than that in healthy volunteers [20, 25-27]. A statistical comparison with other patient populations 
did not yield a significant different AUC (see Table 3) [19, 20, 22, 27, 28]. This might suggest a negative 
impact of disease on the exposure of micafungin. We found 57.9% interindividual variability in 
micafungin C
24
. To our knowledge, interindividual variability in micafungin C
24
 in ICU patients 
has not been reported prior to this study. In comparison, caspofungin interindividual variability 
Table 3. Micafungin (100 mg) exposure in reference populations
Reference Population n AUC P-value
Study population ICU patients 20 88.1 (± 33.3, AUC0-24; day 3, mean) N/A
86.65 (± 49.1, AUC0-24; day 7, mean)
Hebert et al. A (20) Healthy controls 8 125.9 (± 26.4; AUC0-inf, mean) 0.082
Hebert et al. B (25) Healthy controls 26 136.4 (± 26.1; AUC0-24, mean) <0.0001
Hebert et al. C (26) Healthy controls 27 133.4 (± 19.0; AUC0-24, mean) <0.0001
Undre et al. C (27) Healthy controls 8 142.4 (± 28.9; AUC0-inf, geometric mean) 0.0004
Hiemenz et al. (19) Cancer patients undergoing bone 
marrow or peripheral stem cell 
transplantation
8 101.6 (No SD reported; AUC0-24) N/A
Hebert et al. A (20) Patients with moderate hepatic 
dysfunction
8 97.5 (± 19; AUC0-inf, mean) 0.4624
Maseda et al. (22) ICU patients receiving renal replace-
ment therapy
10 104.54 (± 21.23; AUC0-24, mean) 0.1675
Undre et al. C (27) Severe hepatic dysfunction 8 100.1 (± 34.5; AUC0-inf, geometric mean) 0.4014
Undre et al. B (28) Patients with invasive candidiasis/
candidemia
20 97.11 (± 28.97; AUC0-24, mean) 0.3670
AUC: area under the concentration-time curve
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in ICU patients was reported to be 45.6% (n=21) in a study from our group and 57% (n=6) in the 
Defining Antibiotic Levels in Intensive Care Unit Patients (DALI study) [14, 29].
We can think of four possible explanations for the lower exposure of micafungin: (i) altered 
protein binding, (ii) changes in metabolic route, (iii) impact of disease severity, and (iv) a higher 
average body weight in this cohort than in reference populations. These are discussed below.
(i) As a general rule, an increased free fraction due to protein displacement will lead to a lower total 
drug exposure [30]. Micafungin is highly protein bound (>99%). Hence, a lower exposure due to 
lower protein binding (a higher free fraction) is possible. This would also match previous findings 
in subjects with severe hepatic dysfunction and findings with caspofungin [27, 31]. Due to the 
limited variability in albumin status (all were hypoalbuminemic), we could not make a distinction 
between micafungin exposure in patients with normal albuminemia versus hypoalbuminemia. 
Unfortunately, no unbound micafungin plasma concentrations were analyzed, thus, protein 
displacement cannot be confirmed or rejected as a possible cause for the lower exposure. 
(ii) In patients with severe hepatic dysfunction, lower exposure of micafungin parent compound 
and higher and more variable plasma concentrations of the M-5 metabolite were reported [27]. 
This has also been confirmed in younger patients [32]. The authors suggested this was either 
due to a higher rate of formation or lower CL of the M-5 metabolite. Decreased clearance of 
the M-5 metabolite seems the most plausible explanation, but increased formation of the 
M-5 metabolite is a possible explanation for lower micafungin exposure. We did not measure 
exposure of micafungin metabolites, and therefore were unable to confirm this as a possible 
explanation. 
(iii) This ICU population was heterogeneous in terms of APACHE II and SOFA scores. For 
anidulafungin, it has been hypothesized that exposure is lower for patients with a higher disease 
severity score, although this correlation did not reach statistical significance [16]. For caspofungin, 
an identical study by our group demonstrated that disease severity did not impact exposure [29]. 
For micafungin, disease severity (both APACHE II and SOFA scores) did not reveal a correlation 
with exposure and therefore can be ruled out as a possible cause for the low exposure. 
(iv) Last, Gumbo et al. demonstrated that micafungin systemic clearance in bone marrow 
transplant patients increased as a function of body weight >66.3 kg [33]. Recently, a formula 
has been proposed to individualize micafungin doses for overweight and obese patients 
[34]. Bodyweight and other weight-derived parameters, BMI and FFM, were not identified as 
covariates in this study, possibly a result of the average weight in this study being close to the 
ideal body weight. Also, the weight distribution in the current study was comparable to that 
in other studies, thereby ruling out a relative high bodyweight as possible cause for the low 
exposure. 
In addition to the above findings, these data suggest that steady-state concentrations of 
micafungin are reached at by day 3 at the latest, which is consistent with previous reports [18, 35]. 
At the initiation of micafungin therapy, the C
24
 at 24 h was significantly lower than that at 48 h 
(but not comparing t of 48 h to t of 72 h). Despite the fact that micafungin demonstrated clinical 
efficacy in pivotal trials at current regimens, the use of a loading dose of micafungin in ICU 
patients should be evaluated to increase exposure on the first day of therapy.
We did not observe altered micafungin PK in a small subcohort of patients with renal dysfunction 
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(modification of diet in renal disease [MDRD], 10 to 30 ml/min/1.73 m2) or in those receiving renal 
replacement therapy (see Table 2), which confirms previous findings in the literature [20-22, 36, 37].
The clinical consequence of the lower exposure in this cohort is subject to debate as in the 
setting of lower exposure efficacy might be compromised [38, 39]. Recently, Andes et al. [40] 
demonstrated by analysis of two micafungin phase III trials that the probability of mycological 
cure in adult patients with invasive candidiasis or candidemia receiving micafungin therapy 
(55% were admitted to the ICU) was higher if the patient attained an AUC/MIC ratio between 
3,000 and 12,000 compared to a ratio of <3,000 (98.0% versus 85.1%, respectively). The authors 
concluded that if the MIC was <0.06 mg/liter, the vast majority of the patients would attain the 
lower target of 3,000 [11, 12, 40]. A subgroup analysis of the 55% ICU patients in this cohort is lacking 
in this paper. Unfortunately, no hypothesis can be generated from this paper on the efficacy of 
micafungin in the selected group of patients in the ICU. 
In our population with median AUC
0-24
s of 78.6 mg • h/liter and 65.7 mg • h/liter on days 3 
and 7, respectively, setting a target AUC/MIC ratio of 3,000 and a clinical breakpoint (CBP) of 
0.03 mg/liter would result in 75% of our population not being able to attain the target value 
(AUC
0-24
 ≥90 mg • h/liter) on both days on which PK was measured for micafungin. Obviously, 
using higher CBPs would result in even larger proportions of patients not achieving this PK/PD 
target. The success of therapy in our cohort might be driven by pathogens with low MICs 
(<0.03 mg/liter) which would result in 100% target attainment. However, data on susceptibility 
are lacking in this research and conclusions on the exposure response in relation to the suscep-
tibility of the pathogen as drawn by Andes et al. [40] cannot be substantiated. 
Unfortunately, in daily practice we are confronted with a critical delay in obtaining MICs from 
cultured species. In the absence of these susceptibility data/MICs, the population average 
exposure of healthy volunteers might serve as a reference value, as these average concen-
trations represent the best-case scenario (for the standard dose). An individual who achieves 
this exposure is less likely to demonstrate a suboptimal clinical response. Further inducing the 
likeliness of achieving mycological cure, higher standard doses of micafungin in this patient 
population could be considered, as it has been confirmed that micafungin has a favorable 
tolerability profile and displays dose-proportional linear pharmacokinetics [19, 20, 41]. Last, to avoid 
concentration-dependent therapeutic failure, therapeutic drug monitoring of micafungin (TDM) 
could be a valuable tool in this especially vulnerable patient population.
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Abstract
Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients 
is lacking. We determined anidulafungin pharmacokinetics (100mg single dose) in eight morbidly 
obese subjects (BMI>40kg/m2). Anidulafungin exposure was on average 32.5% lower compared 
to the general patient population, suggesting dose increases may be required in this population.
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Introduction
The global prevalence of overweight and obesity has increased at an alarming rate during the 
past few decades. If recent trends continue, nearly 58% of the world’s adult population will be 
overweight or obese in 2030 [1]. Obesity increases the risk of a wide array of comorbidities and 
is an established risk-factor for nosocomial infections. Because obese patients are subject to a 
variety of (patho)physiological changes compared to non-obese patients, the pharmacokinetic 
(PK) and/or pharmacodynamic (PD) profile of antimicrobials might be altered [2]. 
Anidulafungin is an echinocandin antifungal agent approved for intravenous treatment of invasive 
candidiasis and candidemia [3]. At standard doses (200mg loading dose, 100mg maintenance 
dose), anidulafungin displays linear pharmacokinetics, with a volume of distribution close to total 
body water (0.6 L/kg), a clearance of about 1 L/h and an elimination half-life of approximately 
24 hours [3, 4].
The PK of anidulafungin has been well described in healthy subjects and several patient 
populations [4-10], although the weight range in these studies was small (only 7 patients were 
>120 kg). Because increased bodyweight has been linked to reduced anidulafungin exposure in 
non-obese patients [4, 7, 9, 10], suboptimal exposure of  anidulafungin in obese patients may occur 
and different dosing recommendations may be required for this population. In this study, we aim 
to describe the PK of anidulafungin in morbidly obese subjects with BMI>40kg/m2.
Materials and Methods
Study design and subjects
This open-label, phase IV study (ClinicalTrials.gov Identifier: NCT02021123) was approved by 
the ethics committee of the Radboud University Medical Center in 2014 and conducted in 
accordance with the declaration of Helsinki. Before inclusion, all subjects gave written informed 
consent. 
From August until October 2014, adult morbidly obese subjects (BMI>40kg/m2; not suffering 
from fungal infection) undergoing laparoscopic gastric bypass or sleeve surgery were eligible for 
inclusion.  Subjects were excluded in case of hypersensitivity to echinocandins and/or abuse of 
alcohol or drugs for the past 3 months. 
Study procedure
Upon inclusion, patient demographics, clinical characteristics and concomitant medications 
were reported. Subjects received a single, intravenous 100 mg dose of anidulafungin before 
laparoscopic bariatric surgery. The anidulafungin infusion was administered 2.5 hours before 
induction of anesthesia with an infusion rate of 1.1 mg/min[3]. There were no restrictions in the 
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protocol with regards to concomitant medication.
A PK curve was drawn at predefined times of T=0.5, 1, 1.5 (end of infusion), 2, 4, 6, 8, 10, 12, 
24 and 48 hours post-infusion. Blood samples were collected in lithium-heparin containing 
tubes (non-gel) and centrifuged at 1.900g (3.000 rpm) for 5 minutes at 4°C within 30 minutes of 
collection. Plasma was immediately stored at -80°C. Anidulafungin samples were measured by 
ultra performance liquid chromatography (UPLC) with fluorescence detection[9].
Safety
Blood samples for the purpose of laboratory safety were collected at T=0, 24 and 48 hours 
for determination of biochemical and hematologic parameters (sodium, potassium, chloride, 
calcium, phosphate albumin, blood urea nitrogen, aspartate aminotransaminase (AST), alanine 
aminotransferase (ALT), gamma-glutamyltransferase, alkaline phosphatase, bilirubin (total), 
lactate dehydrogenase, C-reactive protein, triglycerides, creatinine kinase, creatinine, uric acid, 
hemoglobin, hematocrit, white blood cells differential, platelets and red blood cell count).
Adverse events (AEs) were reported regardless of potential relationship to anidulafungin 
(including adverse drug reactions, illness that developed during the study, exacerbations 
of pre-existing illness, or abnormal laboratory values requiring intervention or diagnostic 
evaluation) until discharge.
There were no restrictions in the protocol with regards to concomitant medication. 
Anidulafungin PK data analysis
Pharmacokinetic parameters were calculated using non-compartmental analysis (Phoenix 
WinNonlin 6.3; Pharsight Corp, CA, USA). The area under the plasma concentration-time curve 
from 0 to time of last sample (AUC
0-48
) was calculated using the linear up-log down trapezoidal 
rule. The AUC from 0 to infinity (AUC
0-inf
) was determined as follows:
 AUC
0-inf 
= AUC
0-48
+ last observed concentration/k
e
 
Anidulafungin exposure in this cohort of morbidly obese subjects was compared to the exposure 
in the general patient population [7], given that AUC
0-inf
 (single dose) = AUC
0-24
 (steady state).
C
max
 was directly observed from the data. Total body clearance (CL) was calculated as D/AUC
0-inf
 
and volume of distribution (VD) was calculated as D/AUC
0-inf
 • k
e
. Half-life was calculated by 
ln(2)/k
e
. Elimination rate constant (k
e
) was estimated by log-linear regression of the terminal 
portions (minimum of 4 points, user defined) of the plasma concentration-versus-time curves.
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Statistical analysis
Descriptive statistics (e.g. geometric mean (GM), range, interpatient variability (calculated 
as geometric coefficient of variation]) were calculated for anidulafungin PK parameters. A 
Spearman’s correlation was run to assess the correlation between AUC and weight in SPSS 20.0 
(SPSS inc., IL, USA). A p-value of <0.05 was considered statistically significant. 
Results
Subjects
Eight subjects (3 male, 5 female; all Caucasian) were included. Median (range) age was 43 years 
(29–66). Geometric mean (range) weight, BMI, LBM (calculated according to Janmahasatian) [11], 
Body Surface Area and Waist/Hip ratio were 144.7kg (124.1–166.5), 48.9kg/m2 (39.9–57.6), 72.4kg 
(58.3–91.0), 2.49m2 (2.20–2.78) and 0.93 (0.85–1.11), respectively (Table 1).
Anidulafungin pharmacokinetics
Geometric mean (range) PK parameters were: AUC
0-inf
 72.9 mg • h/L (46.3–100.1), AUC
0-48
 
54.1 mg • h/L (35.0–68.9), C
max
 3.2 mg/L (2.6–4.1), VD 46.9 L (39.6–56.7), CL 1.4 L/h (1.0–2.2), t
1/2
 
23.7 h (17.0-29.8) and k
e
 0.029 1/h (0.023–0.041), see Table 1. Limited inter-individual variability 
was seen with AUC
0-inf
 (22.6%). No concurrent medications known to significantly influence 
anidulafungin PK were administered [3]. A strong, non-significant, negative correlation between 
both anidulafungin AUC
0-inf
 and AUC
0-48
 versus weight was found: r
s
(8)=-0.6429, p=0.096 and 
r
s
(8)=-0.6905, p=0.069, respectively. The mean AUC
0-inf
 (74.4 mg • h/L, coefficient of variation (CV 
20.7%) ; range 46.3 – 100.1) following single dose in our patient population was on average 
32.5% lower compared to the mean AUC
0-24
 at steady state in the general patient population 
(110.3 mg • h/L, CV 32.5%) [7]. With this, the AUC
0-inf
 in this cohort of morbidly obese patients is at 
the lower end of the exposure distribution of the general patient population.
Safety
No serious AEs were reported. All single dose infusions were well tolerated. Subjects experienced 
48 new or aggravated AEs during follow up (lab safety until 48h and clinical side effects until 
discharge), of which 16 (33.3%) were possibly related to anidulafungin. These AEs are most likely 
related to the surgical procedure (e.g. increase in ASAT, ALAT, creatinine kinase, nausea, headache) 
but a relation with anidulafungin infusion could not excluded. All AEs were mild, transient and 
resolved spontaneously.
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Discussion
To our knowledge, this is the first clinical study investigating the influence of extreme bodyweight 
(BMI>40kg/m2) on anidulafungin PK. The findings from this study show that this cohort of 
morbidly obese subjects has a lower exposure compared reports on non-obese individuals in 
literature [5, 7]. The inter-individual variability of anidulafungin in this population is comparable to 
healthy, non-obese volunteers [8]. 
Previously, it has been suggested that increased body size results in lower anidulafungin 
exposure, as weight was identified as covariate affecting anidulafungin CL [4, 7, 10] and central 
VD [4, 9]. Although the weight range was limited in those studies (only 7 patients were >120 kg), it 
was predicted that anidulafungin exposure could be 30% lower in a typical 150 kg male patient 
compared to a typical 60 kg male patient [7]. In the study of Liu et al., a patient weighing 240 kg 
was included, in whom a dose increase to 150 mg/day resulted in exposure comparable to other 
critically ill patients, albeit at the lower end of the AUC range (AUC
0-24
 92.7 vs. 55.3 mg • h/L; 
37 mg • h/L if extrapolated to 100 mg) [8]. The above findings of decreasing exposure as a function 
of weight were also observed with the other echinocandins caspofungin and micafungin. 
We show that none of the morbidly obese patients included in our study obtain the AUC of 
the general patient population at standard doses of anidulafungin (Table 1), thereby possibly 
introducing the risk of therapeutic failure. No specific clinical target AUC value for anidulafungin is 
established. Also it must be noted that a successful clinical response was observed in patients with 
invasive candidiasis (including candidemia) and low exposure in another study [7]. Our hypothesis 
is that a favourable response is likely associated with an infection with very susceptible species. 
Nevertheless morbidly obese patients infected with pathogens with reduced susceptibility are 
still at risk for therapeutic failure. Considering the fact that anidulafungin is well tolerated in doses 
up to 300 mg [9], and pathogen susceptibility at start of therapy often unknown, we propose 
an approach to adapt the empiric dose to achieve the general population average exposure 
(AUC
0-24
 110 mg • h/L) in this cohort of patients (BMI >40 kg/m2) [7]. To normalize the exposure 
to population values, increasing the anidulafungin maintenance dose to 150 mg (+50%) would 
proportionally increase the AUC
0-24
 to nearly 110 mg • h/L (based on linear kinetics) [3]. In parallel, 
increasing the loading dose by 50% (i.e. 300 mg) could be considered to achieve adequate 
exposure at the beginning of therapy [5, 7]. 
A different approach would be to increase the dose based on clinical failure or by using therapeutic 
drug monitoring (individualized drug dosing based on the measurement and interpretation 
of drug concentrations taking into account pathogen susceptibility). The first option will likely 
save drug costs. The latter approach is a more personalized schedule that can be deployed in 
patients with a high a priori risk of low exposure such as the ICU population [7]. Being obese may 
have an additive effect on exposure. In other words, the exposure in critically ill, morbidly obese 
patients with candidemia/invasive candidiasis may be even more pronounced compared to ICU 
or obesity alone. The use of TDM in such a clinical situation deserves further study.
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Our study is conducted with a relatively small sample size, without a non-obese control group. 
A 100 mg single-dose design was chosen to allow for comparisons with AUC
0-24
 at steady state in 
literature. Ideally, anidulafungin PK in this cohort of morbidly obese patients is directly compared 
with PK in non-obese individuals also receiving a single 100 mg dose. Therefore, these results 
should be regarded as explorative for anidulafungin PK in obese subjects.
In summary, the lower anidulafungin exposure in our “healthy” morbidly obese subjects 
compared to literature values in non-obese patients suggests that anidulafungin dosing 
could be optimized in (extreme) morbidly obese patients with fungemia. As a priori dosing 
information regarding the appropriate dose of anidulafungin for heavy patients is lacking, the 
results of the current study show that increases of both the loading dose and maintenance dose 
should be considered in patients with a BMI >40 kg/m2. We propose a 50% increased loading 
and maintenance dose for morbidly obese patients. 
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Abstract
The management of drug-drug interactions (DDIs) between azole antifungals (fluconazole, 
itraconazole, posaconazole and voriconazole) and immunosuppressants (cyclosporine, 
tacrolimus, everolimus and sirolimus) in transplant patients remains challenging, as the impact 
of altered immunosuppressant concentrations puts the patient at high risk for either toxicity or 
transplant rejection. As a result, it is a complex task for the clinician to maintain immunosuppres-
sant concentrations within the desired therapeutic range and this requires a highly individualized 
patient approach. We provide important tools for adequate assessment of the drug interactions 
that cause this pharmacokinetic variability of immunosuppressants. A stepwise approach for the 
evaluation and subsequent management options, including a decision flow chart, are provided 
for optimal handling of these clinically relevant DDIs. 
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Introduction
Immunosuppressants are standard of therapy for the prevention and treatment of graft-versus-
host-disease (GvHD) in hematopoietic stem cell and transplant rejection in solid organ transplant 
recipients. Because of the wide application of chemosuppressive or immunosuppressive 
therapy, these patients are at risk for the development of invasive fungal infections (IFIs). Azole 
antifungals (i.e. fluconazole, itraconazole, posaconazole and voriconazole) are often used 
for prevention as well as therapy of these infections. Unfortunately, azoles interfere with the 
metabolism and transport of immunosuppressants (i.e. cyclosporine, tacrolimus, sirolimus 
and everolimus), causing clinically relevant drug-drug interactions (DDIs) [1]. Initiation of azoles 
increases immunosuppressant exposure introducing side effects of these drugs [2], whereas 
subsequent discontinuation of azoles without dose adjustment of the immunosuppressant may 
lead to sub-therapeutic immunosuppressant exposure and risk of transplant rejection or GvHD. 
Although changes in exposure of immunosuppressants upon coadministration with azoles have 
been extensively described [1, 3-5], it remains a challenge for the clinician to adequately manage 
these DDIs (see Box 1 for an example). This article provides strategies for the management of 
these DDIs, ultimately increasing patient safety by reducing the risk of immunosuppressant 
toxicity or loss of efficacy.
In seven kidney transplant recipients with stable renal function, coadministration of 
voriconazole (200 mg twice/day for 7.5 days) and cyclosporine (150-375 mg/day) increased 
cyclosporine AUC(0-12h), C
max
 and C
min
 by 1.7, 1.13 and 2.5-fold, respectively, compared to 
cyclosporine alone [44]. Vice versa, discontinuation of voriconazole without dose adjustments 
of cyclosporine resulted in inadequate exposure of cyclosporine [45]. The great interindividual 
variability in cyclosporine AUC during concomitant voriconazole use indicates the 
magnitude of this interaction is widely variable [46, 47]. At initiation of voriconazole, the 
cyclosporine dose should be reduced by 50%, with subsequent monitoring of cyclosporine 
blood concentrations. At discontinuation of voriconazole, the cyclosporine dose should be 
increased and cyclosporine blood concentrations should be carefully monitored [36, 44-47].
Box 1. Management of drug-drug interaction of voriconazole and cyclosporine.
Principles of drug-drug interactions between azoles and 
immunosuppressants
Drug interactions can be categorized as either pharmacokinetic (PK; involving drug absorption, 
distribution, metabolism, or excretion) or pharmacodynamic (PD; antagonistic, synergistic or 
additive actions on the same receptor/physiological process) in nature [6]. Although we are 
aware that concomitant use of azoles and immunosuppressants can result in PD interactions, 
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this review will focus solely on PK interactions between azoles (‘precipitant drug’; causing the 
interaction) and immunosuppressants (‘object drug’; affected by the interaction).
These PK interactions involve azole inhibition of drug metabolizing enzyme cytochrome (CYP) 
P450 3A4/5 and/or drug transporter P-glycoprotein (P-gp) within the gastro-intestinal tract and 
the liver, for which immunosuppressants are substrates [1, 4, 7]. The magnitude of these interactions 
varies greatly, as azole inhibition of relevant enzymes can be dose-dependent and differs in 
potency and selectivity [1]. As an example, itraconazole and voriconazole are reported to be 
more potent inhibitors of CYP3A4 than posaconazole and fluconazole, and only itraconazole 
and posaconazole are capable of inhibiting P-gp [1, 8, 9].
Multiple genetic polymorphisms of CYP3A4, CYP3A5 and P-gp have been identified, associated 
with altered metabolic turnover [10]. These polymorphisms can also influence the magnitude of 
DDIs between azoles and immunosuppressants [11, 12]. The details of the interplay between DDIs 
and genetic variability in metabolizing enzymes are beyond the scope of this review and will not 
be further discussed. 
Tools to assess drug-drug interactions
Different approaches can be distinguished in order to adequately assess DDIs between azoles 
and immunosuppressants. In the next paragraphs a lay out of tools necessary for assessment of 
DDIs is presented. 
Sources of information on drug-drug interactions
Multiple sources on PK and DDIs between azoles and immunosuppressants are available and 
one should consider how the multidisciplinary team could use this information [13]. The summary 
of product characteristics (SmPC) is freely accessible and regularly updated, but unfortunately 
often lacks clinical guidance [14]. Regarding primary literature, in vitro, in vivo, case-reports and 
DDI studies can be assessed. In vitro and in vivo studies are prone to uncertainties regarding 
extrapolation to the clinical setting [15]. Case-reports can help in the management of the 
individual patient, generate hypotheses, and stimulate further research. DDI studies have the 
advantage that they are specifically designed to identify and quantify a DDI. Unfortunately, 
such studies are often not performed in the specified patient population but rather in healthy 
volunteers, making the translation to the patient population difficult. Commercially available 
drug compendia such as Micromedex® or Lexicomp®Online™ provide valuable and updated 
information on DDIs. As a licence is costly, not all healthcare professionals have access to 
these drug compendia. Drug-interaction databases, such as the recently launched Fungal 
Pharmacology (http://www.fungalpharmacology.com) might offer a solution. This web-based 
interaction tool is freely available and provides up-to-date peer-reviewed advice on DDIs with 
antifungal agents to improve patient safety and strengthen health systems [16]. 
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In the case of few or no data on DDIs, a theoretical interaction can be predicted based on the 
pharmacological mechanisms involved (e.g. evidence for a DDI with itraconazole based on its 
strong inhibition of CYP3A can be assessed to predict non-described DDIs with the (weaker) 
CYP3A4-inhibitor posaconazole). Conflicting data on DDIs require assessment of the external 
validity of the existing literature. Note that conflicting data may sometimes exist due to different 
concentrations, duration of therapy, route of administration, and time-effects of DDIs for example, 
inhibition followed by induction as seen with voriconazole and St. John’s wort [17]. 
Actual medication overview
An actual medication overview including prescribed and over-the-counter drugs is essential. For 
an accurate overview, medication reconciliation at admission to the hospital, before transfer and 
discharge is pivotal. Ideally, patients adhere to one outpatient pharmacy for all their prescriptions 
in order to keep the medication record of the individual patient complete and up-to-date.
Multidisciplinary team in interaction checks
A multidisciplinary team is imperative for the management of DDIs [18]. The clinician (together 
with the microbiologist and infectious disease doctor) is responsible for the diagnosis, treatment 
plan and selection of drugs and will first consider whether a DDI may occur. The hospital 
pharmacist/clinical pharmacologist has expertise on the PK of azoles and immunosuppressant 
drugs and their DDIs. Especially in complex patient populations, using multiple interacting 
drugs, it is advisable to actively involve a hospital pharmacist/clinical pharmacologist as a team 
member to review medication charts and interpret the magnitude of the DDI in light of the 
individual patient. 
Computerized provider order entry
Importantly, the use of computerized provider order entry (a system which allows clinicians to 
directly enter medication orders into a computer system, which then will be directly transmitted 
to the pharmacy) paired with clinical decision support systems (yielding automated warnings 
in case of possible DDIs) enables clinicians and pharmacists to identify DDIs [19]. Ideally, no ‘alert 
fatigue’ exist and warnings are tailored and graded for severity to increase the usefulness for 
assessment of DDIs [20, 21]. So, if well designed, this tool can facilitate decision-making in DDIs, 
although its use might be restricted in resource-limited settings due to its high costs.
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Clinical monitoring
Clinical monitoring (i.e. check for signs and symptoms of altered drug response, side effects/
toxicity and monitoring of biochemical and hematologic parameters) is essential to assess 
the impact of DDIs during coadministration. Especially at start, in case of dose-adjustments, 
during changes in clinical condition and upon discontinuation of an interacting drug, regular 
monitoring (e.g. liver and/or renal function tests) is indicated.
Therapeutic drug monitoring
Therapeutic drug monitoring (TDM), that is, individualized drug dosing based on the 
measurement and interpretation of drug concentrations, is an important tool to maintain 
drug concentrations between predefined target concentrations [22, 23]. Blood concentration 
measurement should be performed using an assay that is internally and externally validated 
according to international guidelines [24-26]. Information on sampling time, dose, frequency, 
route of administration, formulation, co-medication and patient characteristics is essential for 
adequate interpretation of the drug concentration [22, 27]. TDM should ideally be used in every 
patient using immunosuppressants and azoles concomitantly. 
Because the inhibiting effect on CYP450 enzymes starts immediately after the azole is initiated [3], 
TDM of the immunosuppressive agent is ideally performed before initiation of the azole and 2 
times a week for 2 weeks afterwards [28] with regular drug concentration measurement (e.g. every 
2-3 weeks) thereafter [29]. Upon discontinuation of the azole, the duration of the inhibitory effect 
depends on the triazole’s half-life [3]. Monitoring of immunosuppressant blood concentrations 
can then guide dose optimization, until immunosuppressant concentrations are within the 
therapeutic window. Novel sampling techniques such as dried blood spot (DBS) sampling can 
be performed at home and samples are sent to the laboratory by mail, facilitating sampling in 
the outpatient setting. Only a single drop of blood is required, which can easily be obtained by 
a finger prick and sampled on filter paper [30].
Teaching on knowledge and awareness in relation to drug-drug 
interactions
Dedicated education and lifelong learning helps to develop awareness towards possible DDIs. 
Clearly, understanding the underlying mechanism of DDIs optimizes subsequent management. 
An important item to be covered during teaching is the narrow therapeutic window of immu-
nosuppressants. Although pharmacists are well positioned to provide education on DDIs, using 
the combined expertise of all team members will result in better understanding of all aspects 
concerning the management of DDIs. Patients should also be taught for awareness of DDIs by 
careful medication education and counselling, to avoid unsupervised discontinuation of the 
azole and to provide insight in the interactions with over-the-counter drugs (e.g. omeprazole [31, 32] 
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Table 1. Rating, classification and interpretation of drug-drug interactions.
Rating Classification Interpretation
A No known interaction Data have not demonstrated pharmacokinetic/pharmacodynamic alterations following 
concomitant use
B No action needed Data demonstrate that the drugs may interact, but this DDI is of limited clinical significance
C Monitor therapy Data demonstrate that the DDI may be clinically significant, but generally would not require a 
major alteration in therapy. An appropriate monitoring plan should be implemented to identify 
possible negative effects. Dose adjustments are only required in a minority of patients.
D Consider therapy 
modification
Data demonstrate that the DDI may be clinically significant and requires specific clinical decision 
making (e.g empiric dose adaptation, continuous TDM, alternative agents) to realize the benefits 
and minimize or prevent the risk of toxicity.
X Avoid combination Data demonstrate that the DDI may be clinically significant and concomitant use is 
contraindicated. The risks of interaction usually outweigh the benefits of therapy.
and herbs such as St John’s wort [17, 33]). 
Evaluation of drug-drug interactions: a stepwise approach
The following paragraph aims to guide clinicians in the evaluation of DDIs using a stepwise 
approach, thereby contemplating the pharmacological mechanism of DDIs between 
immunosuppressants and azoles and using the tools described above to adequately assess the 
interaction.
Step 1: predict
Understanding the pharmacological mechanisms underlying DDIs (substrate/inhibitor for 
CYP-enzymes and/or drug transporters) together with the pharmacological properties of 
azoles and immunosuppressants enables predicting potential DDIs. In this, the SmPC or drug 
compendia provide good sources of information (see tool: Sources of information), and teaching 
on these underlying mechanisms raises awareness towards these DDIs (see tool: Teaching on 
knowledge and awareness).
Step 2: identify
Identification of DDIs can be facilitated using sources of information (see Sources of information). 
To determine the extent and quality of evidence on the DDI, the study design and possible 
limitations in primary literature should be taken into account [34]. For example, DDI studies (e.g. 
cross-over steady-state PK studies with AUCs) provide better quality compared to case reports.
Step 3: quantify
The expected change in blood concentration (e.g. C
min
, AUC, C
max
) of the object drug following 
the DDI should be determined using available evidence (see step 2). The DDI effect may be 
influenced by dose or concentration, duration of therapy and route of administration (intravenous 
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Drug-drug
interaction?
Relevant
interaction?
(A, B, C, D, X,
see Table 1)?   
No
No (C)
Dose adaptation
immunosupressive agent
required? 
Concentration 
TDM 
immunosuppressive
agent 
No
adequate?
Yes Continue therapy
Alternative
strategies: 
Stop azole
Yes
Yes (C, D or X)No (A or B)
Transplant patient treated with azole and
immunosuppressive agent*
 
Repeat
Yes (D, X)
Switch to non-
azole antifungal
agent 
Adapt dose
Desired eect
not obtained?† Not recommended:
*Rational clinical de cision guided by immunosuppressive therapy and antifungal stewardship 
†Target attainment not possible for individual patient 
No intervention 
required
Spacing  dosing times
Decrease dose of azole 
Changing route of administration of immunosuppressant
and azole (oral to intravenous)
Figure 1. Decision flow chart for treatment options in the management of drug-drug interactions.
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versus oral). Co-medication is also of importance, since the object drug can be influenced by 
more than one precipitant drug. The predicted time of onset and off-set should be determined, 
which depends on the interaction mechanism that is inhibitory or inducing (inhibitory in case of 
azole antifungals and immunosuppressants) [1]. In clinical practice, the effect of the DDI can be 
quantified by means of TDM (see tool: Therapeutic drug monitoring).
Step 4: classify 
Changes in exposure should be regarded in light of the therapeutic window of the object drug 
to estimate the clinical significance of the DDI. Because of the narrow therapeutic window of 
immunosuppressants, relatively small changes in exposure may lead to adverse drug reactions 
or loss of efficacy. Vice versa, drugs with a wide therapeutic window allow for large changes in 
exposure without affecting patient response.
Risk classification as used by specified drug-interaction databases (see Sources of information) 
can be of help in classifying the severity of DDIs (Table 1) [16]. 
Step 5: assess patient-related factors 
Patient-related factors capable of altering drug blood concentrations (e.g. disease status, co 
morbidities, and co-medication) may influence the magnitude of the effect and significance of a 
DDI [35]. For example, the addition of erythromycin to a patient already treated with voriconazole 
and cyclosporine will intensify the DDI, due to additional CYP3A inhibiotion, resulting in increased 
cyclosporine exposure.
Step 6: appropriately circumvent or manage the DDI
Taking into account the tools for assessment and the above steps (steps 1-5, Table 1) for evaluation 
of DDIs, the management options to handle DDIs between azoles and immunosuppressants are 
provided below. The ultimate goal of these management options is to maintain immunosup-
pressant concentrations within predefined target concentrations, thereby avoiding unnecessary 
toxicity or loss of efficacy. A structured management plan, based on the clinical significance of 
the DDI is provided in Figure 1. 
• Discontinue the azole antifungal drug if possible
If allowed by the antifungal therapy management, discontinuation of the azole (or switch to a 
non-azole, see below) can be an option to prevent a DDI. For instance antifungal prophylaxis can 
be discontinued, for example posaconazole prophylaxis in hematopoietic stem cell transplant 
(HSCT) recipients. When doing so, the risk profile of the patient has to be taken into account and 
countermeasures must be taken (e.g. a proper diagnostic driven approach for fungal infections 
must be instituted in these cases to safeguard early detection of possible invasive fungal 
infection). 
• Empirically decrease the dose of the immunosuppressive agent
Empirically decreasing the dose of the immunosuppressant can decrease the risk of adverse 
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effects associated with increased immunosuppressant concentrations (e.g. nephrotoxicity). The 
magnitude of dose reduction during concomitant azole use depends on the selected immuno-
suppressant [4]. For example, when starting therapy with voriconazole in a patient treated with 
tacrolimus, a dose reduction of about 66% is indicated [36]. 
• Decrease the dose of the immunosuppressive agent based on TDM
Although it should be acknowledged that not all healthcare settings have access to a validated 
assay for the measurement of immunosuppressant blood concentrations, TDM is considered 
helpful in the management of the DDIs between azoles and immunosuppressant, both in the 
case of empirical dose reductions as when no empirical dose reductions are required. The latter 
can be explained by the DDI between fluconazole and cyclosporine. In our institute, we have 
chosen not to emperically decrease the dose of cyclosporine in case of coadministration with 
low-dose fluconazole (e.g. 100–200 mg/day), given the low inhibitory potency of this azole 
antifungal against CYP3A4 [37]. Instead, TDM is used to guide dose adaptations of cyclosporine.
• Switch to a non-azole antifungal agent
In case the DDI is difficult to manage despite dose adaptations and TDM, either the immuno-
suppressant or the antifungal can be substituted. Alternatives to azoles are lipid formulations 
of amphotericin B or echinocandins. It is advisable to consult an ID specialist and/or a clinical 
microbiologist for the determination of the susceptibility of the offending pathogen in relation 
to the alternative agent [38]. Both these agents show little to no interference with CYP-enzymes 
and therefore do not significantly impact exposure of immunosuppressants [38, 39]. Of note, one 
should be aware of a pharmacodynamic interaction between amphotericin B and calcineurin 
inhibitors as both classes of drugs have nephrotoxic properties [40].
Alternative considerations not recommended
Some strategies suggested in the literature [41] are not recommended for the management of 
DDIs between azoles and immunosuppressants. Spacing dosing times, that is introducing a 
time-gap between intake of the azole antifungal and the immunosuppressant, or increasing 
the dose interval of azoles are not recommended as the inhibitory effects of azoles are 
considered independent of dosing time. Decreasing the dose of the azole antifungal also is not 
recommended as the efficacy of azoles is strongly correlated with plasma concentrations [42]. The 
strategy to change the route of administration of the immunosuppressant and azole from oral 
to intravenous to circumvent inhibitory effects of triazoles in the GI-tract on immunosuppressant 
metabolism is not patient friendly and difficult to implement in outpatient settings [28, 43]. 
101
Antifungal drug-drug interactions
Conclusions and future directions
Because of the narrow therapeutic window of immunosuppressants, transplant patients are at 
high risk for DDIs when concomitantly treated with azole antifungals, compromising patient 
safety. Increased understanding of the pharmacological mechanism underlying the DDI is a 
critical step to reduce adverse outcomes. Although literature extensively describes the changes 
in exposure to immunosuppressants introduced by azoles, strategies for optimal management in 
clinical practice are currently lacking. Adequate management of these interactions is challenging 
and requires a systematic approach. 
We distinguished different tools for the assessment of DDIs. In the optimal situation, healthcare 
professionals cooperate by a multidisciplinary approach and have access to all tools to safely 
assess DDIs. Our stepwise approach helps to predict, identify, quantify and classify DDIs as basis 
for the actual management of the DDI. We feel that the best management option for these 
DDIs is empirical dose reduction of the immunosuppressant upon the initiation of the azole, 
taking into account the magnitude of the interaction. Subsequent individualization of immu-
nosuppressant doses by means of TDM is highly recommended. One should bear in mind that 
although the focus of this review is on DDIs between azoles and immunosuppressive agents, 
other interactions with these drugs in the transplant setting are common.
By using the provided tools, following the stepwise approach and management options, we 
provide the optimal strategy to manage the DDIs between azoles and immunosuppressants. 
This should ultimately promote patient safety, minimize complications and optimize treatment 
outcome. Future directions should focus on the implementation of the proposed strategies in 
clinical practice.
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Abstract
The Information Age has revolutionized the ability of healthcare professionals (HCPs) to oversee 
a substantial body of clinically relevant information literally at one’s fingertips. In the field of 
clinical pharmacology, this may be particularly useful for managing drug–drug interactions 
(DDIs). A thorough understanding of the underlying mechanisms of DDIs allows the HCP to 
predict such interactions and avoid those of greatest clinical significance. Specifically, successful 
treatment with antifungal agents is complicated by the high potential to interact with other 
concomitant medications. We describe here the development of a real-time knowledge base of 
DDIs with antifungal agents, providing expert recommendations to HCPs on how to handle DDIs 
with these drugs. This new resource will facilitate rapid identification, quantification and classi-
fication of these DDIs by clinicians with varying levels of experience and resources worldwide, 
ultimately improving patient safety and strengthening health systems.
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Introduction
Invasive fungal diseases (IFDs) are an important cause of morbidity and mortality in immuno-
compromised and otherwise debilitated patients. Although prophylactic or therapeutic use 
of antifungal drugs has substantially improved the outcome of IFDs, effective treatment can 
be complicated by drug-drug interactions (DDIs). Specifically, the antifungal class of azoles 
causes a high degree of significant DDIs, impacting the pharmacokinetics (PK) of either azoles, 
concomitant medications or both [1, 2]. This could result in either supratherapeutic plasma con-
centrations with subsequent risk of toxicity or subtherapeutic plasma concentrations potentially 
leading to therapeutic failure. Echinocandins, lipid and other formulations of amphotericin B, 
and flucytosine are also involved in DDIs [3-5], although these interactions are mostly of limited 
clinical importance compared with the azoles. Nevertheless, these interactions should be taken 
into account for clinical management in specific settings. 
Despite widespread efforts to monitor for DDIs with antifungal agents, it is almost impossible for 
the clinician to be conversant with all possible DDIs and assess their potential consequence for 
an individual patient. In 2009, we published a review to provide recommendations on the clinical 
management of nearly 200 such DDIs [1]. The complexity of the DDIs we described prompted us 
to develop a new approach for managing antifungal drug interactions.
A new approach in identifying DDIs with antifungal agents
The list of potential DDIs involving antifungal agents continues to grow as more evidence 
becomes available, so the literature requires constant re-evaluation of the clinical management 
of these DDIs. Drug-interaction databases are a solution, but are not without disadvantages. 
Access to commercial databases (e.g. Lexi-Interact™) might be hindered due to the high costs 
associated with its use (membership-fee), especially in resource-limited settings. Other databases 
such as DrugBank are freely available and afford up-to-date information [6], but they seldom offer 
a general approach to identifying DDIs or provide advice on specific clinical management. In 
our opinion, an ideal resource should not only provide a comprehensive, up-to-date overview of 
DDIs with antifungal agents, but should also describe the underlying mechanism and scientific 
evidence as well as offer tailor-made clinical advice on how to manage these interactions.
The clinical value of tailor-made web sites that provide information on managing DDIs in 
HIV-infected patients treated with antiretroviral drugs has been clearly demonstrated [7]. Among 
these web sites, pharmacist ranked the HIV Drug Interactions database of the University of 
Liverpool [8] among the highest by quality and usefulness [9]. Given that antifungal drugs have 
similar potential for complicated DDIs as do antiretroviral drugs [10] and the clear unmet need 
for a similar initiative based on the questions we received after publishing our review [1], we 
decided to adopt a similar approach for antifungal drugs entitled Fungal Pharmacology 
(http://www.fungalpharmacology.com) [11].
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How we developed Fungal Pharmacology
Several years ago, we initiated the development of Fungal Pharmacology with the aim of 
providing up-to-date, easily accessible information on DDIs between antifungal agents and 
other prescription drugs, over-the-counter medicines and natural products. The intended users 
included hospital and general medical practitioners, hospital and community pharmacists, 
clinical pharmacologists, medical microbiologists, infectious diseases physicians, and nursing 
staff. To promote its use, especially in resource-limited settings, we wanted Fungal Pharmacology 
to be completely free of charge. Mobile devices have also become commonplace in healthcare 
settings, so our goal was to also make the DDI application available to devices using Apple® 
and Android® operating systems. DDIs could be retrieved by entering a single drug or a class 
of drugs. Alternate therapeutic options with drugs from the same class would also be listed 
with their relevant severity. A data sharing function was also added to enable clinicians to share 
relevant information with other colleagues. A detailed overview of the development process is 
shown in Figure 1. 
A PhD student was appointed to gather all the primary information on DDIs acting under 
supervision. An international panel of hospital pharmacists, clinical pharmacologists, clinicians 
and microbiologists with extensive knowledge on the treatment of IFDs was convened to help 
design the web site and app. A communications agency and web designer were then employed 
to develop a facility for storing information and the initial version of the web site and app. By 
employing a usability test constructed by our web designer, the web site’s content, navigation, 
interaction, layout and system functionality were evaluated by a user panel of clinicians and 
hospital pharmacists. 
After an initial review and trial, the test panel offered suggestions for improvements and additional 
requirements (e.g. both a choice in alphabetical and severity listing of DDIs). Completion of data 
entry and composing clinical advice was achieved by continuous data integrity checks by our 
user panel. Every single DDI and clinical advice was peer-reviewed by our expert panel before 
the web site and the app went live at the end of 2014. The interface of the web site is illustrated 
in Figure 2.
We included all currently licensed antifungal drugs for treatment of IFDs including azoles 
(fluconazole, itraconazole, posaconazole, and voriconazole), echinocandins (anidulafungin, 
caspofungin, and micafungin), lipid and other formulations of amphotericin B, and flucytosine. 
Information was obtained from multiple sources including primary literature, product 
information, Micromedex®, Stockley’s Drug Interactions, Lexi-Interact™ and G-Standard 
(medicines standard in Dutch healthcare). Possible theoretical interactions were described 
referring to the pharmacological mechanism. For example, we extrapolated DDIs with 
ketoconazole to the azoles fluconazole, itraconazole, voriconazole and posaconazole based 
on their CYP3A4 inhibition potential [1]. Besides drugs selected based on reported DDIs, an 
additional 100 drugs (not necessarily interacting drugs) were added to the database based 
on their frequent use in daily practice [12]. Generic drug names were reported (using both the 
International Nonproprietary Name and United States Adopted Name, e.g. paracetamol/
acetaminophen), which were categorized according to the WHO Anatomical Therapeutical 
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Figure 1. Development process and project timeline for Fungal Pharmacology.
Explore (12 months)
Defined overarching project objective and end-user 
Wrote project plan and determined project timelines
Explored possibilities for funding
Contracted PhD student
Assembled expert panel to investigate scope and requirements for website/app
Contracted communication agency, webdesigner and graphic designer
Grouped content (determine which drugs to include and information sources)
Set up automatic searches and new record alerts for search engines
Assembled test-panel to explore technical requirements and system functionality
Check whether CE marking is necessary (our App is not in scope for CE marking)
Construct (18 months)
Constructed facility for storing information and initial version of website
Simultaneous construction of application for smartphones
Gathering literature / data
Test initial version of website with subset of gathered data of DDIs
Data integrity check by user-panel (verify all information has been correctly  stored andis displayed in interface)
Testing and feedback on initial version of website by testpanel (additional requirements)
Gathered all possible information on DDIs from multiple sources with subsequent data storage 
Consult (6 months)
Performed data-integrity check
Peer-reviewed DDIs by expert panel and specialists in the field 
Modification of advices DDIs based on input by expert panel
Publish (3 months)
Go-live of website in secure area, validated with testpanel.
Go-live of application in secure area, validated with testpanel.
Go-live of website and application on internet, Android and Apple platform 
Track (ongoing) 
Incorporate new information, discuss with expert panel (biweekly meetings)
Inventarise on new possibilities and end-user requirements (monthly meetings) 
Status reports on statistics using Google Analytics
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Chemical (ATC) classification system [13]. Severity of the DDI was classified using the Grading of 
Recommendations Assessment, Development and Evaluation approach [14, 15]. This approach 
was also used to evaluate the quality of available evidence, which led to an adapted algorithm 
also used by the HIV Drug Interactions database [offering four levels of evidence quality: high, 
moderate, low and very low (see Table 1)] [8, 14, 16]. Both grading of quality of evidence and strength 
of recommendation were compared with the grading in multiple sources described above, 
which was then peer-reviewed by the expert panel. In case of the discrepant data described 
Figure 2. Composite screen shot representing the structure of Fungal Pharmacology (displaying a drug-drug interaction between 
itraconazole and immunostimulants/suppressants i.e. ciclosporin).
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in literature or product information [Summary of Product Characteristics (European) and US 
prescribing information (USA)], these differences were described in the clinical advice. Final 
recommendations and approval were done by the expert panel. Additional information on QT 
interval prolongation of both interacting drugs was retrieved from the CredibleMeds® QT drugs 
list (available at https://www.crediblemeds.org/). Automatic searches and new record alerts 
using search engines (PubMed/EmBase) were undertaken weekly to ensure all information on 
DDIs with antifungal drugs was up-to-date. With this, Fungal Pharmacology is, to our knowledge, 
the first web-based resource for keeping abreast of DDIs with antifungal drugs in such great 
detail.
To further provide a better understanding of the underlying mechanisms of DDIs, detailed 
information on the PK of antifungal drugs is provided on the web site. Reports of new abstracts 
from major conferences and articles are presented in a news bulletin. More general information, 
recent notifications and changes in the product information by licensing agencies such as the 
EMA and US FDA are also shown. 
Unfortunately, our approach only allows for paired DDIs rather than predicting tertiary 
interactions (groups of three or more drugs). In order to enhance our database with the ability to 
predict multiway interactions, this would require a tailor-made network inference algorithm [17], 
which cannot be readily applied to our website. 
Future directions
In the light of new information available and new drugs on the market, we implemented a quality 
control system for data on new and already existing DDIs. In biweekly meetings, new key data 
from published papers, abstracts and product information are reviewed by one pharmacist and 
this information is assessed by an additional three assessors. Final comments and suggestions 
are then added to Fungal Pharmacology. Additionally, we address the feedback from our users in 
order to maintain quality and keep bias as low as possible. Collaborations are also being sought 
with Dutch healthcare organizations such as the Dutch Medicines Evaluation Board, to provide 
additional sources of data input. 
Knowledge bases such as Fungal Pharmacology should not be used as a standalone solution, 
but rather should aid clinical decisions and support electronic health records by incorporating 
therapeutic drug monitoring data, patient demographics, laboratory tests (e.g. liver function 
tests and glomerular filtration rate values) and clinical information such as side effects, laboratory 
abnormalities and ECG read-outs. In this way, the clinical advice on the DDI with antifungal drugs 
could be even more patient-specific, anticipating altered PK parameters in the target population. 
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Conclusions
Healthcare professionals involved in the prevention and treatment of life-threatening IFDs now 
have a comprehensive tool at their disposal for managing >1,000 clinically important DDIs 
with antifungal agents. Together with in-depth advice on the clinical management of these 
interactions, Fungal Pharmacology can greatly assist in maximizing the chance of clinical and 
microbiological success while minimizing the risk of treatment-related side effects due to DDIs. 
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Abstract
Inhibition of ABC transporters is a common mechanism underlying drug-drug interactions 
(DDIs). We determined the inhibitory potential of antifungal drugs currently used for invasive 
fungal infections on ABC transporters P-gp, MRP1–5, BCRP and BSEP in vitro. Membrane vesicles 
isolated from transporter-overexpressing HEK293 cells were used to investigate the inhibitory 
potential of antifungal drugs (250µM) on transport of model substrates. Concentration-inhibition 
curves were determined if transport inhibition was >60%. IC
50
 values for P-gp and BCRP were 
both 2µM for itraconazole, 5 and 12µM for hydroxyitraconazole, 3 and 6µM for posaconazole 
and 3 and 11µM for isavuconazole, respectively. BSEP was strongly inhibited by itraconazole and 
hydroxyitraconazole (3 and 17µM, respectively). Fluconazole and voriconazole did not inhibit 
any transport for >60%. Micafungin uniquely inhibited all transporters, with strong inhibition 
of MRP4 (4µM). Anidulafungin and caspofungin showed strong inhibition of BCRP (7 and 6µM, 
respectively). Amphotericin B only weakly inhibited BCRP-mediated transport (127µM). Despite 
their wide range of DDIs, azole antifungals exhibit selective inhibition on efflux transporters. 
Although echinocandins display low potential for clinically relevant DDIs, they demonstrate 
potent in vitro inhibitory activity. This suggests that inhibition of ABC transporters plays a crucial 
role in the inexplicable (non-cytochrome P450 mediated) DDIs with antifungal drugs.
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Introduction
Invasive fungal infections are a leading cause of infection-related mortality in immunocompro-
mised individuals and patients with serious underlying conditions. Although prophylactic or 
therapeutic use of azole antifungal drugs has substantially improved treatment outcome, these 
drugs display a significant potential for clinically relevant drug-drug interactions (DDIs) [1, 2]. As a 
result, the pharmacokinetics (PK) of both drugs may alter, resulting in either increased plasma 
concentrations with subsequent risk of adverse events or sub-therapeutic plasma concentra-
tions potentially leading to therapeutic failure.
With regards to phase I and II enzymes, the pharmacokinetic profiles of antifungal drugs have 
been quite well characterised [2, 3]. Yet, it also appears that both uptake and efflux transporters are 
considered a major intervenient in drug PK, and inhibition of such transporters is an important 
mechanism underlying DDIs [4, 5]. 
Transporters of the ATP-binding cassette (ABC) transporter protein family are involved in unidi-
rectional, cellular efflux of drugs [6]. They are multidomain, integral membrane proteins, which all 
exhibit the capacity to actively transport physiological substrates (e.g. peptides, lipids, inorganic 
ions) across extra –and intracellular membranes at the expense of ATP hydrolysis. Expression of 
these transporters in the cellular membranes of the gastrointestinal tract, blood-brain barrier, 
liver and kidney suggest they also hold a key position in the cellular protection against toxic 
compounds and drugs [7]. Specifically, P-glycoprotein (P-gp/ABCB1), several isoforms of Multidrug 
Resistance-associated Proteins (MRP/ABCC) and Breast Cancer Resistance Protein (BCRP/ABCG2) 
have been shown to influence drug PK by extruding a large variety of xenobiotics from cells back 
to either external medium or blood [8]. In addition, although Bile Salt Export Pump (BSEP/ABCB11) 
mediates the canalicular export of bile salts from liver into bile, which can be inhibited by several 
drugs and may result in cholestatic liver injury [9, 10], it has also been demonstrated to transport 
drugs [11]. 
Because ABC transporters have a broad substrate spectrum, interaction of drugs with such a 
transporter could result in mutual transport inhibition [5]. This inhibition could consequently alter 
the PK of substrates of the inhibited transporter and promote DDIs [5, 6]. 
Knowledge of the inhibitory potential of antifungal drugs on ABC-mediated transport activity 
is crucial in understanding the molecular mechanisms underlying non-cytochrome P450 (CYP) 
mediated DDIs of these drugs. Also, this may be of great importance in explaining variations in 
local (non-systemic) concentrations of drugs, thereby increasing safety and efficacy.
In the present study, we examined the inhibitory potential of ten antifungal drugs currently 
used in the treatment of invasive fungal infections (fluconazole, itraconazole, hydroxyitracona-
zole, voriconazole, posaconazole, isavuconazole, anidulafungin, caspofungin, micafungin and 
amphotericin B) on the efflux of model substrate via ABC transporters P-gp, MRP1–5, BCRP and 
BSEP, using a vesicular overexpression transport assay.
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Materials and Methods
Inside-out membrane vesicles were isolated from Human Embryonic Kidney (HEK) 293 cells 
(overexpressing a single ABC transporter). These vesicles were used to determine the inhibitory 
potential of antifungal drugs (250 µM) on ATP-dependent transport of model substrates. IC
50 
values were determined if an antifungal drug inhibited transport for >60%. 
A detailed description of these individual steps is outlined below.
Materials
The following antifungal drugs were kindly provided by the manufacturer: hydroxyitraconazole 
(Janssen Pharmaceuticals, Inc.), voriconazole and anidulafungin (Pfizer, Inc.), posaconazole 
and caspofungin (Merck, Sharp and Dohme Corp.), isavuconazole (Basilea Pharmaceutica) and 
micafungin (Astellas Pharma). Fluconazole, itraconazole and amphotericin B were purchased 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Substrates [3H]-estrone sulfate ([3H]-E
1
S), 
[3H]-estradiol 17β-glucuronide ([3H]-E
2
17βG) and [3H]-taurocholic acid ([3H]-TCA) were purchased 
from PerkinElmer, Inc. (Waltham, MA, USA). [3H]-methotrexate ([3H]-MTX) was purchased from 
Moravek Biochemicals (Brea, CA, USA). [3H]-N-methyl-quinidine ([3H]-NMQ) and unlabelled 
NMQ were obtained from Solvo Biotechnology (Szeged, Hungary). Adenosine 5’-triphosphate 
disodium salt (ATP; from bacterial source) was purchased from Sigma-Aldrich (Zwijndrecht, the 
Netherlands). MultiScreenHTS filter plates and Vacuum Manifold filtration devices were purchased 
from Millipore (Etten-Leur, the Netherlands). Opti-fluor scintillation fluid was purchased from 
PerkinElmer, Inc. (Waltham, MA, USA).
Transporter-overexpressing membrane vesicles
Membrane vesicles from Human Embryonic Kidney (HEK) 293 cells with overexpression of a 
single type of ABC transporter (i.e. P-gp, MRP1–5, BCRP, BSEP or enhanced Yellow Fluorescent 
Protein (eYFP, a cytosolic protein, as negative control) were purchased from PharmTox (Nijmegen, 
the Netherlands; http://www.pharmtox.nl).  
Vesicular transport assay
By means of quality assurance, the vesicles were tested for functionality using a rapid filtration 
technique [12]. Vesicles overexpressing the transporter MRP1, MRP3 or MRP4 were incubated 
with [3H]-E
2
17βG (0.1 µM/0.15 µCi), vesicles overexpressing MRP2 or MRP5 with [3H]-MTX 
(0.4 µM/0.15 µCi) and BSEP vesicles with [3H]-TCA (0.1 µM/0.15 µCi) for 5 min at 37°C. P-gp over-
expressing vesicles were incubated with [3H]-NMQ (0.1 µM/0.015 µCi) and BCRP overexpressing 
vesicles with [3H]-E
1
S (0.1 µM/0.1 µCi) for 1 min at 37°C. The activity of the eYFP vesicles (negative 
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control) was measured for all substrates. Incubations were performed using 7.5 µg protein in TS 
buffer (pH 7.4) supplemented with 10 mM MgCl
2
, 4 mM ATP or 4 mM AMP (negative control) in 
a total volume of 30 µL. The process of incubation was stopped on ice. After addition of 150 µL 
ice cold TS buffer, the samples were filtered using a MultiScreenHTS-vacuum manifold filtration 
device through TS preincubated 0.45-µm-pore 96-wells Millipore filters. The filters were washed 
twice with 200 µL TS buffer. After adding 2 mL of Opti-fluor scintillation fluid, the samples were 
counted using a liquid scintillation counter. A ratio was calculated dividing the ATP by the AMP 
values. Experiments were performed in triplicate. 
Antifungal inhibitory effects on model substrate transport
The vesicular transport assay was performed as described above. Antifungal drugs were 
dissolved in dimethyl sulfoxide (DMSO; fluconazole, itraconazole, hydroxyitraconazole, 
voriconazole, posaconazole, isavuconazole, anidulafungin and amphotericin B) or in ultrapure 
water (caspofungin, micafungin) to a final concentration of 12.5 mM. At higher concentrations, 
maximum solubility of itraconazole in DMSO was reached. Therefore, concentration-dependent 
analysis of itraconazole was limited to 100 µM. Antifungal drugs (250 µM) or solvents (DMSO 
or ultrapure water) were added to the mixture before incubation. For all mixtures, ATP was 
added and enhanced yellow fluorescent protein (eYFP) was used as negative control. Screens 
were performed in triplicate. After subtraction of eYFP, mean values of substrate transport were 
expressed as percentages (100% for samples with solvent). The concentration of 250 µM was 
used to ascertain that most inhibitory effects would be observed. Antifungal drugs inhibiting 
transport of model substrate for more than 60% at 250 µM (empirically chosen based on 
previous experiments) were selected to further determine concentration-dependent inhibition 
and ultimately 50% inhibitory concentrations (IC
50
). 
Concentration-dependent inhibitory effects 
Transport studies were performed as described above, but with antifungal drug concentrations 
ranging from 0–250 µM. For each concentration, four data points were recorded and the control 
values (eYFP) were subtracted. 
Data Analysis
Mean values of substrate specific transport were expressed as percentages relative to control 
(after subtraction of eYFP background transport), with the solvent control representing 100% 
transport. Mean percentages of relative transport per transporter interaction were pooled. All 
transport data were expressed as mean ± standard deviation. Drug concentrations were plotted 
as logarithmic concentrations. Concentration-dependent inhibition data were analyzed by 
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nonlinear regression analysis according to a one-site binding model with variable slope (also 
called the Hill equation), using GraphPad Prism Software, version 5.03, (Graphpad Software Inc., 
San Diego, CA, USA).
Results
Functionality of the transporter-overexpressing membrane vesicles
The vesicular transport assay showed functionality of all transporters compared to the negative 
control. The AMP-ATP ratios of the transporters P-gp, MRP1–5, BCRP and BSEP are shown in 
Table 1.
Antifungal inhibitory effects on model substrate transport
The inhibitory potential of antifungal drugs (250 µM) on the transport of radiolabeled model 
substrates via ABC transporters P-gp, MRP1–5, BCRP and BSEP are shown in Figure 1. 
The azole antifungals fluconazole and voriconazole did not inhibit the transport of model 
substrate of any selected transporter. Itraconazole, hydroxyitraconazole and posaconazole all 
significantly inhibited (>60%) P-gp, BCRP and BSEP. Isavuconazole was capable of significant 
inhibition of P-gp and BCRP.
Table 1. Functional activity (AMP-ATP ratio) per transporter with respect to their model substrate.
eYFP: enhanced Yellow Fluorescent Protein (negative control), P-gp: P-glycoprotein, MRP: Multi Resistance Protein, BCRP: Breast Cancer Resistance 
Protein, BSEP: Bile Salt Export Pump, NMQ: N-methyl-quinidine, E
2
17β-G: Estradiol 17β-glucuronide, MTX: Methotrexate, E
1
S: Estrone sulfate, TCA: 
Taurocholic acid
Transporter Substrate AMP (pmol/mg/min) ATP (pmol/mg/min) AMP/ATP Ratio
eYFP NMQ 23.6 29.2 1
P-gp NMQ 24.8 125.4 5
eYFP E217βG 0.1 0.1 1
MRP1 E217βG 0.2 1.1 5
MRP3 E217βG 0.2 4.5 26
MRP4 E217βG 0.2 1.0 5
eYFP MTX 0.02 0.03 1
MRP2 MTX 0.03 0.1 4
MRP5 MTX 0.05 0.5 9
eYFP E1S 0.8 0.9 1
BCRP E1S 1.2 13.1 11
eYFP TCA 0.3 0.7 2
BSEP TCA 0.4 8.1 19
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Table 2. Overview of antifungal drug concentrations (µM) at 50% inhibition (95% CI) of ATP-dependent uptake of model substrate 
(IC50). 
FLZ: fluconazole, ITZ: itraconazole, hITZ: hydroxyitraconazole, PSZ: posaconazole, VCZ: voriconazole, ISA: isavuconazole, 
ANF: anidulafungin, CAS: caspofungin, MCF: micafungin, AMB: amphotericin B
Inhibition potentials range from relatively strong inhibition (dark grey, diagonal line; 0-5µM) to relatively mild inhibition (light grey, diagonal line; 
20-25µM) and eventually relatively low inhibition (dark gray, no line; 50 µM and up), using intermediate colours with increments of 5µM. 
P-gp MRP1 MRP2 MRP3 MRP4 MRP5 BCRP BSEP
FLZ . . . . . . . .
ITZ 2
(1.1–2.3)
. . . . . 2 
(1.6-3.6)
3 
(2.7-3.4)
hITZ 5 
(2.9-7.7)
. . . . . 12 
(7.4-20.2)
17 
(16.1-18.6)
VCZ . . . . . . . .
PCZ 3 
(2.2-4.1)
. . . . . 6 
(3.9-8.1)
34 
(29-40.4)
ISA 3 
(2.7-3.9)
. . . . . 11 
(5.2-2.3)
.
ANF 38 
(23-61.8)
. . . 28 
(21.7-36.3)
. 7 
(6.1-8.3)
.
CAS 34 
(26.8-43.7)
112 
(88.7-140.7)
. 158 
(91.6-272.1)
. . 6 
(2.5-13.2)
186 
(113.5-305.6)
MCF 45 
(29.2-70.5)
21 
(19.9-23.0)
148 
(81.8-266)
42 
(38.2-46.7)
4 
(3-5.4)
22 
(19.3-26.0)
21 
(17.4-25.4)
85 
(72.8-100)
AMB . . . . . . 127 
(86.8-186.3)
. 
The echinocandin anidulafungin inhibited P-gp, BCRP and MRP4-mediated transport of model 
substrates. Caspofungin inhibited P-gp, BCRP, BSEP, MRP1 and MRP3-mediated transport. 
Micafungin was capable of inhibiting substrate transport of all transporters for more than 60%.
Amphotericin B was only capable of inhibiting substrate transport below the threshold of 60% 
for BCRP.
Stimulation of transport was observed in some cases (Figure 1). This uptake of model substrate 
for >100% compared to control was especially seen with MRP2 (all antifungals with exception of 
micafungin and amphotericin B). 
Concentration-dependent inhibitory effects 
IC
50
 values of the concentration-dependent inhibition by selected antifungal drugs (showing 
>60% inhibition at concentrations of 250 µM) are presented in Figures 2-4. Subsequent IC
50 
values for each interaction are shown in Table 2.
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Figure 1a. Inhibitory potential of antifungal drugs (250 µM) on ABC transporter activity.
Inhibition of substrate transport >60% is marked with a dashed line at 40% ATP-dependent uptake. The solid line at 100% ATP-dependent uptake 
marks no net inhibition of substrate transport
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Figure 1b. Inhibitory potential of antifungal drugs (250 µM) on ABC transporter activity.
Inhibition of substrate transport >60% is marked with a dashed line at 40% ATP-dependent uptake. The solid line at 100% ATP-dependent 
uptake marks no net inhibition of substrate transport
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We found a 50% inhibitory effect (95% CI) on P-gp-mediated transport of NMQ for azole 
antifungals itraconazole, hydroxyitraconazole, posaconazole and isavuconazole at the low 
micromolar range of 2 (1.1-2.3), 5 (2.9-7.7), 3 (2.2-4.1) and 3 (2.7-3.9) µM, respectively (Table 2, 
Figure 2). In addition, IC
50
 values (95% CI) for P-gp were seen at somewhat higher concentrations 
for echinocandin antifungals anidulafungin, caspofungin and micafungin at 38 (23-61.8), 34 
(26.8-43.7) and 45 (29.2-70.5) µM, respectively (Table 2, Figure 3).
The echinocandins were the only antifungals capable of inhibition of MRP transporters. For 
MRP1, MRP3 and MRP5, IC
50
 values (95% CI) of micafungin were 21 (19.9-23.0), 42 (38.2-46.7) and 
22 (19.3-26.0) µM, respectively. Although less potent, caspofungin inhibited transport of E
2
17βG 
via MRP1 and MRP3 for 50% (95% CI) at 112 (88.7-140.7) and 158 (91.6-272.1) µM, respectively 
(Table 2, Figure 3). 
Transport of MTX via MRP2 was inhibited for 50% (95% CI) at a relatively high concentration 
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Figure 2. Concentration-dependent inhibition of substrate transport by azole antifungals itraconazole (A), hydroxyitraconazole (B), 
posaconazole (C) and isavuconazole (D).
NMQ: N-methyl-quinidine, E1S: Estrone sulfate, TCA: Taurocholic acid
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Figure 3a and 3b. Concentration-dependent inhibition of substrate transport by echinocandin antifungals anidulafungin (A), 
caspofungin (B).
NMQ: N-methyl-quinidine, E217βG: estradiol 17β-glucuronide, E1S: Estrone sulfate, TCA: Taurocholic acid
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Figure 3c. Concentration-dependent inhibition of substrate transport by echinocandin antifungal micafungin (C).
NMQ: N-methyl-quinidine, E217βG: estradiol 17β-glucuronide, E1S: Estrone sulfate, TCA: Taurocholic acid
Figure 4. Concentration-dependent inhibition of substrate transport by the polyene antifungal amphotericin B.
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of micafungin (148 (81.8-266) µM) compared to IC
50
 values for other efflux pumps (Table 2, 
Figure 3). Micafungin showed strong inhibitory effects (95% CI) on MRP4-mediated transport 
(4 (3-5.4) µM), whereas anidulafungin had an IC
50
 value at a somewhat higher concentration of 
28 (21.7-36.3) µM (Table 2, Figure 3).
Inhibition of substrate transport via BCRP at low micromolar range was found for itraconazole, 
hydroxyitraconazole, posaconazole, isavuconazole, anidulafungin and caspofungin (IC
50 
(95% CI) = 2 (1.6-3.6), 12 (7.4-20.2), 6 (3.9-8.1), 11 (5.2-2.3), 7 (6.1-8.3), 6 (2.5-13.2), respectively, see 
Table 2 and Figure 2 and 3). Inhibitory effects (95% CI) on transport at higher concentrations of 
21 (17.4-25.4) and 127 (86.8-186.3) µM were found for micafungin and amphotericin B (Table 2, 
Figure 2 and 4).
For BSEP, IC
50
 values (95% CI) of itraconazole and hydroxyitraconazole were 3 (2.7-3.4) and 17 
(16.1-18.6) µM, respectively (Table 2, Figure 2). Posaconazole, caspofungin and micafungin all 
showed IC
50
 values (95% CI) at higher concentrations of 34 (29-40.4), 186 (113.5-305.6) and 85 
(72.8-100) µM, respectively (Table 2, Figures 2 and 3).
Discussion
In the present study, we assessed the in vitro inhibitory potential of ten established and novel 
antifungal drugs currently used in the treatment of invasive fungal infections on the transport of 
radiolabeled model substrates via ABC transporters shown to influence drug pharmacokinetics 
due to their involvement in drug transport, i.e. P-gp, MRP1–5, BCRP and BSEP. Inhibition of these 
transporters may be an important mechanism underlying clinically significant DDIs. We found 
Table 3. Overview of antifungal drug peak concentrations (Cmax), protein binding at steady state during typical adult dosing, and LogP 
value.
FLZ: fluconazole, ITZ: itraconazole (oral solution formulation), hITZ: hydroxyitraconazole (oral solution formulation), PSZ: posaconazole, VCZ: 
voriconazole, ISA: isavuconazole, ANF: anidulafungin, CAS: caspofungin, MCF: micafungin, AMB: amphotericin B, LogP: octanol/water partition 
coefficient. 
Information obtained from Product information Isavuconazole, Lewis et al. , Muilwijk et al., and the PubChem Compound Database 
(http://pubchem.ncbi.nlm.nih.gov/). [33, 38, 44]
Cmax (mg/L) Cmax (µM) Protein binding (%) LogP
FLZ 6 -20 19.6 – 65.3 10.0 0.4
ITZ 0.5 – 2.3 0.7 – 3.3 99.8 5.7
hITZ 0.6 – 2.1 0.8 – 2.9 99.5 4.5
VCZ 3.0 – 4.6 8.6 – 13.2 58.0 1.5
PCZ 1.5 – 2.2 2.1 – 3.1 99.0 4.6
ISA 7.5 21.6 >99 3.5
ANF 7.2 6.3 99 2.3
CAS 12.1 11.1 97 0.3
MCF 8.8 6.9 >99 -1.6
AMB 0.5 – 2.0 0.5 – 2.2 >95.0 0
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that azole antifungals fluconazole and voriconazole were unable to inhibit transport of model 
substrate of any of the studied transporters for more than 60% at 250 µM. Itraconazole, hydroxy-
itraconazole, posaconazole and isavuconazole inhibited a selection of transporters, but in a very 
potent fashion. In contrast, echinocandin antifungals seemed appreciable inhibitors of transport 
activity throughout the range of transporters investigated. 
The clinical context of our findings is outlined in the following examples. The azole antifungal 
itraconazole showed strong inhibition of P-gp-mediated transport with an IC
50
 value of 2 µM 
(Table 2). Inhibitory effects of similar magnitude on P-gp have been previously reported [13, 14]. 
This in vitro interaction supports the findings of a clinically significant DDI of itraconazole and 
digoxin, a cardiac glycoside mainly excreted unchanged in the urine and a known substrate of 
P-gp in vitro and in vivo [15, 16]. During concomitant treatment, itraconazole was thought to inhibit 
P-gp-mediated digoxin secretion in the renal tubular cells [17, 18], which can now be confirmed by 
the conducted experiment. 
Itraconazole showed strongest inhibition of BCRP-mediated transport (IC
50
 = 0.4 µM; Table 2). 
This inhibition at concentrations below 1 µM is in agreement with other in vitro cellular uptake 
experiments [19]. In clinical practice, the inhibition of BCRP by itraconazole may be the mechanism 
behind the unexplained increases in exposure and peak concentrations of rosuvastatin (a known 
substrate of BCRP, but only a poor substrate for CYP enzymes) during concomitant itraconazole 
use [20, 21]. 
Itraconazole also showed strong inhibition of BSEP (IC
50
 = 3 µM, Table 2), a transporter mediating 
secretion of bile salts into bile [22]. As itraconazole has been shown to induce cholestatic liver 
injury [23], inhibition of either MDR3 [24] or BSEP [9, 10] have been reported as underlying mechanism. 
Our data indicate that itraconazole only inhibits BSEP and is likely capable of obstructing efflux 
of bile acids out of the hepatocyte and inducing cholestasis. This emphasises that inhibition of 
efflux transporters does not only contribute to DDIs with concomitant medications, but also 
interactions of endogenous substrates are possible with the consequence of toxicity. 
Similar to itraconazole, our data demonstrate strong inhibition of P-gp and BCRP activity by 
hydroxyitraconazole and posaconazole (Table 2). Because the molecular structures and 
physicochemical properties of these three azole antifungals are closely related [25-27], they 
may exert a similar inhibitory potential for ABC transporters. This may also be hypothesized 
for the structural analogues fluconazole and voriconazole [28, 29], which are both incapable 
of inhibiting transport for more than 60% at 250 µM (Figure 1). The absence of inhibitory 
potential of fluconazole for P-gp and both fluconazole and voriconazole for BCRP has 
been demonstrated by others [13, 14, 19, 30, 31]. Compared to both fluconazole and voriconazole, 
itraconazole, hydroxyitraconazole and posaconazole show a more pronounced lipophilic 
character [32]. A positive correlation between the lipophilicity of azole antifungals and inhibition 
of P-gp was reported [31], underpinning our findings. Substrates that are translocated by P-gp 
can be presented to the transporter binding site directly from the lipid bilayer, which is different 
for the other transporters where compounds reach the external loops from the cytosol [5], 
possibly explaining the high affinity of lipophilic azoles itraconazole, hydroxyitraconazole and 
posaconazole for P-gp. Lastly, this study is the first to report that isavuconazole showed strong 
inhibition of P-gp and BCRP (Table 2). This is in agreement with in vitro studies of isavuconazole, 
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although this inhibition does not alter the PK of digoxin and methotrexate (probe substrates of 
P-gp and BCRP, respectively) in clinical studies performed in healthy volunteers [33-35].
For the echinocandins, we demonstrated inhibition over a wide range of ABC transporters 
(Figure 1). Contradictory, echinocandins show relatively few clinically significant DDIs in vivo, of 
which the underlying pharmacological mechanisms are mostly unknown. Because echinocandins 
show a low potential for inhibition of CYP enzymes, inhibition of the ABC transporters as found 
in our study might be a plausible underlying mechanism causing the few reported DDIs. For 
example, concomitant use of micafungin (a weak inhibitor of CYP3A4 [14]) and sirolimus resulted 
in an increased sirolimus area under the plasma concentration time curve (AUC) of 22% [36]. This 
clinically significant increase could possibly involve the inhibition of P-gp, as sirolimus is reported 
to be a substrate of this transporter [37]. 
Comparing IC
50
 values with plasma concentrations should be done with greatest caution, since 
the obtained IC
50
 values represent free-drug concentrations. Most antifungal drugs are all highly 
bound to plasma proteins, reducing the free concentration able to inhibit transport of substrate 
(Table 3). In addition, due to possible accumulation of antifungal drugs in tissue compartments, 
intracellular concentrations at the target site may be higher compared to plasma concentrations. 
Amphotericin B was only found to inhibit BCRP for >60% at high concentrations (Table 3). 
Although amphotericin B is in widespread clinical use, little is known about clinically relevant 
transporter-mediated DDIs. Because amphotericin B is associated with nephrotoxicity, it is 
known to decrease clearance of other renally eliminated drugs [38]. In agreement with previous 
literature [14], P-gp mediated transport of substrate was not inhibited by amphotericin B in our 
study. Moreover, we did not observe any inhibition of other transporters at relevant concentra-
tions (Figure 1).
Besides inhibition of transport, stimulation was also observed in some cases (Figure 1), especially 
for MRP2. This is in concordance with other transport assays, where increased transport of E
2
17βG 
via MRP2 was seen. It was suggested that MRP2 can be allosterically stimulated by drugs, causing 
increased transport of model substrate [39]. These stimulatory effects on ABC transporters have 
also been observed for other drug classes, e.g. tuberculosis drugs [40].
A limitation of this study is that the observed inhibition of the transporters may be dependent on 
the translocated substrate. Different probe substrates can shift IC
50
 values, as previously reported 
for P-gp [41, 42]. Therefore, caution should be exercised by translating these results to different 
transporter/substrate combinations. Regarding the mode of inhibition, the inside-out vesicles 
are not suitable to study inhibition of the transporter from the extracellular part of vesicle, 
since hydrophilic compounds (with an octanol/water partition coefficient (logP) lower than 
approximately 0.3) do not have the ability to diffuse through the membrane [43]. Since micafungin 
and amphotericin B both have logP values lower than 0.3 (Table 3), these compounds might 
possibly not pass the vesicle membrane and therefore inhibition from the extracellular side 
cannot be studied. Moreover, the current study does not provide insight into whether or not the 
investigated antifungal agents are substrates of these transporters themselves. 
Interestingly, despite the wide range and variability of CYP-mediated DDIs by azole antifungals 
in the clinical setting [1, 3], these drugs exhibited selective inhibition of efflux transporters in 
our study. Strikingly, despite the low potential for clinically relevant DDIs by echinocandins [38], 
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an unprecedented inhibitory potential of the echinocandin antifungals on efflux transporters is 
observed. This suggests that the studied efflux pumps might play a crucial role in the inexplicable 
(non-CYP mediated) DDIs of antifungal drugs, specifically for the echinocandins. 
This study demonstrates the inhibitory potential of various established and novel antifungal 
drugs on the transport of model substrates via ABC drug efflux transporters. We are of the 
opinion that data generated in this research provide new insights into molecular mechanisms 
and help in further resolution of inexplicable (non-CYP mediated) DDIs with antifungal drugs. 
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Abstract
Objectives: Since 2007 the Dutch Association for Quality Assessment in Therapeutic Drug 
Monitoring (KKGT) has organized an international interlaboratory proficiency testing (PT) 
programme for measurement of antifungal drugs in plasma. We describe the 5 year results of 
the laboratories’ performance.
Methods: Twice a year, laboratories received a set of blind plasma samples containing low or high 
concentrations of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole 
and flucytosine. Participating laboratories were asked to report their results within 6 weeks 
after dispatch and provide details of their analytical methods. Results deviating >20% from the 
weighed-in concentration were considered inaccurate. Four-way ANOVA was performed to 
assess the effect of antifungal drug measured, concentration, analytical method and performing 
laboratory on the absolute inaccuracy. In 2012, a questionnaire based on the CLSI guidelines was 
dispatched with the request to provide input on sources of error. 
Results: Fifty-seven laboratories (13 countries) reported 2251 results (287 fluconazole, 451 
itraconazole, 348 hydroxyitraconazole, 402 posaconazole, 652 voriconazole and 111 flucytosine in 
5 years. Analyses were performed using HPLC (55.0%), LC-MS(/MS) (43.4%), UPLC (1.4%) or GC-MS 
(0.2%). Overall, 432 (19.2%) analyses were inaccurate. The performing laboratory was the only 
factor clearly associated with inaccuracies. The questionnaire results indicated that laboratories 
encounter significant problems analysing low concentrations (15.4% of all inaccuracies).
Conclusions: Results of the PT programme suggest that one out of five measurements is 
inaccurate. The performing laboratory is the main determinant of inaccuracy suggesting that 
internal quality assurance is pivotal in preventing inaccuracies, irrespective of the antifungal drug 
measured, concentration and analytical equipment.
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Introduction
There has been increasing interest in the analysis of antifungal drug concentrations in recent 
years. A variety of analytical methods have been published for the quantification of these drugs 
in human plasma [1, 2]. These analytical methods can be used to study pharmacokinetic behaviour 
and to characterize drug interactions among antifungal drugs. Several antifungal drugs show 
large inter-patient variability in pharmacokinetics, whereas evolving data show an association 
between plasma concentrations and treatment efficacy or toxicity [3, 4]. This advocates the use 
of therapeutic drug monitoring (TDM), especially for the azoles itraconazole, posaconazole, 
voriconazole and flucytosine [3-8]. TDM allows a clinician to individualize the dosage based on 
drug concentration measurements and thereby helps to optimize the balance between the 
efficacy and tolerability of the drugs involved. In fact, TDM of azoles has been recommended 
in the updated guidelines for the treatment of invasive aspergillosis by the Infectious Diseases 
Society of America (IDSA) [9].
Proficiency testing (PT) or external quality control is a valuable tool in the quality improvement 
process for the analysis of drugs in plasma, enabling laboratories to assess and improve their 
performance with respect to the bioanalysis of drugs. In addition, an interlaboratory (external) 
PT programme is essential to verify whether TDM results conform to expectations of the quality 
required for patient care [10].
In 2007, we initiated an international PT programme for the measurement of azole antifungal 
drugs [11]. From 2008 onwards, the programme was performed in collaboration with the Dutch 
Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology 
[KKGT, a part of the Dutch Foundation for Quality Assessment in Clinical Laboratories: (SKML)]. 
In the current analysis we evaluated 5 year data of the PT programme (2008–2012). Our aim 
was to assess the overall performance of laboratories, as well as possible explanations for 
inaccuracies. More specifically, these data allowed us to assess whether laboratory performance 
was dependent on the antifungal drugs measured, their concentrations, analytical techniques 
used and the laboratory that performed the analyses.
Methods
Design of the PT programme
The design of the programme was described previously [11]. In summary, drug-free plasma from 
healthy volunteers was obtained from the Dutch Blood Bank and spiked with high and low con-
centrations of antifungal drugs. The programme started with the following five azole antifungal 
drugs and metabolites: fluconazole, itraconazole, hydroxyitraconazole, voriconazole and 
posaconazole. After two years, flucytosine was added to the programme. The sample volume 
was 3 mL. High and low concentrations were based on concentrations generally achieved in 
clinical practice after oral or intravenous administration of the selected antifungal drugs (Table 1).
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After the samples were analysed with our own validated methods as a confirmative check 
(allowing ≤ 5% deviation from the weighed-in concentrations), they were released into the PT 
programme. Stability was proven for at least 14 days at various conditions (-40°C, 4°C and at 
ambient temperature with daylight) and after three freeze-thaw cycles, supporting the dispatch 
of samples at room temperature and transport within cold aircraft cargo holds. Samples were 
sent around twice a year. Laboratories were requested to report their results and provide 
details about their analytical assays within 6 weeks after dispatch of the samples. These results 
were recorded anonymously in a central database. Feedback was provided to participating 
laboratories within 3 months after the deadline of a single round.
After round 2 in 2012, an error evaluation form together with laboratories’ individual results from 
previous rounds was sent to all participating laboratories, regardless of their performance. Based 
on the CLSI guideline Using Proficiency Testing to Improve the Clinical Laboratory–Second 
Edition: Approved Guideline GP27-A2 [12], the error evaluation form specified clerical activities 
associated with the test (C), technical operation of method (T), methodological problems (M), 
equipment problems (E), organizational factors (O) and other problems. Laboratories were asked 
to complete the error form for each drug that was analysed in the past. Results were recorded 
anonymously.
Table 1. Weighed-in concentrations (mg/L) in the quality control samples per round per year.
FLC, fluconazole; ITC, itraconazole; hITC, hydroxyitraconazole; POS, posaconazole; VRC, voriconazole; 5-FC, flucytosine
Year – round
Drug 2008–1 2008–2 2009–1 2009–2 2010–1 2010–2 2011–1 2011–2 2012–1 2012–2
Low concentrations
FLZ 0.915 3.71 1.50 6.50 8.00 4.00 4.00 6.00 2.36 7.88
ITC 0.247 1.00 0.05 0.20 0.40 0.30 0.20 0.60 0.49 0.791
hITC 0.428 1.35 0.30 0.05 0.90 0.40 0.30 0.50 0.59 0.187
POS 0.108 0.22 0.15 0.80 0.30 – 0.20 0.40 0.21 2.06
VRZ 0.311 0.105 0.61 4.10 0.30 1.00 0.50 0.80 0.10 5.18
5-FC – – – – 8.00 42.00 10.00 15.00 10.11 36.07
High concentrations
FLZ 20.610 10.26 12.10 16.00 20.00 23.00 15.00 30.00 19.54 23.6
ITC 3.130 1.99 1.20 0.80 3.80 5.10 6.00 4.00 2.45 4.93
hITC 3.630 2.36 0.80 1.80 5.40 8.00 3.40 3.00 2.90 2.34
POS 1.370 2.05 2.00 4.60 1.20 2.50 2.30 0.70 0.51 2.57
VRZ 1.320 2.18 2.85 8.50 13.00 3.20 6.50 4.50 3.43 10.34
5-FC – – – – 64.00 128.00 75.00 110.00 71.59 144.1
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Statistical analysis
Descriptive statistics were performed after standardization of all laboratory results to 
percentages with reference to the weighed-in concentrations. The relative deviation from 
the weighed-in concentration (inaccuracy) was determined by subtraction of 100% from 
these percentages. The absolute inaccuracy was defined as the absolute deviation from the 
weighed-in concentration. Concentrations reported within 20% limits around the weighed-in 
concentrations were considered to be accurate, based on guidelines for bioanalytical method 
validation and maximum allowable error specifications for drug measurements defined by the 
US Clinical Laboratory Improvement Amendments (CLIA) of 1988 [13, 14]. Results of the programme 
were presented descriptively and no inferential statistics were performed as available data 
related to all PT measurements rather than a sample. Differences in accuracy related to the drug 
to be analysed, concentration, method of analysis and performing laboratory were presented. 
Four-way ANOVA was conducted to disentangle the simultaneous effects of these factors on the 
absolute inaccuracy. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc., 
Chicago, IL, USA). A P value of <0.05 was considered statistically significant. 
Results
Participating laboratories and overall results
The programme started in 2008 with 35 participants. By the end of 2012, 57 laboratories from 
four different continents participated in the programme, with the majority of laboratories (n=44) 
located in Europe [the breakdown per continent is shown in Table 2]. Over 5 years, 10 laboratories 
withdrew from participation in the programme and 32 new members joined the programme. 
A total of 2251 results were reported between 2008 and 2012. Most results were reported for 
voriconazole, representing 29.0% (n=652) of the total number of analyses. This was followed by 
itraconazole (20.0%, n=451), posaconazole (17.9%, n=402), hydroxyitraconazole (15.5%, n=348), 
fluconazole (12.7%, n=287) and flucytosine (4.9%, n=111, Table 3). Conventional HPLC was most 
frequently used (55.0%), followed by LC-MS(/MS) (43.4%), UPLC (1.4%) and GC-MS (0.2%) see 
Table 3. For the analysis of antifungal drugs in 2012 (round 10), laboratories used conventional 
HPLC (n=27) with fluorescence, UV or photodiode array detection, followed by LC-MS(/MS) 
(n=14), UPLC-MS (n=1) or a combination of these analytical methods (n=15). 
Overall, 80.8% of the 2251 analyses were within the predefined range of 80% - 120% and thus 
were considered to be accurate. For those analyses outside the predefined range, 11.5% were 
<80% and 7.7% were >120% of the weighed-in concentrations (Table 3). The median absolute 
inaccuracy for all analyses was 8.0% (IQR 13.0%; range 0.0% - 3340.0%). In total, 25/57 laboratories 
participated in all rounds of the programme (2008–12). The median absolute inaccuracy for all 
analyses per year of the programme gradually declined from 12.1% (0.0%–852.4%) in 2008 to 
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6.4% (0.0%–118.4%) in 2012 (Figure 1). In addition, their percentage of accurate analyses increased 
from 71.0% in 2008 to 87.7% in 2012, both indicating a possible trend of improvement over time. 
Results by antifungal drug
A relatively small difference in median absolute inaccuracy was found between the individual 
antifungal drugs: fluconazole (6.4%; 0% - 96.3%), voriconazole (6.6%; 0% - 852.4%), flucytosine 
(7.8%; 0% - 52.5%), posaconazole (9.0%; 0% - 960.0%), itraconazole (9.4%; 0% - 3340.0%) and 
hydroxyitraconazole (10.4%; 0% - 1620.0%), see Table 3. In line with this, fluconazole had the 
highest percentage of accurate analyses (87.5%), followed by voriconazole (86.2%), itraconazole 
(78.0%), hydroxyitraconazole (77.3%), flucytosine (76.6%) and posaconazole (74.6%; Table 3). 
Results by concentration 
Laboratories analysed a roughly equal number of low and high concentrations over time (1106 
and 1145 analyses, respectively). High concentrations were reported with a slightly lower median 
absolute inaccuracy than lower concentrations: 7.3% (range 0.0% – 530.1%) and 9.3% (range 
0.0% – 3340.0%), respectively. In addition, 24.9% of all low concentrations were reported as 
inaccurate (i.e. outside the 20% limits of the weighed-in concentrations) versus 13.7% of high 
concentrations.
Table 2. Participating laboratories per continent, divided by country (2012).
Continent 2008 2012
Europe 34 44
 - Belgium: 4
 - France: 3
 - Germany: 3
 - Italy: 4
 - The Netherlands: 13
 - Spain: 5
 - Sweden: 1
 - Switserland: 5
 - United Kingdom: 6
North America - 11
 - Canada: 3
 - United States of America: 8
Asia - 1
 - South Korea
Australia 1 1
  - Australia
Total 35 57
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Fluconazole had the lowest median absolute inaccuracy for low concentrations (6.7%), followed 
by voriconazole (8.0%), itraconazole (10.0%), posaconazole (11.0%), hydroxyitraconazole (11.1%) 
and flucytosine (11.5%). For high concentrations, voriconazole was analysed most accurately 
with a median absolute inaccuracy of 5.7%, followed by fluconazole (6.2%), flucytosine (6.7%), 
posaconazole (8.0%), itraconazole (8.5%) and hydroxyitraconazole (10.3%; Figure 2).
Results by analytical method
Median absolute inaccuracy was 8.1% (0.0% – 1620.0%; n=1238) for HPLC, 7.8% (0.0% – 3340.0%; 
n= 977) for LC-MS(/MS), 5.0% (0.0% – 194.7%; n=31) for UPLC and 13.3% (3.02% – 35.6%; n=5) for 
GC-MS. The percentage of accurate analyses was 78.4% for HPLC, 83.8% for LC-MS(/MS), 83.9% for 
UPLC and 60.0% for GC-MS.
Results by performing laboratory
The results by performing laboratory are presented for the most recent time period, considering 
that the performance of laboratories may change over time. Median absolute inaccuracy per 
laboratory participating in rounds 9 and 10 of the PT programme (2012; 671 analyses) ranged 
between 0.8% and 17.4%. Among all participating laboratories, 41.5% had all analyses within 
the 20% limits (1–24 analyses, 267 analyses in total). The performance of the remaining 58.5% of 
laboratories (404 analyses) ranged from 6.7% inaccurate results (15 analyses) to 75% inaccurate 
results (4 analyses). 
Table 3. Analytical methods used and overall performance in the PT programme.
FLC, fluconazole; ITC, itraconazole; hITC, hydroxyitraconazole; POS, posaconazole; VRC, voriconazole; 5-FC, flucytosine.
Analytical method Performance
Drug
analyses, n; 
(% of total)
HPLC,
n (%)
LC-MS(/MS),
n (%)
UPLC,
n (%)
GC-MS
n (%)
median absolute 
inaccuracy, % 
(range) n (%)
accurate,
n (%)
<80%,
n (%)
>120%,
n (%)
FLC 287 (12.7) 171 (59.6) 116 (40.4) 0 (0) 0 (0) 6.4 (0.0–96.3) 251 (87.5) 17 (5.9) 19 (6.6)
ITC 451 (20.0) 232 (51.4) 211 (46.8) 6 (1.33) 2 (0.44) 9.4 (0.0–3340.0) 352 (78.0) 58 (12.9) 41 (9.1)
hITC 348 (15.5) 168 (48.3) 172 (49.4) 6 (1.72) 2 (0.57) 10.4 (0.0–1620.0) 269 (77.3) 56 (16.1) 23 (6.6)
POS 402 (17.9) 181 (45.0) 214 (53.2) 7 (1.74) 0 (0) 9.0 (0.0–960.0) 300 (74.6) 69 (17.2) 33 (8.2)
VRZ 652 (29.0) 383 (58.7) 258 (39.6) 10 (1.53) 1 (0.15) 6.6 (0.0–852.4) 562 (86.2) 48 (7.4) 42 (6.4)
5-FC 111 (4.9) 103 (92.8) 6 (5.4) 2 (1.80) 0 (0) 7.8 (0.0–52.5) 85 (76.6) 10 (9.0) 16 (14.4)
Total 2251 1238 (55.0) 977 (43.4) 31 (1.38) 5 (0.22) 8.0 (0.0–3340.0) 1819 (80.8) 258 (11.5) 174 (7.7)
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Table 4. Explanations for inaccuracies (results outside 80%–120%) as indicated by participating laboratories (n=23).
Number Percentage of total
Clerical errors
C1: results not correctly transcribed to report form 10 9.6
C2: result reported for the wrong sample 10 9.6
C12: other 2 1.9
Technical problems
T1: incorrect testing method chosen 1 1.0
T5: inadequate mixing of sample 1 1.0
T6: material improperly prepared/stored 4 3.8
T9: incorrect pipetting (other than dilution/calibration) 1 1.0
T10: misidentification of the peak 1 1.0
T12: run accepted in nonlinear range 1 1.0
T14: aging stock solutions 3 2.9
T16: concentration below quantitation limit 12 11.5
T17: inadequate equipment maintenance 4 3.8
T22: inability of staff to apply knowledge to situation 1 1.0
T24: other technical problem (please specify in comment box) 6 5.8
Methodological problems  
M4: problem in manufacture of reagents or reference materials 2 1.9
M5: imprecision due to result being close to detection limit 16 15.4
M8: result not within measuring range (linearity) for instrument or reagent system 1 1.0
M9: method is biased 7 6.7
M10: method lacks sensitivity 1 1.0
M11: method lacks specificity 4 3.8
M14: method used without validation 3 2.9
M17: other method problem 7 6.7
Other problems
various problems 6 5.8
Total 104 100
Analysis of variance on antifungal drug, concentration, method of analysis and 
laboratory
Four-way ANOVA was performed to assess the effect of the factors antifungal drug, concentration, 
analytical method and laboratory on absolute inaccuracy. A significant main effect of performing 
laboratory on absolute inaccuracy was found (F=2.083, P<0.005). Other factors did not affect the 
absolute inaccuracy and no interaction between factors was observed. This was to be expected, 
considering the large variability in median absolute inaccuracy among laboratories during the 
years of the programme and the small effect of other factors found in the descriptive analyses 
presented above.
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Sources of error
Twenty-three out of 57 laboratories (40.4%) returned error forms related to 769 out of 2251 
analyses (34.2%). Of these analyses, 125 (16.3%) were inaccurate and could be used to identify 
a total of 104 possible sources of error. Every single reported source of error is included in 
Table 4 [23 unique sources of error; see Table 5 for comprehensive error form]. The majority 
of explanations for deviating results were found in methodological problems (39.4%), followed 
by technical problems (33.7%), clerical errors (21.2%) or other problems (5.8%). No laboratory 
reported equipment problems or organizational factors as the explanation for deviating results. 
Figure 1. Median absolute inaccuracy (+ upper quartile limit) per year.
Figure 2. Median absolute inaccuracy (+ upper quartile limit) per concentration. 
FLC, fluconazole; ITC, itraconazole; hITC, hydroxyitraconazole; POS, posaconazole; VRC, voriconazole; 5-FC, flucytosine. 
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Table 5. Error form to identify individual sources of error and/or explanations for inaccuracy.
Clerical activities associated with the test
C1 Results not correctly transcribed to report form
C2 Result reported for the wrong sample
C3 Incorrect instrument/method code reported
C4 Incorrect reporting code selected
C5 Incorrect drug reported
C6 Sample or vial was mislabelled
C7 Computer keying or data entry error
C8 Incorrect units reported
C9 Misplaced decimal point
C10 Result omitted on analysis worksheet
C11 Final check not performed on analysis worksheet
C12 Other (please specify in comment box)
Technical operation of method
T1 Incorrect testing method chosen
T2 Failure to follow instructions on analysis worksheet
T3 Failure to add sample to test system
T4 Samples mixed up at bench or wrong sample tested
T5 Inadequate mixing of sample
T6 Material improperly prepared/stored
T7 Pipette not appropriately calibrated
T8 Dilution error
T9 Incorrect pipetting (other than dilution/calibration)
T10 Misidentification of the peak
T11 Calculations performed incorrectly
T12 Run accepted in nonlinear range
T13 Run accepted even though controls were out of range
T14 Aging stock solutions
T15 Stock solutions not made of pure substances
T16 Concentration below quantitation limit
T17 Inadequate equipment maintenance
T18 Misinterpretation of instrument error message
T19 Failure to observe problem with system; e.g. equipment
T20 Incorrect instrument calibration
T21 Misinterpretation of test result
T22 Inability of staff to apply knowledge to situation   
T23 Failure to follow written procedures
T24 Other technical problem (please specify in comment box)
Methodological problems
M1 Method change before QC program
M2 Inaccurate or inadequate written procedure
M3 Procedure with reagent performance/ reagent failure
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Table 5. - Continued Error form to identify individual sources of error and/or explanations for inaccuracy.
Clerical activities associated with the test
M4 Problem in manufacture of reagents or reference materials
M5 Imprecision due to result being close to detection limit
M6 Imprecision due to variation between reagent lots
M7 Erroneous calibrator value (instrument)
M8 Result not within measuring range (linearity) for instrument or reagent system
M9 Method is biased
M10 Method lacks sensitivity 
M11 Method lacks specificity
M12 Carry-over from previous samples
M13 Inappropriate incubation conditions (time. temperature and/or atmosphere)
M14 Method used without validation
M15 Software problem
M16 Scheduled instrument maintenance not performed appropriately
M17 Other method problem (please specify in the comment box)
Equipment Problems
E1 Obstruction of instrument tubing or aperture
E2 Misalignment of instrument probes
E3 Detection system error
E4 Instrument software error
E5 Other equipment function problem (please specify in the comment box) 
Organizational Factors
O1 Failure to ensure situational knowledge is transferred to all rotating staff
O2 Inadequate or inappropriate equipment 
O3 Inadequate staffing
O4 Inadequate training to perform task
O5 Lack of organizational awareness or prioritization
O6 Other organizational factor (please specify in the comment box)
Other
X1 Unexplained/unassigned cause
As can be seen in Table 4, frequently reported sources of error related to problems with the 
analysis of low concentrations were the concentration of the antifungal drug  being below the 
lower limit of quantification (LLOQ; 11.5% of inaccuracies) and imprecision due to the result being 
close to the lower limit of detection (LLOD; 15.4%).
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Discussion
The purpose of our PT programme is to provide external assessment of a laboratory’s analytical 
performance in the measurement of antifungal drugs, thereby alerting the participating 
laboratory to potential problems. To our knowledge, we are the first independent institution 
organizing an international PT programme for the measurement of six antifungal drugs in 
varying analytical concentrations. Recently, the UK National External Quality Assessment Service 
(UK-NEQAS) has set up a similar programme with a comparable objective, but this programme 
covers fewer antifungal agents (voriconazole, posaconazole, and (hydroxy)itraconazole) [15]. 
Our results over a 5 year period show that almost one fifth (19.2%) of antifungal drug 
measurements in the PT programme were inaccurate. The performing laboratory was the only 
factor clearly related to the absolute inaccuracy based on descriptive analysis and ANOVA, 
although descriptive analysis and evaluation of error forms suggested that lower concentrations 
may be related to inaccuracies as well. 
A total of 19.2% inadequate analyses is considered displeasingly suboptimal, as this may be a 
source of bias in pharmacokinetic studies performed by these laboratories and could influence 
the clinical decision making following TDM, ultimately leading to therapy failure or concentra-
tion-related toxicity. Moreover, although an overall median absolute inaccuracy of 8.0% may be 
considered acceptable, the range of 0% - 3340% indicates that measurement of antifungal drugs 
needs improvement in a number of laboratories. 
Based on our analysis of 5 year data, the performing laboratory was the only factor clearly related 
to inaccuracies in the measurement of antifungal drugs. This probably means that internal 
(intralaboratory) quality assurance, as reflected in adequate validation of assays, validation of 
equipment and qualification of technicians, is the main determinant of inaccuracy. In other 
words, accurate results can be obtained with sufficient internal quality assurance, irrespective of 
the antifungal drug to be measured, its concentration and the analytical equipment available. 
Apart from this, descriptive analysis of dichotomized results and evaluation of error forms 
suggested that laboratories do encounter problems with analysing lower concentrations. This 
may be considered as a reflection of insufficient internal quality assurance as well (e.g. inadequate 
range of the method and suboptimal validation of the limit of quantification). Difficulty with lower 
concentrations is in line with our previous findings [11], and with findings in other PT programs 
[16, 17]. As trough concentrations of antifungal drugs are considered the most reliable predictor 
for therapeutic efficacy [18], laboratories should put extra effort in measuring low concentrations.
Alerting the laboratories to inaccuracies and dispatching error forms regarding inadequate 
performance supported the identification of possible sources of error. It was reported that 
methodological problems were the greatest source of error (39.4%; Table 4). This is in line 
with results from other PT programs [19-22] which also reported methodological errors as being 
responsible for most of the inadequate results in their programs (28%, 31%, 33% and 51%, 
respectively). Again, error forms suggested that analysis of lower concentrations is a problem, 
as most of the methodological problems were caused by an imprecise analysis due to a 
concentration close to the LLOD (15.4%) and laboratories also encountered technical problems 
due to the concentration of the antifungal drug being below the LLOQ (11.5%; Table 4). We 
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assume that these laboratories have developed an assay with a higher LLOQ or LLOD than the 
concentrations generally achieved in clinical practice (Table 1). 
Even though clerical errors seem to be avoidable, they remain another major source of error for 
inadequate results (21.2%; Table 4). 
Fortunately, the PT programme (including the dispatching of error forms) is available to 
alert laboratories to inaccuracies and to previously undetected problems. In view of the low 
percentage of unexplained or unassigned causes for inaccuracies as reported by the error forms 
(5.8%), corrective action could lead to improved performance over time, ultimately enhancing 
accuracy for everyday samples.
Indeed, over 5 years, the percentage of accurate analyses of all laboratories participating from 
2008 until 2012 gradually improved from 71.0% to 87.7%. This was in line with a progressive 
decrease in median absolute inaccuracy of all drugs from 12.0% (2008) to 6.4% (2012), indicating 
a possible contribution of our programme to a more adequate analysis of antifungal drugs 
(Figure 1). It should be noted that overall performance of the laboratories over time is difficult 
to interpret because of changing numbers of participating laboratories per year. For instance, 
experienced laboratories possibly withdrew from the programme due to repetitive good 
results or new laboratories were included once they had their assay operational. To make a valid 
statement of improvement over time we performed the analysis only with those laboratories 
that participated throughout the complete period of the programme.
The programme in its current form was developed to represent the real-life performance of 
the participating laboratory as closely as possible. Therefore, we used human plasma instead of 
lyophilized plasma which needs to be reconstituted. Moreover, no reference substrates or plasma 
samples were distributed. Nevertheless, there are still some aspects to consider. By adding all 
antifungal drugs to a single sample, laboratories using bioassays are precluded. Furthermore, 
as indicated by the error forms (various problems, see Table 4), some laboratories encounter 
interference from other antifungal drugs during their analyses (e.g. hydroxyitraconazole 
interfering with posaconazole analysis). In our opinion, this reflects an analytical method that 
was not adequately validated for specificity/selectivity. Thus, a combined sample of antifungal 
drugs assists in the resolution of adequate specificity and selectivity of the method of analysis. 
This is specifically needed when patients switch antifungal therapy in the clinical setting.
There is a general consideration with regard to the programme. As many laboratories use 
their analytical assay for the purpose of TDM, it could be interesting to interpret inaccuracies 
in relation to clinical breakpoints. Unfortunately, clinical breakpoints of antifungal drugs are 
still subject to debate and furthermore are determined by the MIC of the causative pathogen, 
making this approach somewhat complicated. In addition, the programme can also be used for 
improving an analytical method used in the setting of pharmacokinetic research. Here clinical 
breakpoints are not an issue. Hence, we decided to refrain from using clinical concentrations 
for the interpretation of results as this would not be straightforward, and to restrict ourselves to 
using the conventional analytical concentrations. 
From the questionnaire it was noted that several laboratories reported problems measuring low 
concentrations due to the fact that their LLOQ was above the weighed-in concentration. We 
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have chosen to define such concentrations below the LLOQ as inaccurate. This approach can 
be debated. Some laboratories developed an assay with an LLOQ that was close to the lower 
target concentrations when used for TDM. Obviously, these assays have a greater chance of poor 
performance for low concentrations (concentrations below the LLOQ), resulting in inaccurate 
measurement. It should be stressed once more that this PT programme is instituted for the 
purpose not only of TDM but also of achieving a sound quality of analytical assay regardless of 
its intended goal. Setting an LLOQ low enough is a prerequisite for good performance when the 
purpose is for pharmacokinetic research. Therefore, we felt it was justified to classify concentra-
tions below the LLOQ as inaccurate.
In summary, the 5 year results of our PT programme indicate that the analysis of antifungal drug con-
centrations in plasma is complex and that improvement is warranted for several laboratories. In view of 
the results of the PT programme and the growing number of participating laboratories, there is a clear 
need for such a PT programme. In the future, more antifungal drugs will be added to the programme 
(e.g. echinocandins). Based on the high percentage of inaccurate results and their subsequent clinical 
implications, laboratories can improve the measurement of their antifungal drug concentrations by 
participation in the PT programme and they are invited to subscribe (see www.kkgt.nl).
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Abstract
Background: Voriconazole is the mainstay of treatment for invasive fungal diseases in immuno-
compromised pediatric patients. Although Therapeutic Drug Monitoring (TDM) of voriconazole 
is recommended, it remains unknown if TDM-based dose adaptations result in target attainment. 
Methods: Patients ≤18 years from 2 pediatric hematologic-oncology wards were retrospectively 
identified based on unexplained high voriconazole C
min
 (>6mg/L). Patient demographics, clinical 
characteristics, dosing information, voriconazole concentrations and target attainment after 
TDM were obtained. 
Results: From 2007-2014, 21 patients (8 male, 13 female; median (range) age 7.0 years (1.2-18.5]) 
were identified. Median therapy duration was 118 days (17-866) with a median total daily dose of 
23.1 mg/kg (6.1-109.6). First TDM was performed after 3 days (0-27) of treatment, with median C
min
 
of 3.1 mg/L (0.1-13.5). Median C
min
 (n=485, median 11 per patient) was 2.16 mg/L (0.0–28.0), with 
24.1% of C
min
 <1mg/L, 48.9% 1-4mg/L, 9.3% 4-6mg/L and 17.7% >6mg/L. Intrapatient variability 
was large (94.1% for IV, 88.5% for PO). No correlation between first (r
2
=0.05, p=0.82) or all (r
2
=0.02, 
p=0.59) C
min
 and dose was observed. Dose increases at C
min
 <1 mg/L  resulted in an increased C
min
 
in 76.4%, with 60% between 1-4 mg/L. Dose decreases at C
min
 >6 mg/L resulted in a decreased 
C
min
 in 80%, with 51.1%  between 1-4 mg/L.
Conclusions: Only 45% of dose adaptations following sub –and supratherapeutic voriconazole 
C
min
 did result in target attainment after single dose. In the remaining 55%, multiple interventions 
were required to achieve therapeutic C
min
. Intensive and continuous TDM of voriconazole is a 
prerequisite for ensuring adequate exposure in pediatric patients.
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Introduction
Invasive Fungal Infections (IFI) are increasing in incidence and are important causes of 
morbidity and mortality in severely immunocompromised pediatric patients [1]. Voriconazole is 
a broad-spectrum triazole antifungal agent which has emerged as the preferred treatment of 
invasive pulmonary aspergillosis in older children and adults [2, 3].
Increased voriconazole exposure has been related to improved treatment outcome in adults, 
with suggested provisional cut-off points for voriconazole trough plasma concentrations (C
min
) 
of 1-6 mg/L [4-6]. An exposure-response relationship was also established for pediatric patients, 
in which a voriconazole C
min
 >1 mg/L was associated with improved outcome [7-9]. Because of 
the pharmacodynamic relationship between voriconazole exposure and efficacy and adverse 
events, together with the high inter –and intrapatient variability in pediatric patients [10-15], the 
importance of voriconazole TDM in pediatric patients is now generally acknowledged [16]. 
Although TDM-based dose adjustments are performed to optimize plasma concentrations, 
it remains unclear if these dose adaptations in pediatric patients correspond well to target 
attainment. 
We conducted a retrospective analysis in a cohort of pediatric patients with difficult to manage 
voriconazole concentrations and assessed the result of TDM-based dose adaptations on target 
attainment.
Materials and Methods
Study design and patients
This retrospective study was carried out in two pediatric hematology wards at university 
hospitals in the Netherlands (Radboud university medical centre, Nijmegen and Erasmus 
Medical Centre, Rotterdam). From August 2007–May 2014, the results from routinely performed 
TDM of voriconazole in both hospitalized and ambulant pediatric patients were evaluated. All 
patients ≤18 years who received voriconazole orally (PO) or intravenously (IV) at these units were 
included if more than one voriconazole C
min
 was determined, of which at least one concentration 
was >6 mg/L. Due to the retrospective nature of the study, written informed consent was not 
deemed necessary. 
Data collection
Data was collected from the patients’ medical records and included patient demographics (e.g. 
age, gender, bodyweight), clinical characteristics (underlying disease, IFI definition according to 
EORTC/ MSG criteria [17]), microbiological characteristics (infection location, pathogen species) 
and therapy-related data (information on voriconazole plasma concentrations; route, timing 
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and formulation of voriconazole doses; treatment duration; concomitant medications known or 
suspected to alter voriconazole exposure [18]). Target attainment following dose adaptations was 
obtained. 
Voriconazole dosing and dose adjustments
Initial dosing and administration of voriconazole was generally according to the Summary of 
Product Characteristics (SmPC) of voriconazole, but could be increased or decreased based on 
therapeutic management. Treatment was ended based on the clinical response, or discontinued 
based on the results of cultures or toxicity. Consistent with institution guidelines, adequate 
voriconazole exposure was defined as C
min
 between 1-4 mg/L. If the patient showed no signs 
of hepatotoxicity (i.e. liver function tests no more than three times the upper limit of normal), 
adequate exposure was defined as 1-6 mg/L. For sanctuary infection sites or disseminated 
disease, the lower threshold was set to 2 mg/L (in which adequate treatment was defined as 
2-4 mg/L or 2-6 mg/L).
In case of a non-therapeutic voriconazole C
min
 (< 1 or > 6 mg/L), linear dose adjustments assuming 
(pseudo)-linear pharmacokinetics in children [9, 12] to reach adequate C
min
 were subsequently 
advised by the clinical pharmacologist/pharmacist. A follow-up sample within 1 week was 
recommended. Dosing frequency was initially two times daily, but could be increased to three 
times daily in an attempt to reach adequate exposure.
Therapeutic Drug Monitoring
TDM was instituted as standard of care, but frequency of sampling was performed at discretion 
of the treating physician/clinical pharmacologist. It was recommended to perform TDM at 
voriconazole steady state concentrations, which is 4 to 5 times the half-life in clinical practice 
(at least two days after initiation of voriconazole therapy or dose adaptations) [18, 19]. Only blood 
samples withdrawn at a maximum of 1 hour prior to the next dose were included to ascertain 
the voriconazole concentration was a trough concentration.
Analytical assay
Voriconazole plasma concentrations were measured twice weekly using an in-house, validated 
high-performance liquid chromatography (HPLC) method with fluorescence detection (dynamic 
range for voriconazole in plasma: 0.101–10.14 mg/L with a concentration-dependent accuracy 
range (n=15) of 96.1% to 101.4%). A five-point calibration curve with three quality control 
samples was used. Intraday precision ranged between 0.77% and 3.28% (n=5) and interday 
precision varied between 0.91% and 2.14% (n=15). Voriconazole recovery was 98 ±5%. Stability of 
voriconazole was not impacted by three freeze-thaw cycles (100.2 ± 1.5). 
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Data analysis
A Spearman rank-order correlation was run to determine the relationship between voriconazole 
dose and C
min
 using SPSS 20.0 (SPSS inc., IL, USA). A p-value of <0.05 was considered statistically 
significant. Intrapatient variability on voriconazole C
min
 was analyzed in patients who had at least 
three detectable voriconazole C
min
 at similar doses and formulations. 
Results
Patients
Twenty-one patients (8 male, 13 female) were eligible for analysis. Median (range) age at first 
dose was 7.0 years (1.2–18.5), of which 3 patients (14.3%) were <2 years, 11 (52.4%) between 2 and 
12 years, and 7 (33.3%) between 12 and 18 years. Median (range) weight, BMI and Lean Body Mass 
were 21.9 kg (9.5–65), 17.7 kg/m2 (14–25.4) and 20.9 % (8.4–52.7), respectively (Table 1). 
Voriconazole dosing
Patients received voriconazole therapy for a median (range) of 118 days (17–866; Table 1). The 
median total daily dose per kg (range) was 23.1 mg/kg (6.1–109.6). Four patients received 
voriconazole TID (both IV and PO) as part of their therapy strategy for a median (range) of 60 days 
(6–397) with a median total daily dose of 34.4 mg/kg (13.6–109.6). Voriconazole was initiated as IV 
or PO treatment in 15 (71.4%) and 6 (28.6%) of patients, respectively. The majority of voriconazole 
administrations (87.5%) were PO (5 patients received voriconazole PO only during therapy, 2 
IV only, 14 both). Median intra-individual variability of voriconazole IV was 94.1% (dose range: 
12.2–16.0 mg/kg/day) and PO was 88.5% (dose range: 10.5–44 .1 mg/kg/day). 
Therapeutic drug monitoring – initial Cmin
First TDM was performed after a median (range) of 3 days (0–27), with a median (IQR) C
min
 
of 3.1 mg/L (1.34-7.0; Table 1) with a median total daily dose of 14.1 mg/L. Upon first measurement, 
11 (52.4%) patients reached a C
min
 between 1-6 mg/L (7 patients received voriconazole IV, 4 PO). 
The median total daily dose in patients achieving a therapeutic plasma concentration was 14 
mg/kg. Of the remaining patients who had sub –or supratherapeutic target concentrations at 
initial TDM, 5 out of 9 patients (55.5%; one patient was unable to achieve target values following 
TDM-based dose adaptations) required only 1 dose adaptation to achieve a C
min
 between 
1-6 mg/L. This target in these 9 patients was attained after a median (range) of 15 days (8-123). 
After the first suboptimal C
min
, TDM-based dose adaptations were performed within a median 
160
CHAPTER 9
Table 1. Baseline characteristics (n=21).
Demographics
Gender
 Male (n [%]) 8 (38.1)
 Female (n [%]) 13 (61.9)
Median age at start (yrs [range]) 7.0 (1.2 – 18.5)
Age class (yrs)
 0 – <2 (n [%]) 3 (14.3)
 2 – <12 (n [%]) 11 (52.4)
 12 – 18 (n [%]) 7 (33.3)
Race
 Caucasian (n [%]) 18 (85.7)
 Negroid (n [%]) 2 (9.5)
 Asian (n [%]) 1 (4.8)
Median weight (kg [range]) 21.9 (9.5 – 65)
Median BMI (kg/m2 [range]) 17.7 (14 – 25.4)
Median Lean Body Mass (% [range]) 20.9 (8.4 – 52.7)
Voriconazole therapy
Median days of VCZa therapy (n [range]) 118 (17-866)
 Intravenous administrations (%) 12.5
 Oral administrations (%) 87.5
Median total daily dose (mg [range]) 400 (120-2400)
Median total daily dose per kg (mg/kg [range]) 23.1 (6.1 – 109.6)
Patients on temporarily TIDb dosing (n [%]) 4 (19)
TID dosing administrations (% of total) 11.1
Therapeutic drug monitoring
Median days until first TDM after start treatment (n [range]) 3 (0 – 27)
Median concentration of first Cmin
c (mg/L [IQRd]) 3.1 (1.34 – 7.0)
Initial Cmin adequate (% of all patients)
e 11 (52.4)
 Intravenous administration (%) 7 (63.6)
 Oral administration (%) 4 (36.4)
Initial Cmin below therapeutic range (% of all patients) 4 (19)
 Intravenous administration (%) 3 (75)
 Oral administration (%) 1 (25)
Initial Cmin above therapeutic range (% of all patients) 6 (28.6)
 Intravenous administration (%) 4 (66.7)
 Oral administration (%) 2 (33.3)
Median concentration of all Cmin (mg/L; range) 2.16 (0 – 28.0)
Total Cmin 485
 <1 mg/L (n [%]) 117 (24.1)
 1 – 4 mg/L (n [%]) 237 (48.9)
 4 – 6 mg/L (n [%]) 45 (9.3)
 >6 mg/L (n [%]) 86 (17.7)
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Table 1. - Continued Baseline characteristics (n=21).
aVCZ = voriconazole, bTID = three times per day, c C
min
 = trough concentration, dIQR = Interquartile range, eAdequate therapeutic range of voricon-
azole C
min
 is considered to be between 1 and 4 mg/L (1-6 if adequate liver function tests). Subtherapeutic C
min
 are <1 mg/L, supratherapeutic C
min
 
are >6 mg/L.
Demographics
Dose adaptations
Dose adaptations (n [%]) 243 (5.2)
Dose increase at Cmin <1 mg/L (n [%]) 55 (47)
 Resulted in increase in Cmin 42 (76.4)
 Resulted in Cmin 1 – 4 mg/L 33 (60)
Dose decrease at Cmin >6 mg/L 45 (52.3)
 Resulted in decrease in Cmin 36 (80.0)
 Resulted in Cmin <6 mg/L 23 (51.1)
 Resulted in Cmin 1 – 4 mg/L 12 (26.7)
Figure 1. Overview of all voriconazole trough concentrations at varying doses (n=485) in 21 patients.
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Figure 2. Voriconazole Cmin distribution (%) per formulation per age group.
C
min
: trough concentration. IV: intravenous. PO: Oral.
Cmin (% of total)
Age group Formulation < 1 mg/L (n) 1 - 4 mg/L (n) >4 - 6 mg/L (n) > 6 mg/L (n)
< 2 years IV 28.1 (9) 56.3 (18) 6.3 (2) 9.4 (3)
PO 28.1 (9) 37.5 (12) 12.5 (4) 21.9 (7)
2-12 years IV 23.8 (10) 35.7 (15) 9.5 (4) 31.0 (13)
PO 21.1 (52) 54.5 (134) 8.5 (21) 15.9 (39)
>12 years IV 41.7 (5) 50.0 (6) 0.0 (0) 8.3 (1)
PO 26.3 (32) 43.0 (52) 11.6 (14) 19.0 (23)
Median dose administered (mg/kg/day)
Age group Formulation < 1 mg/L 1 - 4 mg/L >4 - 6 mg/L > 6 mg/L 
< 2 years IV 12.2 11.9 N/A 12.9
PO 12.2 12.3 22.0 12.6
2-12 years IV 17.1 24.5 15.7 57.9
PO 24.0 25.9 22.9 28.2
>12 years IV 10.0 11.1 N/A N/A
PO 18.4 15.7 11.0 10.4
IV PO IV PO IV PO
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of 2 days. A very weak positive correlation between voriconazole dose and initial C
min
 was 
calculated, which was not statistically significant (r
s
 (21)=0.05, p=0.82). 
Therapeutic drug monitoring – all Cmin
In total, 485 samples were obtained with a median (range) concentration of 2.16 mg/L (0-28; 
Table 1). Four concentrations (0.82%) were reported as below the limit of quantification. A median 
(range) of 11 samples (2-109) were withdrawn per patient, of which 117 (24.1%) were <1 mg/L, 237 
(48.9%) between 1-4 mg/L, 45 (9.3%) between 4-6 mg/L and 86 (17.7%) >6 mg/L. An overview of 
all C
min
 per patient is shown in Figure 1. A very weak positive correlation between voriconazole 
dose and all C
min
 was calculated which was not statistically significant (r
s
 (485)=0.02, p=0.59). 
Patients >12 years receiving voriconazole IV most frequently encountered a C
min
 <1 mg/L, 
whereas patients 2-12 years suffered most frequently from C
min
 >6 mg/L (Figure 2).
Voriconazole dose adaptations
A total of 135 dose decreases and 108 dose increases were made, accounting for 5.2% of all 
voriconazole therapy days (see Table 1). A C
min
 <1mg/L (median 0.5 mg/L) prompted a dose 
increase by the clinician in 47.0% (n=55) of occurrences, which resulted in an increased C
min
 at 
follow-up sampling in 76.4% (n=42) of cases. In 60% (n=33), of interventions at concentrations 
<1 mg/L, this led to a therapeutic C
min
 between 1–4 mg/L (median 1.7 mg/L). In these 33 cases, 
the total daily dose was increased from a median of 18.3 mg/kg/day to 22.7 mg/kg/day (24.0%). 
Concentrations of >6 mg/L (median 8.29 mg/L) were followed by dose decreases in 52.3% 
(n=45) of cases, of which 80.0% (n=36) resulted in a subsequent lower C
min
 at follow-up sampling. 
These dose decreases resulted in a C
min
 of <6mg/L in 51.1% (n=23) of cases and even led to 
concentrations between 1-4 mg/L (median 2.3 mg/L) in 26.7% (n=12). In these 12 cases, the total 
daily dose was decreased from a median of 23.5 mg/kg/day to 16.8 mg/kg/day (39.9%). 
Discussion
We present data on voriconazole TDM in a cohort of 21 pediatric patients with difficult to control 
voriconazole C
min
. By selecting patients with at least 1 C
min
 >6 mg/L, we assured that all patients 
required dose adaptations at some time during treatment, enabling us to assess the result of 
TDM-based dose adaptations on voriconazole target attainment. The results of this retrospective, 
multi-center analysis attest to the clinical usefulness and feasibility of voriconazole TDM-based 
dose adaptations in severely immunocompromised pediatric patients. 
Of the total number of 485 voriconazole trough concentrations, 24.1% was below 1 mg/L. This is 
lower than reported values of 34-70% in pediatric patients, although these patients received the 
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licensed dose regimen at that time [7, 9, 15, 20, 21]. It should be noted that the median voriconazole 
dose used in our cohort of 23.1 mg/kg/day is higher compared to the current recommended 
dose (which has been revised to 8 mg/kg BID IV (day 1: 9 mg/kg BID) and 9 mg/kg oral for 
children 2-<12 years of age and 12-14 years of age weighing <50 kg. For adolescents 12-14 years 
of age weighing >50 kg and adolescents 15-17 years of age, a loading dose of 6 mg/kg BID IV on 
day 1 (oral: 400 mg BID) followed by 4 mg/kg IV (oral: 200 mg BID) is recommended) [18]. 
In case of a subtherapeutic C
min
 of < 1mg/L, a dose increase from 18.3 mg/kg/day to 
22.7 mg/kg/day resulted in the desired therapeutic C
min
 of 1-4 mg/L in 60% of cases. Previous 
studies have reported that dose adjustments to median doses of 20–40 mg/kg/day were 
required to obtain therapeutic plasma concentrations of >1 mg/L [9, 20]. This lower threshold is of 
particular importance, as pharmacokinetic and pharmacodynamic studies in pediatric patients 
demonstrated improved outcomes when voriconazole C
min
 were maintained above 1 mg/L [7-9]. 
These trough concentrations can be regarded as a clinical surrogate marker for full area under 
the concentration-time curve (AUC), which is the likely driver of treatment efficacy [22]. 
Overall, 95.2% of patients were able to achieve at least one therapeutic concentration (1-4 mg/L) 
after TDM-based dose adjustments, in similar range of the reported value of 80% in a study 
from Bartelink et al. [23] (using voriconazole target values of 1-5 mg/L). After the first suboptimal 
voriconazole C
min
 was measured, TDM-based dose adaptations were performed  after a median 
of 2 days. Despite these rapid dose adaptations, it took over a median of two weeks (15 days) 
to obtain an adequate C
min
, compromising patient outcome. Of all dose adaptations following 
both sub –and supratherapeutic C
min
, only 45% resulted in a therapeutic C
min
 between 1-4 mg/L 
at the following concentration measurement. If we would stretch the therapeutic targets to 
1-6 mg/L (assuming all C
min
 between 4-6 mg/L were acceptable based on adequate liver function 
tests), 56% of dose adaptations would result in target attainment. Given the long time required 
to achieve adequate C
min
 and the fact that not even half of the dose adaptations following a sub–
and supratherapeutic C
min
  resulted in target attainment, we suggest TDM should be performed 
at least 2 days after start of treatment, followed by at least weekly monitoring throughout 
treatment.
We found no predictable relationship between dose and C
min
 (Figure 1,2) and it remains unclear 
from current literature if such a relationship exists [9, 24]. Although voriconazole has been reported to 
display linear pharmacokinetics in children receiving multiple doses of 3 mg/kg and 4 mg/kg BID 
IV [12], increasing evidence suggests saturated (non-linear) pharmacokinetic behavior is observed 
in children receiving doses higher than 7 mg/kg BID [7, 10, 11, 21]. Given the high maintenance doses 
in our study, this could explain the absence of a dose/concentration relationship. Another 
explanation could be found in the high intra-subject variability in voriconazole C
min
 both after IV 
and PO dosing (figure 1), which is consistent with other pediatric studies [10-15]. 
Due to the retrospective nature of this study, laboratory data on the majority of our patients was 
limited and often obtained only on the day of voriconazole TDM. It was therefore not possible 
to draw any conclusions on the yet unclear relationship between voriconazole C
min
 and hepato-
toxicity in pediatric patients [7, 21, 24]. Because the focus of our study on the relationship between 
dose adjustments and target attainment, we did not monitor for voriconazole-related adverse 
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events (e.g. neurological adverse events, phototoxic skin reactions and potentially proarrhythmic 
conditions [25]) in relation to dose or exposure.
Given the difficulty of target attainment despite dose adaptations, together with the prior 
observed relationship between voriconazole exposure and efficacy and adverse events 
and the large inter -and intrapatient variability in children [7, 11, 15, 21], this study underscores the 
indispensable need for voriconazole TDM in pediatric patients early in the course of treatment 
with multiple follow-up samples during therapy when aiming to optimize treatment outcomes.
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Introduction
The general aim of this thesis was to study the clinical pharmacology of antifungal drugs to 
improve their safe and effective use in patients at risk for or suffering from invasive fungal disease 
(IFD) in clinical practice. In this, we addressed the current challenges in the clinical pharmacology 
of antifungal drugs (see Box 1 in chapter 1). In Table 1, we summarized the aims, findings and 
implications of the individual chapters in relation to these challenges.
In the first section of this thesis, we focussed on antifungal treatment in special patient 
populations. We reviewed the pharmacokinetics of echinocandins in special patient populations 
(chapter 2) and prospectively investigated the pharmacokinetics of micafungin in intensive care 
unit (ICU) patients (chapter 3) and anidulafungin in morbidly obese patients (chapter 4). In 
the second section, devoted to drug-drug interactions (DDIs), we provided recommendations 
on how to manage DDIs between antifungal agents and other frequently used concomitant 
medications (chapter 5 and 6) and described the in vitro results of the inhibitory potential of 
antifungal drugs on ABC transporters (chapter 7). 
The third section of this thesis concerned proficiency testing (PT) and therapeutic drug 
monitoring (TDM) of antifungal drugs. We evaluated the five year data of our antifungal PT 
program (chapter 8) and described the impact of TDM-based dose adaptations on voriconazole 
plasma concentrations in pediatric patients (chapter 9).
By addressing these three major topics, we used a structured approach intended to support 
and stimulate future research. Building such a framework prevents that the very same questions 
in future research do not have to be re-answered and will eventually lead to overcoming the 
current challenges we encounter in the clinical pharmacology of antifungal drugs. 
In this general discussion, we will discuss the results presented in this thesis in light of the following 
main topics: (1) clinical pharmacology of antifungal agents in special patient populations, (2) 
assessing DDIs with antifungal agents, and (3) the importance of interlaboratory external quality 
control and TDM of antifungal agents in clinical practice. This chapter will conclude with future 
directions.
Clinical pharmacology of antifungal agents in special patient populations
To characterize the pharmacokinetics of an investigational drug and explore its relationship 
with efficacy and safety, several studies are performed throughout drug development (from 
pre-clinical to Phase III, see Table 2) [1]. Subjects included in both Phase I and IIa studies (dose-finding 
studies) are often small subsets of healthy volunteers and highly selected patients such as those 
with renal insufficiency (Table 2). Even in later clinical outcome studies (Phase IIb and Phase III), 
actual patients (for instance critically ill patients) are poorly represented. As a consequence, the 
pharmacokinetics (and also pharmacodynamics) of the approved drug may differ significantly 
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Table 2. Phases of drug development; adapted from [3].
aEMA: European Medicines Agency, FDA: U.S. Food and Drug Administration
Phase Goal Subjects Time
Pre-clinical • Laboratory (in vitro) and animal (in vivo) studies N/A ~ 4.5 years
I • Initial safety and tolerability (pharmacology)
• Determine safe dose range
• Identify side effects
20 – 100 healthy 
volunteers/patients
Several months
II • Effectiveness (therapeutic exploratory)
• Dose response 
• Further evaluation of safety
< 100 patients Several months – 2 years
III • Effectiveness (therapeutic confirmatory)
• Monitor side effects
• Compare to commonly used treatments
• Collect information that will allow the drug to be used safely
300 – 3.000 patients 1 – 4 years
Approval • Review by competent authority (i.e. EMA/FDAa) N/A ~ 1 year
IV • Postmarketing (therapeutic use)
• Effectiveness in the general patient population
• Optimizing drug use
Patient population 
(>1.000 patients)
Ongoing 
in the actual patient population compared with the pharmacokinetics derived from registration 
studies by the manufacturer, as described in the Summary of Product Characteristics (SmPC). 
Therefore, post-approval studies (Phase IV, including studies on drug-drug interactions, 
formulation advancement, special safety, and special populations) are of utmost importance to 
expand the knowledge on the approved drug [2]. This is the time when questions not addressed 
during a frantically paced drug development program can be investigated. If well-designed, 
Phase IV studies can identify doses and dose regimens that may improve efficacy and/or reduce 
risks (resulting in an improved risk/benefit ratio).
In this thesis, we reviewed the pharmacokinetics of all echinocandins (anidulafungin, caspofungin 
and micafungin) in special patient populations (chapter 2). Also, echinocandin pharmacokinet-
ics were prospectively investigated in ICU patients (micafungin; chapter 3) and morbidly obese 
patients (anidulafungin; chapter 4).
As opposed to patients in registration studies and (non-critically ill) patients in general ward 
environments, ICU patients have substantially pathology-mediated pharmacokinetic variations. 
The drugs’ volume of distribution, metabolism and clearance may be influenced by, for instance, 
fluid status (retention or ascites), serum albumin concentrations (hypoalbumenia) and/or liver 
and kidney function (hepatic or renal insufficiency) [4]. 
We found that micafungin ‘standard’ dosing regimens as advised in the SmPC (i.e. 100 mg/day 
for invasive candidiasis) [5] leads to suboptimal exposure in ICU patients and hence reduced 
likeliness to consistently achieve the pharmacokinetic/pharmacodynamic (PK/PD) targets 
associated with maximum antifungal activity (chapter 3). To adequately define a PK/PD target, 
not only exposure, but also the minimum inhibitory concentration (MIC) of micafungin for the 
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Figure 1. Factors influencing the PK/PD index in special patient populations.
A Increased volume of distribution (Vd) decreases the peak plasma concentration (Cmax) of the drug during first administration. B Increased 
clearance (CL) reduces the AUC. C Decreased CL increases the AUC and hence the trough concentration (Cmin). D Increased minimum inhibitory 
concentration (MIC) of the offending pathogen will result in decreased PK/PD targets of micafungin (AUC/MIC and/or Cmax/MIC). 
Adapted with permission from [24].
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fungal pathogen should be taken into account. Considering that the MIC is the denominator 
for the PK/PD relationship and the susceptibility of the offending pathogen may vary [6], the 
exposure must increase in parallel to ensure adequate antifungal coverage. The concept of the 
PK/PD relationship and how this can be affected by altered pharmacokinetics in special patient 
populations is displayed in Figure 1.
To unravel the interplay between drug efficacy and pathogen susceptibility, both exposure 
and MIC must be known. We have looked at the largest cohort of ICU patients with invasive 
candidiasis / candidemia up until today and defined pharmacokinetics. The next step would 
be to integrate pathogen susceptibility (pharmacodynamic) information to derive if the lower 
exposure puts this special patient population at increased risk of therapeutic failure. The lower 
exposure found in our cohort compared with healthy volunteers (but not with other patient 
populations [7-11]) is subject to debate as this might suggest that critically ill patients could benefit 
from higher dosages. In addition, a loading dose may be needed to attain early optimal therapy 
as a delay in treatment is considered a potential risk factor for mortality [12]. 
ICU patients are regarded as a special patient population in terms of alterations in pharmacokinetics. 
Likewise, obese patients may be considered a special patient population as the physiological 
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changes of excessive weight, such as increased blood volume, cardiac output, splanchnic blood 
flow, and hepatic blood flow, have been shown to affect drug pharmacokinetics [13].
Knowledge on pharmacokinetics is crucial as obesity has become a worldwide epidemic (the 
proportion of adults with a BMI >25 kg/m2 increased from 28.8% in 1980 to 36.9% in 2013 in men 
and from 29.8% to 38% in women [14]) that is associated with multiple co-morbidities increasing 
the risk of hospitalization. 
There is limited evidence for optimal dosing of antifungal drugs in obese patients. We have set 
a first step in defining pharmacokinetics of anidulafungin in this special patient cohort. Several 
signals were pointing towards altered pharmacokinetics for this drug as increased bodyweight 
had been linked to reduced anidulafungin exposure due to increased clearance and volume of 
distribution [15-18], although these cohorts included only very limited obese patients. In chapter 
4, we describe that anidulafungin exposure in morbidly obese patients (BMI >40 kg/m2) was 
on average 32.5% lower compared to the general patient population. To reach comparable 
exposure within similar time compared to reference populations, increasing the loading and 
maintenance dose by 50% (i.e. to 300 mg and 150 mg, respectively) could be considered. 
For both ICU patients and morbidly obese patients, the findings of lower exposure of the 
administered antifungal drugs compared to other (patient) populations were not unexpected 
(chapter 2). Among other patient populations, lower exposure of both anidulafungin and 
micafungin have been confirmed (e.g. in patients with moderate or severe hepatic dysfunction, 
patients with renal impairment) [7-11, 16, 18-22] but never prospectively confirmed in both obese (for 
anidulafungin) and ICU patients (for micafungin). These changes in pharmacokinetics may be 
explained by alterations in volume of distribution as well as changes in clearance. Both obese and 
ICU patients have a high likelihood of an increased volume of distribution compared to healthy 
volunteers and non-critically ill patients for echinocandins. The consequence of an increased 
volume of distribution is that a (higher) loading dose should be considered to reach adequate 
plasma concentrations as soon as possible. Second, both patient groups suffer from increased 
clearance, requiring an increase of the antifungal maintenance dose. The exact reason for this 
increased clearance (and thus lower exposure) remains to be investigated. We hypothesize that 
the free fraction of micafungin in ICU patients could be higher since a lower plasma albumin 
concentration is typical for those patients. The literature is inconclusive with regards to factors 
explaining these pharmacokinetic alterations. Measuring the free concentration might seem 
a viable option, but this is technically challenging due to the high protein binding (>99%) of 
echinocandins. Another difference between these patient groups which might contribute to 
altered pharmacokinetics of drugs is that ICU patients suffer from hepatic impairment, possibly 
interfering with the metabolism of drugs to their (inactive) metabolites and hence altering the 
exposure. 
Specifically in obese patients, an increased clearance due to a higher free fraction driven by 
hypoalbumenia is unlikely, as all patients had albumin concentrations in the normal range. Thus, 
other factors must contribute to an increased clearance. We can theorize on numerous factors 
that change the pharmacokinetics, as obese patients have several unique physiological changes, 
i.e. increased blood volume, cardiac output, splanchnic and hepatic blood flow. The contribution 
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of each of these factors to an increased clearance needs to be resolved in future research. 
Although the lower exposure in these two cohorts did not come unexpected on a theoretic 
basis, it is essential to demonstrate this in a prospective trial as performed in chapter 3 and 4, 
because sometimes expectations are not confirmed as recently demonstrated in another study 
from our group with caspofungin. In a similar design as described in chapter 3, ICU patients 
unexpectedly showed equal caspofungin exposure compared with non-critically ill patients [23].
In chapter 2, 3 and 4, we have focused on pharmacokinetics only and clearly demonstrated 
that our special patient populations are at increased risk for therapeutic failure. In the absence 
of pathogen susceptibility, the application of TDM may be warranted to safeguard exposure 
that covers at least 90% of wild type MIC distribution. Also, pathogen MIC must be determined 
as soon as possible, specifically in the setting of therapeutic failure due to increased MIC (i.e. 
resistance). This integrated approach is the way to personalize the dose (and thus concentration) 
that optimizes patient outcome (see Therapeutic Drug Monitoring). 
Of note, it is important to realize that both obesity and critical illness in one patient (an obese 
ICU patient) can additionally influence the pharmacokinetics of drugs, posing even more 
increased risk for therapeutic failure if standard doses are used.
Assessing drug-drug interactions with antifungal agents
The overall aim of drug interaction studies is to determine whether or not interactions will 
occur that are sufficiently large to necessitate dose adjustment and the need for additional 
therapeutic monitoring, or whether or not concomitant use should be contraindicated. For a 
newly developed drug, DDIs are investigated throughout the drug development process [25].
In this, in vitro CYP mediated drug-drug interaction studies are performed to provide a 
rationale for clinical trials. These in vitro inhibition studies can be performed using human 
liver microsomes (vesicular fragments of endoplasmic reticulum), hepatocytes, or other cells 
expressing the investigated enzyme. 
Similar to CYP-mediated DDIs, in vitro inhibition studies can be conducted to investigate whether 
the drug inhibits any clinically relevant transporters. To study these possible interactions, it 
is recommended to use an in vitro system where the human in vivo transport functions of 
the transporter are preserved. Hepatocytes could be used for these studies, although their 
isolation may cause rapidly down-regulation of some transporters [26]. We conducted such a 
study using HEK293 cells overexpressing different efflux transporters for a vesicular transport 
assay to assess the inhibitory potential of antifungal drugs on ABC transporters P-gp, MRP1–5, 
BCRP and BSEP (chapter 7). These inverted plasma membrane vesicles offer the major 
advantage that drugs are directly applied to the cytoplasmic compartment and influx, rather 
than efflux, is measured. This enables detailed analysis of inhibitory effects with the targeted 
transporter [27].
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If in vitro studies with metabolizing enzymes indicate there may be a clinically relevant 
interaction, it is recommended to perform in vivo interaction studies (of note, for transporter-
based drug interactions, recommendations on in vitro to in vivo extrapolation are not available 
yet and requires additional experience and continued scientific developments) [28]. These 
studies –usually with a small number of subjects– can be performed in healthy volunteers, 
which will predict findings for the intended patient population. With regard to safety 
and/or tolerability issues however, investigating drug interactions in healthy volunteers may 
not always be possible and interaction studies in patients are warranted. This approach offers 
the benefit that healthy volunteers are not exposed to drugs which could cause them harm 
and that pharmacokinetic differences between the target population and healthy volunteers 
are accounted for (see Figure 1). On the other hand, performing these studies in patients could 
result in lower concentrations of the (antifungal) drug, introducing unnecessary chance of 
treatment failure. The interaction study should provide clear recommendations on the optimal 
dose to use under the circumstances of an interaction. 
Although screening for potential DDIs is part of the drug development and approval process, 
uncertainties still exist after the introduction of the drug into clinical care. Therefore, additional 
pharmacokinetic drug-drug interaction studies are often needed post-approval to optimize 
safe and effective use of drug treatment combinations. 
In the past 50 years, almost 2,000 articles on DDIs with antifungal agents have been published 
(PubMed search Q4 2015). Besides the abundance of DDIs described in literature, theoretical 
DDIs that can be expected based on inhibition and/or induction of the metabolism of either 
the antifungal or co-administered drug should also be regarded in case there is no or few data 
available. Also, the list of potential DDIs involving antifungal agents continues to grow as more 
evidence becomes available, requiring constant re-evaluation of the clinical management 
of these DDIs. To guide clinicians in the evaluation of DDIs of antifungal drugs, a stepwise 
approached as proposed in chapter 5 could be used. Although this six-step method is 
proposed for the adequate management of DDIs between azole antifungals and immunosup-
pressants, it should be emphasized that this also offers an easy approach to estimating the 
effect of DDIs in other therapeutic areas. 
In chapter 6, we described the point-by-point development of a comprehensive, up-to-date 
database of DDIs with antifungal agents (Fungal Pharmacology) to meet in what we considered 
a deficiency in accessible data. With this, we also describe the underlying mechanism and 
scientific evidence as well as offer tailor-made clinical advice on how to manage these 
interactions. Fungal Pharmacology is available both as medical application and web-based 
resource. With an estimated 500 million smartphone users worldwide using some type of 
medical app in 2015, and half of the >3.4 billion smartphone and tablet users in 2018 who will 
have downloaded mobile health applications [29], this poses a serious challenge for regulatory 
oversight on the quality of these medical apps. The FDA, which regulates medical devices 
in the U.S., has come under pressure to evaluate all these medical apps and mobile medical 
devices and consequently provided interim guidelines [30]. By describing the development of 
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Fungal Pharmacology in chapter 6, we provide a structured approach for building a relevant 
and reliable drug-drug interaction database for future initiatives in other therapeutic areas. 
Importance of interlaboratory quality control / proficiency testing for antifungal agents
Interlaboratory PT programs ensure that analytical methods have sufficient accuracy, precision, 
and specificity when used to measure antifungal drugs in patient samples. Over time, PT testing 
has evolved into an essential component of a laboratory’s quality management system [31]. In 
chapter 8, we describe the five year results of an international PT program for measurement of 
antifungal drugs, with the overarching aim to verify on a recurrent basis that laboratory results 
for these measurements conform to expectations for the quality required for patient care. 
In many countries including the Netherlands, PT programs are a component of laboratory 
accreditation requirements [32]. Although an international standard has been published that 
provides management information and requirements to laboratories on organizing and 
conducting such PT programs [33], different designs of PT programs may exist, all with their 
own strengths and limitations. In this, one of the most important concepts affecting the 
design and interpretation of such programs is the commutability of samples i.e. do PT samples 
reflect relationships expected for patient samples containing the same quantity of analyte 
among different measurement procedures? [34, 35]. 
To interpret a PT result of participating laboratories, a target value must be provided along 
with a range for acceptable values around that target. Generally, there are two ways to define 
a target concentration for commutable samples. The first one is to use a single target value 
(the weighed-in value) [37]. Another approach to determine the target value may be set by the 
all-participant mean, the median value after outlier exclusion or by a minimum of ten referee 
laboratories, because the same results are expected for all procedures for a commutable 
sample [38]. Due to the commutability of samples in our antifungal PT scheme, we used the first 
approach by spiking low and high target concentrations and assigned them as target values 
after measurement (chapter 8).
The acceptance limit around the target value is of importance to interpret laboratory 
performance. Our fixed 20% threshold was based on guidelines for method validation for 
bioanalysis of drugs and maximum allowable error specifications for drug measurements 
according to the CLIA [43, 44]. These limits were set as a minimal standard to identify results 
indicating poor performance of laboratories. It is important to realize that meeting these 
standards does not indicate optimal performance nor that performance meets all clinical 
needs. 
The observed proportion of inaccurate results in our program (19.2%) is unacceptable as this 
may be a source of bias in pharmacokinetic studies performed by these laboratories and could 
influence the clinical decision making following TDM, ultimately leading to therapy failure 
or concentration-related toxicity. Even if this 20% threshold would be extended to 25%, the 
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number of inaccurate results would only minimally change. By sending out error forms to 
participating laboratories, the majority of explanations for deviating results were found to be 
methodological problems, technical problems  and clerical errors. This indicates that a vast 
amount of incorrect performances is directly due to human mistakes. 
In an earlier report on the first round of the antifungal PT program, it was concluded that 
measuring low concentrations of azole antifungals yields a lower accuracy as opposed to 
high concentrations [45]. This can be explained because measuring low concentrations is 
technically more challenging and complex, as was also seen in the “sister” PT program for 
antiretroviral drugs [46, 47]. In our current analysis, laboratories also encountered problems when 
analyzing lower concentrations. To address this problem, laboratories should be encouraged 
to extend and validate the range of their analytical assay. This is of utmost clinical importance, 
as antifungal trough concentrations are the most reliable predictor of therapeutic efficacy [48]. 
Therapeutic Drug Monitoring
For certain antifungal drugs, a correlation between drug exposure and treatment outcome 
has been described [49], and the evidence is gradually growing. For TDM to be useful, several 
criteria have to be met such as, but not limited to: the effect of the drug is difficult to assess 
clinically, the drug displays a large interpatient variability in pharmacokinetics, and there is 
a correlation between drug concentration and clinical response / toxicity [50]. The antifungal 
drugs voriconazole, itraconazole, posaconazole and flucytosine meet these criteria, and TDM 
of these drug is thus widely applied [49]. 
With regards to TDM of voriconazole, a drug with a large inter -and intrapatient variability 
in pharmacokinetics [51], we assessed whether voriconazole dose adaptations resulted in 
simultaneous increases or decreases in voriconazole trough concentrations (C
min
) in chapter 9. 
Only 45% of dose adaptations following sub –and supratherapeutic voriconazole C
min 
did result 
in target attainment. In the remaining 55%, multiple interventions were required to achieve 
a therapeutic C
min
. It has previously been suggested that plasma levels of voriconazole 
correlate with adverse events (including visual disturbance, encephalopathy, rash, and hepatic 
enzyme elevation) [52, 53] and, as demonstrated in several observational studies, treatment 
response [51, 54-56].
Despite the evidence in literature and guidelines (such as the upcoming ESCMID guideline 
on the treatment of Aspergillus infections and the ECIL guidelines) which will cover the role 
of antifungal TDM [57], only one randomized controlled trial has been conducted to evaluate 
the clinical utility of routine TDM for voriconazole [58], albeit that this was a single-center study. 
Single-center studies in general have the drawback of limited external validity (i.e. the study 
findings are not necessarily generizable to a broader population). For posaconazole, such a 
randomized trial has not been conducted so far. 
Ideally, the design for such a trial would be a large, multicenter, prospective, randomized 
controlled trial of two groups of patients suffering from IFD (i.e. wild type Aspergillus fumigates). 
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In this, subjects receiving voriconazole according to the SmPC are randomly assigned to either 
a ‘TDM group’ in which results of drug concentration measurements plus advice is reported 
to the clinician to obtain voriconazole concentrations within the predefined target concentra-
tions, and a ‘no TDM group’ in which TDM results are not reported and dose adaptations are 
made based on clinical or laboratory parameters. An alteration to this approach would be 
to conduct a cluster randomized trial, allowing hospitals to perform voriconazole TDM for a 
sufficient time period (e.g. one year), and then switch to another arm (no TDM) and compare 
voriconazole target attainment during both time periods. 
In infectious diseases, such trials have been conducted in treatment-naïve patients receiving 
the protease inhibitors nelfinavir and indinavir, in which it was proven that TDM of these 
drugs improves treatment response [59]. With regards to voriconazole, only one study aimed 
to determine whether routine TDM of voriconazole reduces drug adverse events or improves 
treatment response in IFD [58]. Although this study was a randomized, assessor-blinded, 
controlled, single center trial, voriconazole dose was adjusted one time only on the fourth day 
after starting treatment, whereas voriconazole-related adverse events and treatment response 
were assessed three months after the initiation of therapy. In this, it is important to realize that 
the drawing of a single sample (on the fourth day of treatment) and providing dose advice 
based on the plasma concentration can hardly be correlated with voriconazole toxicity and 
efficacy three months after initiation of therapy. Rather, to confirm the value of voriconazole 
TDM, multiple samples with simultaneous dosing advices should be given during treatment. 
Besides this trial, other single center studies that have been conducted to investigate the role of 
TDM of voriconazol were prone to inaccuracies, e.g. the use of antifungal combination therapy, 
voriconazole use for different causative fungal species, and different time of assessment of 
outcome [54].
Given the large intrapatient variability of voriconazole [60], which has also been demonstrated in 
chapter 9, it seems that there is still a lack of confirmative evidence to prove that voriconazole 
TDM improves treatment. Therefore, the added value or impact of TDM in clinical practice 
should be evaluated and demonstrated where possible.
Findings of this thesis: future perspectives
Pharmacokinetic research in special patient populations
Currently, morbidly obese patients and critically ill patients are not subjected to pharmaco-
kinetic studies during drug development. There is a clear need for more pharmacokinetic 
studies in these populations. 
Despite the increasing incidence of obesity on a global scale, there is a paucity of data on 
the pharmacokinetics of antifungal drugs in this special patient population. Also, the average 
bodyweight of patients is expected to increase as the obesity epidemic continues, given 
that the mean bodyweight of hematology patients treated with anidulafungin was already 
182
CHAPTER 10
reported to be 77 kg (range 52 – 113) [19]. It is to be expected that other antifungal drugs 
might also be affected by excessive bodyweight. Therefore, future studies should focus on 
other antifungal drugs and obesity to explore the pharmacokinetics of antifungals dosed on 
bodyweight (e.g. liposomal amphotericin B) and be integrated into the registration process.
From a pharmacological standpoint, the morbidly obese patient population differs in terms 
of their physiologic changes affecting the pharmacokinetics of the investigated drug. Three 
populations can be discriminated: (1) “healthy” morbidly obese patients who will undergo 
bariatric surgery (e.g. gastric bypass or gastric sleeve). Because of this surgery, these patients 
are admitted to the hospital and selected for research given the ‘controlled’ environment 
(the hospital) they are already in. In this population, the surgery procedure (e.g. anesthetic 
drugs) might influence the pharmacokinetics of drugs. Furthermore, (2) “healthy” morbidly 
obese patients, who (only) suffer from excessive bodyweight and possible comorbidities 
(e.g. diabetes) could be included, or (3) morbidly obese patients who are administered to the 
hospital due to their illness (for instance the morbidly obese ICU patient).
Studies for registration of a drug conducted by the manufacturer (pre-approval studies) 
include healthy volunteers or highly selected patients with the focus on a single variable (e.g. 
liver -or renal function). Real-life cohorts, such as ICU patients, display vastly different drug 
pharmacokinetics compared to the subjects in registration studies (due to altered clearance 
and/or distribution) [4]. There is still limited pharmacokinetic data in ICU patients and other 
special populations. We experienced that 20 patients in the ICU was excellent for descriptive 
pharmacokinetics but not large enough to resolve covariates. Future studies should include 
substantially larger critically ill population to detect possible covariates on drug pharmacoki-
netics, for example with larger differences in albumin status or disease status. 
Also, using the greater power of a pooled analysis of data from more than one clinical study 
should be performed to examine in more detail the influence of covariates on the pharma-
cokinetic parameters of antifungal agents in special patient populations (requiring cautious 
interpretation regarding differences in study designs, treatment practices, and important 
demographic or disease characteristics). Therefore, collaborative networks involving 
institutions willing to share data on the pharmacokinetics in these special patient populations 
would be an important step in improving our scientific knowledge on the optimization of 
antifungal therapy.
Because critically ill and morbidly obese patients are associated with many physiological 
changes affecting pharmacokinetics, it can be advocated that in both these patients 
populations drug safety and efficacy is explored during drug development. The inclusion of 
these patients in a clinical development plan during drug development similar to e.g. geriatric 
or pediatric patients will assure optimal drug dosing during therapy.
A second step in this framework must be to resolve clinical pharmacodynamic endpoints. For 
most antifungal drugs, safe and effective target concentrations have not been adequately 
defined and provisional target concentrations are used for clinical interpretation. These 
tentative breakpoints are developed early in the course of drug development based on in vitro 
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activity, in vivo (animal) model data, and pharmacokinetic information (including pharmaco-
dynamic correlates to establish a PK/PD index). Clinical breakpoints are set by determining a 
pharmacodynamic target that distinguishes between patients who either respond successful 
or unsuccessful to therapy (based on observations in experimental and clinical studies) or 
could be based on surrogate parameters such as galactomannan. Even though these clinical 
breakpoints are highly anticipated, they are often completely lacking or determined in Phase 
IV studies by independent research groups. During Phase III trials, the pharmacodynamics 
should be more extensively determined. Only then, modeling and simulation with advanced 
techniques (e.g., NONMEM) will aid to determine clinical breakpoints before approval of the drug. 
Several options are available to define these PK/PD relations. First, the authorities are the central 
source for data analysis. Recently a first step has been taken by the FDA by single-handedly 
performing an analysis to determine the optimal target for posaconazole prophylaxis. This is 
a first step towards a procedure that should become common strategy [61]. Another option 
is that regulatory authorities should make an effort to request pharmaceutical industries 
to determine target concentrations that correspond with efficacy and toxicity during drug 
development. Such an approach would provide more insight into possible clinical breakpoints. 
To achieve this task, the study design (incorporating a large cohort) should include intensive 
pharmacokinetics, resolution of pathogen susceptibility and link this to therapeutic success 
i.e. survival or surrogate endpoints such as galactomannan. Lately this has been carried out for 
drugs in the field of antifungal treatment [18, 62] but this should become a standard procedure.
Drug-drug interactions
In recent years, the issue of DDIs has generated significant concern for drugs under development 
within the pharmaceutical industry and amongst regulatory authorities. Evidence for and 
against a DDI should be examined at all stages of drug development.
In the pre-approval process, in vitro studies represent a valuable tool for the assessment of 
DDIs. With the use of our vesicular transport assay, we have shown that antifungal agents 
are capable of in vitro inhibition of clinically relevant efflux transporters. Clearly, the vesicular 
transport assay could be of great value to assess the inhibitory potential of other antifungal 
and anti-infective drugs on efflux transporters during the pre-approval process. This vesicular 
transport or similar approaches warrant more attention in the evaluation of future drugs, 
considering that transporters mediate many DDI, as shown by rapidly evolving evidence in 
the past decade [63].
Patient populations at risk for IFD and requiring antifungal treatment are at increased risk for 
DDIs because they typically require several concomitant medications. This requires knowledge 
of the pharmacokinetic characteristics of the drugs and a strategy for optimal clinical 
management. A large subset of DDIs with antifungal agents could be prevented if concomitant 
administration of drugs was preceded by correct prediction, identification, quantification and 
classification of DDIs in the light of the patient-specific factors. Thus implementation of our 
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six-step method by physicians and pharmacists together warrants attention. It will remain 
a complex task to be aware of all possible DDIs with antifungal agents. This is even more 
complex regarding the addition of new drugs to the market (e.g. isavuconazole), along with 
their unique, sometimes unpredictable interactions [64]. Hence, consulting adequate sources 
of information such as Fungal Pharmacology  is of crucial benefit in the prevention of DDIs. 
Although the intent of medical apps is to provide point-of-care access to medical information 
from the pocket to the patient, any developer can label their app as ‘medical’. With a plethora 
of medical apps and current lack of oversight and regulation, this requires the healthcare 
professional to be cautious when relying on such a medical app. In my opinion, the most 
well-designed medical app poses a significant risk to patient care if the content is inaccurate, 
outdated or too difficult to navigate. Therefore, definite regulatory guidelines for the 
development of medical apps are highly anticipated, because until now the FDA only evaluates 
medical apps that are “used as an accessory to a regulated medical device; or transform a 
mobile platform into a regulated medical device” [29]. Future initiatives of medical apps are 
encouraged to use several stages (explore, construct, consult, publish and track), including 
an expert and test panel all with a vast experience in the treatment of infectious diseases, 
as a starting point for the development of a medical app that improves patient safety. Also, 
implementation of a quality control system, including periodic (e.g. monthly) updates of data 
on new and already existing DDIs and a feedback system from users of the medical app is 
essential. It is encouraged to establish collaborations with healthcare authorities in order to 
provide additional sources of data input such as label-revisions of drugs regarding DDIs.
Ideally, knowledge bases such as Fungal Pharmacology should not be used as a standalone 
solution, but rather should aid clinical decisions and support electronic health records by 
incorporating therapeutic drug monitoring data, patient demographics, laboratory tests (e.g. 
liver function tests and glomerular filtration rate values) and clinical information such as side 
effects, laboratory abnormalities and ECG read-outs. In this way, the clinical advice on the DDI 
with antifungal drugs could be even more patient specific, anticipating altered pharmacoki-
netic parameters in the target population and allowing Fungal Pharmacology to be adopted 
into the clinical decision support systems of hospitals. 
Given the increasing page views of our web site and increasing downloads on both Apple and 
Android platforms, there is a clear need for Fungal Pharmacology. It will remain a priority to 
keep this database up-to-date, which will require close collaboration of pharmacists, clinicians, 
clinical pharmacologists, medical microbiologists and the Dutch Medicines Evaluation Board.
External quality control of antifungal drugs 
The starting point for introducing TDM of antifungal agents in your laboratory is an adequate 
analysis, which can be examined by participating in a PT program. The number of inadequate 
analysis (19.2%) by laboratories over the years is displeasingly suboptimal, although the 
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percentage of accurate analyses of all laboratories over five years time gradually improved 
from 71.0% to 87.7%, indicating a possible contribution of our program to a more adequate 
analysis of antifungal drugs. 
Based on the Clinical & Laboratory Standards Institute (CLSI) guideline [65], we uniquely distributed 
error evaluation forms to all participating laboratories regardless of their performance in the past 
years. In this, the majority of explanations for deviating results were found in methodological, 
technical or clerical errors. As the quality control samples in our program are prepared by the 
Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology 
(KKGT) in close collaboration with the Dutch Foundation for Quality Assessment in Medical 
Laboratories (SKML), it can be advocated that these professional bodies are in the unique 
position to add substantial value to the practice of laboratory medicine. For this, two extreme 
options could be considered. The first option would be to focus solely on the analytical 
aspects (i.e. reporting [inadequate] measures back to the performing laboratory). At the other 
end, a strong interference of these professional bodies with both analytical aspects as well as 
procedures involving the TDM process could be proposed [57]. We advocate a hybrid model 
with analytical tests as primary focus combined with clinical cases and periodic dispatching 
of CLSI-based error forms in the process. Authorities should therefore not only focus on the 
analysis by reporting (inadequate) measurements back to the performing laboratories, but 
rather focus on the interpretation of these measurements regarding clinical-decision making. 
This will result in more accurate measurement of antifungal drug concentrations and thus 
optimize antifungal treatment in terms of efficacy and toxicity.
To add value to the PT program of antifungal drugs, the antifungal concentrations as measured 
by the laboratory are used to solve a clinical case (answers of multiple choice question type). 
In this, an incorrect measurement will lead to a false answer, which directly means that the 
process of TDM is counterfactual and the wrong clinical advice was given upon measurement 
of patient samples. 
The few antifungal PT programs that exist (INSTAND e.V. and UKNEQAS) do not provide such 
clinical cases along with their antifungal PT samples. It is encouraged that PT programs provide 
a clinical case to interpret the result of the sample measurement in the light of clinical decision 
making.
Based on the large number of laboratories that continue to participate in our program and 
several other laboratories that have joined the program in recent years, I am confident that 
there is a need for such a service. One of the challenges when organizing an international PT 
program is to remain up-to-date to fulfill the needs of the participants. For our antifungal PT 
program, addition of other antifungal drugs (e.g. echinocandins and isavuconazole) would 
encourage laboratories to optimize the analysis of these drugs, given that measuring plasma 
concentrations of these drugs for both research or clinical purposes is becoming increasingly 
acknowledged. However, one could argue that the poor stability of echinocandins in plasma 
or whole blood requires freeze-drying of the spiked plasma samples, which limits the 
commutability of these samples by introducing a matrix-effect. This remains to be investigated.
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Therapeutic drug monitoring
Over the past years, Radboudumc has been advocating the use of TDM of azole antifungal 
drugs despite that an overall consensus for therapeutic drug monitoring of antifungal drugs 
has only recently been reached. The 2008 guideline for treatment of aspergillosis suggests 
that “determination of a plasma drug level, in conjunction with other measures of clinical 
assessment, may be another factor in evaluating reasons for therapeutic failure attributable 
to suboptimal drug exposures or for toxicity attributable to the drug (B-III)” [66]. The guidelines 
of the ECCMID and ECIL now have a dedicated section that will cover the topic of antifungal 
TDM in more detail [personal communication] [57]. The importance of measuring antifungal 
drug concentrations is expected to be increasingly acknowledged. In difficult to treat patient 
populations, such as pediatric patients, significant inter- and intrapatient variability makes the 
use of TDM indispensible. TDM of antifungal drugs has been shown to be clinically relevant 
for antifungal drugs, although new randomized trials would be warmly welcomed. A step 
forward in this would be conducting such a large, prospective clinical trial as described above 
(see Therapeutic Drug Monitoring). A multicenter, prospective, cluster randomized trial has 
been initiated in 12 hospitals in The Netherlands already in 2008 (headed by the University 
Medical Center Groningen) with the primary endpoint of efficacy and toxicity of voriconazole 
TDM. Results from this study are highly anticipated and are expected in 2016. 
A challenge for the pharmacist/pharmacologist, is to define an optimal dose for the individual 
patient based on previous drug concentration assessments. Currently, this is done by simple 
decision algorithms. Obviously, better techniques for upfront prediction of an optimal dose are 
slowly becoming available. To optimize antifungal treatment, the pharmacist is encouraged 
to use software programs that find optimal doses for individual patients by integrating 
mathematical models, patient physiology, pharmacogenomics, drug concentrations and 
biomarkers (e.g., InsightRX, Best Dose). Our group has a collaboration with InsightRX to set 
up and validate this software in clinical practice. Using such clever software , the dose of the 
antifungal drug is optimized to reach and maintain a desired therapeutic range, ultimately 
leading to increased efficacy, decreased adverse events and increased cost savings. 
Assessing C
min
 concentrations is standard practice for TDM of azole antifungals. As alternative 
strategy, a limited sampling strategy (LSS) with 2 to 4 samples can be used. LSS allows for 
more accurate AUC predictions than using C
min
 only. LSS are however not ideal to implement if 
a multiple linear regression approach is used, as strict adherence to the predefined sampling 
times (i.e. T=0, 2 and 4 hours) is mandatory for correct calculation of the AUC. Using the 
benefit of the above described programs, this strict adherence to the sampling protocol is 
not necessary. 
For long term follow-up, novel sampling strategies such as dried blood spot finger pricks 
(requiring only one drop of blood applied on filter paper) could be of great value to address 
the challenges with AUC determination and LSS. For drugs such as voriconazole with a high 
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intraindividual clearance (and thus highly variable C
min
), AUC determination with LSS might 
optimize treatment.
Overview
In the introduction of this thesis we highlighted several aspects in the clinical pharmacology of 
antifungal drugs that remained untouched or unknown (see Box 1). The chapters of this thesis 
all provide a structured approach to improve the understanding of the clinical pharmacology 
of antifungal drugs and promote their safe and effective use in patients at risk or suffering 
from IFDs: the building of a clinical pharmacology framework for the safe and effective use of 
antifungal agents.
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Summary
Fungi are among the most evolutionarily and ecologically diverse organisms on the planet. The 
fungus is ubiquitously incorporated in daily life: we inhale the spores present in air, encounter 
them trough the environment (i.e. food, animals, plants and soil) and they are even present in the 
human body itself. Although human health has immensely benefited from this organism trough 
fungal-derived antibiotics (e.g. penicillin), fungi can also interact with humans in pathogenic 
ways. The frequency of opportunistic invasive fungal disease (IFD) has increased significantly 
over the past two decades. This is correlated with the increasing number of patients who are 
at risk of developing IFD, including cancer patients, hematopoietic stem cell or solid-organ 
transplant patients receiving immunosuppressive therapy, critically ill patients, premature 
infants, and HIV-infected patients. Given that these systemic fungal infections (caused by e.g. 
Candida and Aspergillus species) are associated with increased morbidity and mortality together 
with the complexity of the of the patient populations at risk, IFDs have evolved as a major health 
problem. Antifungal drugs play an important role in the adequate prophylaxis and treatment of 
these fungal infections. 
This thesis focuses on the clinical pharmacology of antifungal drugs in order to optimize their 
safe and effective use in clinical practice. The thesis comprises of 10 chapters, which are divided 
in three sections.
Section I evaluates the pharmacokinetic behaviour of antifungal drugs in special patient 
populations. 
Section II of this thesis focuses on the management of pharmacokinetic drug interactions 
between antifungal drugs and other frequently used concomitant medications in clinical 
practice. 
Section III of this thesis focuses on interlaboratory (external) quality control and therapeutic drug 
monitoring (TDM), with the aim to optimize treatment with antifungal drugs for the individual 
patient.
This thesis ends with a general discussion that addresses the individualization of treatment with 
antifungal drugs. 
Section I: Antifungal pharmacokinetics in special patient populations
The studies in chapter 3, 4 and 5 focused on defining the behaviour of antifungal drugs in special 
patient populations (pharmacokinetics, i.e. drug absorption, distribution, metabolism and 
excretion). During the registration phase of a drug, special patient populations such as critically 
ill patients or extremely obese patients are usually not included in registration studies by the 
manufacturer of the drug. Therefore, it is often unknown if the licensed dose of the drug is also 
suitable for the intended patient group, since the pharmacokinetics and the blood concentra-
tion may alter due to patient-specific factors, including age (paediatrics vs. adults), body surface 
area and body composition (normal weight vs. obesity), disease status (e.g., critically ill and burn 
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patients) and organ dysfunction (kidney and liver impairment). These subsequent effects of 
altered exposure might eventually impact efficacy and safety of the drug.
In chapter 2, we reviewed the pharmacokinetics of echinocandins (anidulafungin, caspofungin 
and micafungin), which are widely used in many different patient populations for the prevention 
and treatment of Candida infections. Patient populations addressed were neonates, children 
and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients 
(including burn patients) and patients with haematological diseases. Despite comparable 
guideline recommendations of these three echinocandins in adults, we report that limited and 
conflicting data are available regarding the pharmacokinetic behaviour of the three echinocan-
dins in these special patient populations. However, we doubt that these differences in pharma-
cokinetics should be regarded as a basis for preferring a specific echinocandin over another. 
Rather, we conclude that for an individual patient the echinocandin dose could be adjusted to 
another (fixed) dose based upon patient characteristics or comorbidities.
In chapter 3, we prospectively investigated the pharmacokinetics of micafungin in intensive care 
unit (ICU) patients and set out to explore the parameters that influence micafungin plasma con-
centrations (e.g. weight, disease status). We included 20 ICU patients receiving the licensed dose 
of micafungin for suspected or proven fungal infection or as prophylaxis (100 mg intravenous 
once daily). On day 3 and day 7, multiple samples at different time points after infusion were 
withdrawn, a so-called pharmacokinetic curve. Also, we withdrew daily samples just prior to the 
next micafungin dose (trough concentrations). Subsequently, we could estimate the micafungin 
pharmacokinetics on both days in these patients. The pharmacokinetic parameters (e.g. exposure, 
peak and trough plasma concentrations) on day 3 were not significantly different from those on 
day 7, indicating that maximum micafungin exposure was achieved at latest on day 3. Daily 
trough concentrations differed moderately between patients (57.9%), but differed only limited 
within patients on different days (12.9%). In this cohort of patients, no covariates of influence on 
micafungin exposure were identified and micafungin was considered safe and well tolerated. 
The micafungin exposure in our cohort of ICU patients was significantly lower if compared to 
healthy volunteers, but not significantly different from that of other patient populations. At the 
initiation of micafungin therapy, the trough concentration prior to the second dose was sig-
nificantly lower than the trough concentration prior to the third dose. Based on the results of 
our study, we advise that the use of a loading dose of micafungin in ICU patients should be 
evaluated to increase exposure on the first day of therapy. Also, a higher standard maintenance 
dose of micafungin in this patient population could be considered, as it has been confirmed that 
micafungin has a favourable tolerability profile and displays dose-proportional linear pharmaco-
kinetics. Last, to avoid concentration-dependent therapeutic failure, TDM of micafungin could 
be a valuable tool in this especially vulnerable patient population.
As stated before, body composition may affect the pharmacokinetics of drugs. To determine if 
weight was of influence on the pharmacokinetics of anidulafungin, we performed a prospective 
study in eight morbidly obese subjects (BMI >40 kg/m2; chapter 4). Subjects received a single, 
intravenous 100 mg dose of anidulafungin before laparoscopic bariatric surgery. A pharmaco-
kinetic curve was drawn until 48 hours after infusion. To compare anidulafungin exposure in a 
clinical context, one needs a clinical target. As no clinical target currently exists for anidulafun-
197
gin in patients, the population average exposure of the general (non-obese) patient population 
might serve as a reference value. We show that none of the morbidly obese patients included 
in our study obtained this target exposure at standard doses of anidulafungin, thereby possibly 
introducing the risk of therapeutic failure, particularly if the fungal pathogen has a lower suscep-
tibility to anidulafungin. Based on the findings of our study, we advise that anidulafungin dosing 
could be optimized in (extreme) morbidly obese patients with fungemia. As a priori dosing 
information regarding the appropriate dose of anidulafungin for heavy patients is lacking, we 
advise a 50% increased loading and maintenance dose for morbidly obese patients with a BMI 
>40 kg/m2 i.e. a 200 mg loading dose and a 300 mg maintenance dose. Similar to the findings in 
chapter 3, TDM could be of importance to ensure sufficient exposure in the individual heavier 
patient. 
Section II: Antifungal drug-drug interactions
Antifungal drugs have a high potential for drug–drug interactions. This is a major concern in 
the treatment of IFD, because inhibition or induction of metabolizing enzymes may alter the 
pharmacokinetic profile of the drugs involved. In most cases, these interactions must be avoided 
as this can lead to overdosing with the consequence of toxicity or underdosing with a loss of 
effectiveness. 
One of the most clinically relevant interactions with antifungal drugs of the azole class are those 
with immunosuppressant drugs used in hematopoietic stem cell and solid organ transplant 
recipients. These patients receive immunosuppressive therapy for the prevention and treatment 
of graft-versus-host-disease (GvHD) and are therefore at increased risk for invasive fungal 
infections. Initiation of azoles increases immunosuppressant exposure introducing side effects 
of these drugs, whereas subsequent discontinuation of azoles without dose adjustment of the 
immunosuppressant may lead to sub-therapeutic immunosuppressant exposure and risk of 
transplant rejection or GvHD. For the clinician, it remains a challenge to adequately manage 
these drug-drug interactions. In chapter 5, we provided strategies for the management of drug 
interactions between azole antifungals (fluconazole, itraconazole, posaconazole, voriconazole) 
and immunosupressants (cyclosporine, tacrolimus, sirolimus and everolimus). We present a 
layout of tools necessary for the adequate assessment of drug interactions, i.e. [1] sources of 
information (product information, primary literature, drug-interaction databases), [2] an actual 
medication overview including prescribed and over-the-counter drugs, [3] a multidisciplinary 
team in interaction checks including a treating physician (together with a microbiologist and 
infectious disease doctor) and a hospital pharmacist/clinical pharmacologist, [4] computerized 
provider order entry paired with clinical decision support systems (yielding automated warnings 
in case of possible drug interactions) [5] clinical monitoring (i.e. check for signs and symptoms of 
altered drug response, side effects/toxicity and monitoring of biochemical and haematological 
parameters), [6] TDM, and [7] teaching on knowledge and awareness in relation to drug–drug 
interactions. With regard to these tools, we developed a stepwise approach to guide clinicians in 
the evaluation of drug interactions. In this ‘six step’ approach, we centralize the pharmacological 
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mechanism of drug interactions between immunosuppressants and azoles in the prediction, 
identification, quantification and classification of the effect along with the assessment of pa-
tient-related factors (step 1-5). The sixth step provides a decision tree to appropriately manage 
or circumvent the drug interaction, including the discontinuation of the azole drug if possible, 
empiric or TDM-based dose decrease of the immunosuppressant, and switch to a non-azole 
antifungal agent (e.g. amphotericin B or an echinocandin). Using this systematic approach, we 
provide the optimal strategy to manage the drug interactions between azoles and immunosup-
pressants. This should ultimately promote patient safety, minimize complications and optimize 
treatment outcome.
Besides immunosuppressants, azole antifungals are also involved in a plethora of interactions 
with other concomitant medications. Additionally, echinocandins, lipid and other formulations 
of amphotericin B, and flucytosine are also involved in interactions, which should be taken into 
account for clinical management in specific settings. Despite widespread efforts to monitor for 
interactions with antifungal agents, it is almost impossible for the clinician to be conversant with 
all possible drug interactions and assess their potential consequence for an individual patient. 
In chapter 6, we describe the development of a real-time knowledgebase of drug interactions 
with antifungal agents (Fungal Pharmacology). This database (available as web site and mobile 
application on Apple© and Android© operating systems) was initiated with the aim of providing 
free, up-to-date, easy accessible information on drug interactions between antifungal agents 
and other prescription drugs, over-the-counter medicines and natural products. Together with 
an international expert panel of hospital pharmacists, clinical pharmacologists, clinicians and 
microbiologists with extensive knowledge on the treatment of IFD, tailor-made recommenda-
tions on the drug interactions were provided (including the effect of the interaction, clinical 
management, probable mechanism and a literature summary with hyperlinks to references). 
Also, the severity of the interaction was graded (ranging from A: ‘no action needed’ to X: ‘contra-
indicated’) along with the quality of evidence (ranging from very low to high). Also, the potential 
risk of causing irregular heart rhythms was described. With Fungal Pharmacology, clinicians 
with varying levels of experience and resources worldwide now have a tool at their disposal for 
managing over 1,000 clinically important drug interactions with antifungal agents.
Drug interactions commonly occur via different cytochrome P450 (CYP450) enzyme systems, 
e.g. CYP3A4, CYP2C19 and CYP2C9, of which (azole) antifungal agents can be substrates and/or 
inhibitors. Yet, inhibition of efflux transporters (e.g. ABC transporters), which are found at the 
intestinal wall and blood-brain barrier, is also a common mechanism underlying drug-drug in-
teractions. These efflux pumps transport substrates from the inside to the outside of the cell. 
Knowledge of the inhibitory potential of antifungal drugs on these efflux transporters is crucial 
in understanding the molecular mechanisms underlying non-CYP mediated drug interactions 
of these drugs. In chapter 7, we determined the inhibitory potential of antifungal drugs on the 
transport of model substrates of the ABC transporters P-gp, MRP1–5, BCRP and BSEP using a 
vesicular transport interaction assay. We reported that P-gp and BCRP were strongly inhibited by 
itraconazole, hydroxyitraconazole, posaconazole and isavuconazole. BSEP was strongly inhibited 
by itraconazole and hydroxyitraconazole, whereas fluconazole and voriconazole did not show 
to inhibit any transport of substrate. Micafungin uniquely inhibited all transporters, with strong 
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inhibition of MRP4. Anidulafungin and caspofungin showed strong inhibition of BCRP, but 
amphotericin B only weakly inhibited BCRP-mediated transport. We concluded that despite 
the plethora of drug interactions with azoles in clinical practice, these drugs exhibit selective 
inhibition on efflux transporters. Echinocandins however display a low potential for clinically 
relevant interactions, but demonstrate potent in vitro inhibitory activity on efflux pumps.
Section III: Interlaboratory quality control and Therapeutic drug monitoring 
A crucial parameter for pharmacokinetic research and TDM is the availability of adequate 
analytical techniques. Developing such an accurate and sensitive analysis is complicated and 
requires sufficient expertise. Proficiency testing (PT) or external quality control is a valuable tool 
in the quality improvement process for the analysis of drugs in plasma, enabling laboratories 
to assess and improve their performance with respect to the bioanalysis of drugs. In 2008, an 
international PT program was set up to verify whether the methods of analysis and subsequent 
TDM results conform to expectations of the quality required for patient care and research. In 
chapter 8, we describe the results of a 5-year data evaluation of the antifungal PT programme 
(2008–2012) aiming to assess the overall performance of laboratories, as well as possible expla-
nations for inaccuracies. Fifty-seven laboratories from 13 countries reported 2.251 results in 5 
years. Overall, 432 (19.2%) analyses were inaccurate, in which the performing laboratory was the 
only factor clearly related to inaccuracies in the measurement of antifungal drugs. Regarding 
these inaccuracies, we dispatched a questionnaire to participating laboratories with the request 
to provide input on sources of error. The results of this questionnaire indicated that laborato-
ries encounter significant problems analysing low concentrations (15.4% of all inaccuracies). 
Moreover, even though clerical errors seem to be avoidable, they remain another major source 
of error for inadequate results (21.2%).
Chapter 9 describes a retrospective analysis in a cohort of paediatric patients with difficult 
to manage voriconazole trough concentrations and assessed the result of TDM-based dose 
adaptations on target attainment. Based on findings in literature, a target therapeutic range for 
voriconazole trough concentrations is used from 1 to 6 mg/L, which corresponds with efficacy 
and toxicity. The median voriconazole trough concentration was 2.16 mg/L (range 0.0–28.0), with 
24.1% of trough concentrations below 1 mg/L, 48.9% between 1 and 4 mg/L, 9.3% between 4 
and 6 mg/L and 17.7% above 6 mg/L. Although TDM-based dose adjustments were performed 
to optimize plasma concentrations, only 45% of dose adaptations following sub –or suprathera-
peutic voriconazole trough concentrations did result in target attainment after the first dose. In 
the remaining 55%, multiple interventions were required to achieve therapeutic trough concen-
trations. We found no correlation between dose and first or all trough concentrations, resulting 
from a large within-patient variability (94.1% for intravenous therapy, 88.5% for oral therapy). 
We concluded that intensive and continuous TDM of voriconazole is a prerequisite for ensuring 
adequate exposure in paediatric patients.
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In this thesis, we aimed to improve the understanding of the clinical pharmacology of antifungal 
drugs. We did this by conducting studies in special patient populations, developing a drug-drug 
interaction database, developing a six-step method for the management of drug interactions, 
and analysing the results of our PT program. With this, we designed a structure which enables 
future research and serves in the overcoming of the current challenges we encounter in the 
clinical pharmacology of antifungal drugs. In other words: a clinical pharmacology framework 
for the safe and effective use of antifungal agents.
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Samenvatting
Schimmels behoren evolutionair en ecologisch gezien tot de meest diverse organismen ter 
wereld. Schimmels zijn nadrukkelijk aanwezig in het dagelijks leven: we ademen sporen in die 
zich in de lucht bevinden, komen met hen in aanraking via onze omgeving (bijvoorbeeld door 
voedsel, dieren, planten en aarde) en ze zijn zelfs aanwezig in het menselijk lichaam. Alhoewel 
de menselijke gezondheid enorm heeft geprofiteerd van dit organisme – bijvoorbeeld middels 
antibiotica die van schimmels zijn afgeleid (zoals penicilline) – kunnen schimmels ook de 
gezondheid op een nadelige manier beïnvloeden. Het aantal opportunistische invasieve schim-
melinfecties (o.a. door Candida en Aspergillus species) is in de afgelopen twee decennia sterk 
toegenomen. Dit is gecorreleerd met de toename van het aantal patiënten dat een risico loopt 
op het ontwikkelen van invasieve schimmelinfecties zoals kankerpatiënten, patiënten die een 
hematopoietische stamcel -of orgaantransplantatie ondergaan en daardoor immunosuppres-
sieve geneesmiddelen ontvangen, ernstig zieke patiënten, premature baby’s en HIV-geïnfec-
teerde patiënten. Aangezien deze systemische Candida en Aspergillus infecties geassocieerd zijn 
met een verhoogde morbiditeit en mortaliteit in speciale patiëntpopulaties, hebben invasieve 
schimmelinfecties zich ontwikkeld tot een groot gezondheidsprobleem. Geneesmiddelen 
tegen schimmels (antifungale middelen) spelen een belangrijke rol bij de adequate profylaxe en 
behandeling van deze infecties.
Dit proefschrift richt zich op de klinische farmacologie van antifungale middelen om hun veilige 
en effectieve gebruik in de klinische praktijk te optimaliseren. Dit proefschrift bestaat uit 10 
hoofdstukken, die onderverdeeld zijn in drie delen.
Deel I evalueert het farmacokinetische gedrag van antifungale middelen in speciale patiënten-
populaties.
Deel II van dit proefschrift richt zich op het afhandelen van farmacokinetische wisselwerkin-
gen (interacties) tussen antifungale middelen en andere veel gebruikte geneesmiddelen in de 
klinische praktijk.
Deel III van dit proefschrift richt zich op interlaboratorium (externe) kwaliteitscontrole en 
therapeutic drug monitoring (TDM), met als doel de optimalisering van de behandeling met 
antifungale middelen voor de individuele patiënt. 
Dit proefschrift sluit af met een algemene discussie waarin de klinische impact van ons 
onderzoek, evenals een toekomstperspectief waarin de individualisering van de behandeling 
met antifungale middelen wordt besproken.
Deel I: Antifungale farmacokinetiek in speciale patiëntenpopulaties
De studies in hoofdstuk 3, 4 en 5 zijn gericht op het bestuderen van het gedrag van antifungale 
middelen (ofwel farmacokinetiek: geneesmiddel absorptie, distributie, metabolisme en excretie) 
in speciale patiëntenpopulaties. Gedurende de registratiefasen van een geneesmiddel worden 
speciale patiëntenpopulaties zoals ernstig zieke patiënten of extreem obese patiënten in de 
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regel niet opgenomen in de registratiestudies uitgevoerd door de fabrikant van het genees-
middel. Daardoor is het vaak onbekend of de vastgestelde dosering van het geneesmiddel 
ook geschikt is voor deze bijzondere patiëntengroepen. De farmacokinetiek en de bloedcon-
centraties kunnen namelijk veranderen door patiëntspecifieke factoren, zoals leeftijd (pedia-
trische patiënten versus volwassenen), lichaamsoppervlak en lichaamssamenstelling (normaal 
gewicht versus obesitas), ziektestatus (bijvoorbeeld ernstig zieke patiënten en patiënten met 
brandwonden) en orgaanfalen (nier -en leverinsufficiëntie). Deze effecten van veranderde bloot-
stelling van het geneesmiddel kunnen uiteindelijk van invloed zijn op de werkzaamheid en 
veiligheid.
In hoofdstuk 2 hebben we de farmacokinetiek van echinocandinen (anidulafungine, caspofun-
gine en micafungine) beschreven, welke veelvuldig worden gebruikt in verschillende patiënten-
populaties voor de preventie en behandeling van Candida infecties. Deze patiëntenpopu-
laties zijn neonaten, kinderen en adolescenten, obese patiënten, patiënten met lever- of 
nierinsufficiëntie, ernstig zieke patiënten (waaronder patiënten met brandwonden) en patiënten 
met hematologische aandoeningen. Ondanks dat in de richtlijn geen onderscheid wordt 
gemaakt tussen deze drie echinocandinen bij volwassenen, concluderen wij dat er beperkte en 
tegenstrijdige gegevens beschikbaar zijn over de farmacokinetiek van echinocandinen in deze 
speciale patiëntenpopulaties. Echter betwijfelen we dat deze verschillen in farmacokinetiek als 
basis dienen om een specifiek echinocandine te verkiezen in een speciale patiëntenpopula-
tie. Wel kan voor een individuele patiënt de echinocandine dosis worden aangepast naar een 
andere (vaste) dosis op basis van patiëntkenmerken of comorbiditeiten.
In hoofdstuk 3 hebben we de farmacokinetiek van micafungine prospectief onderzocht in 
intensive care (IC) patiënten en zijn op zoek gegaan naar covariaten (bv gewicht, ziektestatus) die 
de plasmaconcentraties kunnen beïnvloeden. Twintig IC-patiënten werden geïncludeerd die de 
geregistreerde dosering van micafungine ontvingen voor een vermoedelijke of bewezen schim-
melinfectie of als profylaxe (100 mg intraveneus eenmaal daags). Op dag 3 en dag 7 werden 
meerdere bloedmonsters op verschillende tijdstippen na de start van de infusie afgenomen, 
een zogenaamde farmacokinetische curve. Ook werden dagelijks bloedmonsters net voor de 
volgende micafungine dosis afgenomen (dalspiegels). Op deze manier konden we de farmaco-
kinetiek van micafungine op beide dagen bij deze patiënten in kaart brengen. De farmacokine-
tische parameters (zoals blootstelling, piek- en dalspiegels) op dag 3 waren niet significant ver-
schillend van die op dag 7, hetgeen aantoont dat de maximale micafungine blootstelling uiterlijk 
op dag 3 bereikt werd. Dagelijkse dalspiegels verschilden behoorlijk tussen de patiënten (57,9%) 
maar verschilden slechts beperkt in de patiënten zelf op verschillende studiedagen (12,9%). 
In deze groep IC-patiënten werden geen covariaten geïdentificeerd die van invloed waren op 
de micafungine blootstelling. Tevens werd micafungine veilig bevonden en werd het goed 
verdragen door deze patiënten. De micafungine blootstelling in ons cohort van IC-patiënten 
was significant lager in vergelijking met gezonde vrijwilligers, maar niet significant verschil-
lend vergeleken met andere patiëntenpopulaties. Bij start van de micafungine therapie was de 
dalspiegel voorafgaand aan de tweede dosis micafungine significant lager dan de dalspiegel 
voorafgaand aan de derde dosering. Op basis van de resultaten van onze studie adviseren wij 
dat het gebruik van een oplaaddosis van micafungine bij IC-patiënten moet worden overwogen 
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om de blootstelling op de eerste dag van de behandeling te verhogen. Ook zou een hogere 
onderhoudsdosering van micafungine bij deze patiëntenpopulatie kunnen worden overwogen, 
gezien micafungine een gunstig bijwerkingenprofiel heeft en lineaire farmacokinetiek. Tot slot 
kan TDM van micafungine een waardevol hulpmiddel zijn om concentratie-afhankelijk thera-
peutisch falen te voorkomen in deze bijzonder kwetsbare patiëntenpopulatie.
Zoals eerder vermeld kan lichaamssamenstelling van invloed zijn op de farmacokinetiek van 
geneesmiddelen. Om te bepalen of het lichaamsgewicht van invloed is op de farmacokine-
tiek van anidulafungine, hebben we een prospectieve studie uitgevoerd in acht morbide obese 
patiënten (BMI >40 kg/m2, hoofdstuk 4). De proefpersonen kregen een enkele intraveneuze dosis 
van 100 mg anidulafungine toegediend voordat ze een laparoscopische bariatrische operatie 
(maagverkleining) ondergingen. Een farmacokinetische curve werd afgenomen tot 48 uur na 
start van infusie. Om de blootstelling van anidulafungine in deze patiënten te vergelijken in een 
klinische context, heeft men een streefwaarde nodig. Aangezien er momenteel geen klinische 
streefwaarde bestaat voor anidulafungine in patiënten, zou de gemiddelde blootstelling van 
de (niet-obese) patiëntenpopulatie kunnen dienen als referentiewaarde. Bij een standaard 
dosis van anidulafungine haalde geen enkele morbide obese patiënt in ons onderzoek deze 
gemiddelde blootstelling. Hierdoor wordt een eventueel risico op therapeutisch falen geïntro-
duceerd, zeker wanneer de schimmel een lagere gevoeligheid voor anidulafungine heeft. Op 
basis van de bevindingen van onze studie adviseren wij dat de dosering van anidulafungine 
in (extreem) morbide obese patiënten met een invasieve schimmelinfectie kan worden geop-
timaliseerd. Gezien a priori informatie over de meest geschikte dosering van anidulafungine 
voor zwaarlijvige patiënten ontbreekt, adviseren we een 50% hogere oplaad -en onderhouds-
dosis voor morbide obese patiënten met een BMI > 40 kg/m2 d.w.z. een 200 mg oplaaddosis en 
een 300 mg onderhoudsdosis. Vergelijkbaar met de bevindingen in hoofdstuk 3 kan TDM van 
belang zijn om adequate blootstelling in de individuele zwaardere patiënt te waarborgen.
Deel II: Antifungale geneesmiddelinteracties
Antifungale middelen hebben een hoge potentie voor geneesmiddelinteracties. Dit is een 
groot probleem in de behandeling van invasieve schimmelinfecties, omdat remming of inductie 
van metaboliserende enzymen het farmacokinetisch profiel van de betrokken geneesmiddelen 
kunnen veranderen. In de meeste gevallen moeten deze interacties worden vermeden omdat 
dit kan leiden tot overdosering met als gevolg toxiciteit of onderdosering leidend tot een verlies 
in effectiviteit.
Een van de meest klinisch relevante interacties met antifungale middelen uit de azool-klasse zijn 
die met immunosuppressiva, welke gebruikt worden in patiënten die een hematopoietische 
stamcel -of orgaantransplantatie ondergaan. Deze patiënten ontvangen immunosuppressieve 
therapie voor de preventie of behandeling van graft-versus-host-disease (GvHD), waardoor zij een 
verhoogd risico op invasieve schimmelinfecties hebben. Het starten van een azool antifungaal 
middel leidt tot een verhoogde blootstelling van het immunosuppressivum, hetgeen mogelijk 
leidt tot bijwerkingen van deze geneesmiddelen, terwijl het staken van het azool antifungaal 
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middel zonder dosisaanpassing van het immunosuppressivum juist kan leiden tot een verlaagde 
immunosuppressieve blootstelling met het risico van afstoting van het transplantaat of GvHD. 
Voor de clinicus blijft het lastig om deze geneesmiddelinteracties adequaat af te handelen. 
In hoofdstuk 5 zetten we strategieën uiteen voor het afhandelen van interacties tussen azool 
antifungale middelen (fluconazol, itraconazol, posaconazol, voriconazol) en immunosuppressiva 
(ciclosporine, tacrolimus, sirolimus en everolimus). We beschrijven verscheidene ‘tools’ die men 
kan gebruiken voor een adequate afhandeling van interacties tussen deze geneesmiddelen, 
waaronder [1] informatiebronnen (productinformatie, primaire literatuur, geneesmiddelinter-
actie databases), [2] een actueel medicatie overzicht, inclusief recept -en zelfzorg geneesmid-
delen, [3] een multidisciplinair team om controles op interacties uit te voeren, waaronder een 
behandelend arts (samen met een microbioloog en infectioloog) en een ziekenhuisapotheker/
klinisch farmacoloog, [4] een ziekenhuis informatiesysteem gecombineerd met een systeem dat 
automatische waarschuwingen geeft in het geval van mogelijke interacties tussen geneesmid-
delen, [5] klinische monitoring (d.w.z. controleren op tekenen en symptomen van veranderde 
geneesmiddelrespons, bijwerkingen/toxiciteit en monitoring van de biochemische en hemato-
logische parameters), [6] TDM, en [7] kennisoverdracht met betrekking tot geneesmiddelinter-
acties. Om deze ‘tools’ op een juiste manier te gebruiken hebben wij een stapsgewijze aanpak 
ontwikkeld om clinici te begeleiden in de afhandeling van de interacties tussen geneesmiddelen. 
In deze ‘zes stappen’ aanpak, stellen wij het farmacologische mechanisme van de interacties 
tussen immunosuppressiva en azolen centraal: de voorspelling, identificatie, kwantificering en 
classificatie van het effect, samen met de beoordeling van de patiëntgebonden factoren (stap 
1-5). De zesde stap bevat een beslisboom om op juiste wijze de geneesmiddelinteractie af te 
handelen, waaronder het staken van het azool indien mogelijk, empirische of TDM gebaseerde 
dosisverlaging van het immunosuppressivum, en omzetten naar een niet-azool antifungaal 
middel (bijvoorbeeld amfotericine B of een echinocandine). Met behulp van deze systemati-
sche aanpak bieden wij een optimale strategie om de interacties tussen azolen en immunosup-
pressiva af te handelen. Dit minimaliseert complicaties en optimaliseert de uitkomst van de 
behandeling, hetgeen de patiëntveiligheid bevorderd.
Naast immunosuppressiva zijn azool antifungale middelen ook veelvuldig betrokken bij 
interacties met andere geneesmiddelen. Daarnaast zijn de echinocandinen, lipide en andere for-
muleringen van amfotericine B, en flucytosine ook betrokken bij interacties. Ondanks intensieve 
inspanningen om interacties met antifungale middelen tijdig te controleren, is het voor de 
arts bijna onmogelijk om op de hoogte te zijn van alle mogelijke interacties en hun mogelijke 
consequenties voor een individuele patiënt. In hoofdstuk 6 beschrijven we de ontwikkeling 
van een kennisbank voor interacties met antifungale middelen (Fungal Pharmacology). Deze 
database (beschikbaar als website en app op Apple© en Android© besturingssystemen) heeft als 
doel om gratis, up-to-date en makkelijk toegankelijke informatie te verstrekken over interacties 
tussen antifungale middelen en receptgeneesmiddelen, zelfzorgmiddelen en kruidenprepa-
raten. Met behulp van een internationaal panel van ziekenhuisapothekers, klinisch farmacolo-
gen, artsen en microbiologen met een uitgebreide kennis over de behandeling van invasieve 
schimmelinfecties, zijn specifieke aanbevelingen samengesteld over interacties (inclusief het 
effect van de interactie, klinische afhandeling, onderliggend mechanisme en een samenvat-
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ting van de literatuur met hyperlinks naar de referenties). Ook is de ernst van de interactie op 
waarde geschat (variërend van A: ‘geen actie nodig’ tot X ‘gecontraïndiceerd‘) tezamen met 
de kwaliteit van beschikbare bronnen (van zeer laag tot hoog). Daarnaast hebben we het 
risico op het veroorzaken van hartritmestoornissen door de geneesmiddelen beoordeeld. Met 
Fungal Pharmacology hebben clinici met verschillende niveaus van expertise wereldwijd een 
hulpmiddel ter beschikking om meer dan 1.000 klinisch belangrijke interacties met antifungale 
middelen juist af te handelen.
Interacties vinden gewoonlijk plaats via verschillende cytochroom P450 (CYP450) enzymen, bij-
voorbeeld CYP3A4, CYP2C19 en CYP2C9, waarvan (azool) antifungale middelen zowel substraten 
en/of remmers kunnen zijn. Daarnaast is remming van effluxpompen (bijvoorbeeld ABC trans-
porters), onder andere aanwezig in de darmwand en bloed-hersenbarrière, ook een veel 
voorkomend mechanisme voor deze interacties. De effluxpompen transporteren substraten van 
de binnenkant van de cel naar de buitenkant. Kennis van de remmende potentie van antifungale 
middelen op deze effluxpompen is cruciaal om de moleculaire mechanismen van (niet-CYP 
gemedieerde) interacties te begrijpen. In hoofdstuk 7 hebben we de remmende potentie van 
antifungale middelen op het transport van typische substraten van de ABC effluxpompen P-gp, 
MRP1-5, BCRP en BSEP bestudeerd, waarbij gebruik werd gemaakt van een vesicular transport 
assay. We rapporteerden dat P-gp en BCRP sterk geremd werden door itraconazol, hydroxyitra-
conazol, posaconazol en isavuconazol. BSEP werd sterk geremd door itraconazol en hydroxyitra-
conazol, terwijl fluconazol en voriconazol het transport van geen enkel substraat remden. 
Micafungine remde als enige alle effluxpompen, waarbij MRP4 het sterkst geremd werd. 
Anidulafungine en caspofungine lieten een sterke remming van BCRP zien, terwijl amfotericine B 
het transport van substraat over BCRP slechts zwak remde. We concludeerden dat ondanks de 
overvloed aan interacties met azolen in de klinische praktijk deze geneesmiddelen slechts op 
selectieve effluxpompen remming vertonen. Echinocandinen daarentegen, die juist een lage 
potentie voor klinisch relevante interacties hebben, vertonen een potente remmende activiteit 
op effluxpompen in vitro.
Deel III:Interlaboratorium kwaliteitscontrole en Therapeutic Drug Monitoring
Een belangrijke parameter voor farmacokinetisch onderzoek en TDM is de beschikbaarheid van 
analytische methoden. Het ontwikkelen van een dergelijke nauwkeurige analyse is ingewikkeld 
en vereist expertise. Externe kwaliteitscontrole is een waardevol hulpmiddel voor de kwaliteits-
verbetering van de analyse van geneesmiddelen in plasma. Hierdoor worden laboratoria in staat 
gesteld hun prestaties met betrekking tot de bioanalyse van geneesmiddelen te evalueren. In 
2008 werd een internationaal extern kwaliteitscontrole programma opgezet om te controleren 
of de analysemethoden en de daaropvolgende TDM resultaten voor antifungale middelen 
voldoen aan de vereiste kwaliteit voor patiëntenzorg en onderzoek. In hoofdstuk 8 beschrijven 
we de resultaten van een 5-jaars evaluatie van gegevens van het antifungale externe kwali-
teitscontrole programma (2008-2012) met als doel de algemene prestaties van de laboratoria, 
alsmede mogelijke verklaringen voor onjuistheden te beoordelen. Zevenenvijftig laboratoria 
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uit 13 landen correspondeerden 2.251 analyseresultaten gedurende 5 jaar. In totaal werden 432 
(19,2%) analyses onjuist bevonden, waarbij het uitvoerende laboratorium zelf de enige factor 
was die een duidelijk verband liet zien met de onjuiste analyse van antifungale middelen. Met 
betrekking tot de onjuiste analyses werd de deelnemende laboratoria een vragenlijst voorgelegd 
met het verzoek om een reden aan te geven voor deze onjuistheden. De resultaten van deze 
vragenlijst geven aan dat laboratoria aanzienlijke problemen ondervinden met de analyse van 
lage concentraties (15,4% van onjuiste analyses). Ondanks dat administratieve fouten vermijdbaar 
lijken, blijven deze een andere belangrijke bron van onjuistheden (21,2%).
Hoofdstuk 9 beschrijft een retrospectieve analyse in een cohort van pediatrische patiënten met 
sterk wisselende voriconazolspiegels. Tevens werd bestudeerd of dosisaanpassing op geleide 
van TDM resulteerde in het behalen van de gewenste streefwaarde. Op basis van de literatuur 
werd een therapeutische streefwaarde aangehouden van 1 tot 6 mg/L, hetgeen correspon-
deert met effectiviteit en toxiciteit. De mediane voriconazol dalspiegel was 2,16 mg/L (range 
van 0,0–28,0), waarbij 24,1% van de dalconcentraties lager waren dan 1 mg/L, 48,9% zich bevond 
tussen de 1 en 4 mg/L, 9,3% tussen de 4 en 6 mg/L en 17,7% boven de 6 mg/L. Bij een eerste 
voriconazol dalspiegel die buiten de streefwaarde viel, werd in slechts 45% na de opeenvol-
gende dosisaanpassingen een adequate spiegel bereikt. In de resterende 55% waren meerdere 
dosisaanpassingen nodig om therapeutische dalspiegels te bereiken. We vonden geen correlatie 
tussen de dosis en zowel de eerste als alle dalspiegels door een grote intrapatiënt variabiliteit 
(94,1% voor intraveneuze therapie, 88,5% voor orale therapie). We concludeerden dat intensieve 
en continue TDM van voriconazol in pediatrische patiënten een voorwaarde is om een adequate 
blootstelling van voriconazol te waarborgen.
In dit proefschrift hebben we als doel gesteld om het begrip van de klinische farmacologie van 
antifungale middelen te verbeteren. Dit hebben we gedaan door studies uit te voeren in speciale 
patiëntpopulaties, een interactie database te ontwerpen, een zes-staps methode te ontwikkelen 
voor de afhandeling van interacties tussen geneesmiddelen, en resultaten te analyseren 
van ons kwaliteitscontrole programma. Hiermee hebben we een structuur ontworpen die 
toekomstig onderzoek mogelijk maakt en gebruikt kan worden in de huidige uitdagingen die 
we tegenkomen in de klinische farmacologie van antifungale middelen. Met andere woorden:
a clinical pharmacology framework for the safe and effective use of antifungal agents.
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